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Frailty is common among older adults and represents a state of decreased physiological reserve 
which places individuals at risk of increased vulnerability to adverse outcomes such as falls, 
hospitalisation, residential care admission, and mortality. Frailty is a dynamic condition where 
improvement is possible and remaining stable is common. Furthermore, interventions exist that 
may delay or reverse frailty. There are two main approaches to describing frailty: the frailty 
phenotype (FP), which is based on a pre-defined set of physical characteristics of frailty, and the 
accumulation of deficits approach. In the deficits approach, the proportion of deficits, across a 
wide range of body systems and health conditions, is identified in an individual and represented 
as a frailty index (FI).  
Internationally, there is a large and growing body of research focused on frailty. However, 
there are a limited number of Australian population-level studies of frailty prevalence, factors 
associated with frailty, and the diagnostic value of screening instruments for frailty. 
Less attention has been focused internationally on a comparison of the two approaches to frailty 
measurement, the natural course of frailty, its co-presence with sarcopenia (a loss of lean 
muscle mass and function), and minimally important difference in frailty, which is the smallest 
change in a treatment outcome which an individual would perceive as being important.  
The aims of this thesis were therefore to: 
 identify the prevalence of frailty at a population level and determine factors
associated with frailty
 examine the transitions between frailty states and to describe the characteristics
associated with frailty status improving, remaining stable, or worsening
 identify the diagnostic test accuracy (DTA) of self-reported screening instruments
against a frailty reference standard for community dwelling older adults in a
systematic review
 determine the predictive ability of frailty classification, and the effect of recency of
frailty measurement, on mortality prediction
 also examine the predictive ability of sarcopenia alone and sarcopenia in combination
with frailty on mortality
 examine the predictive validity of the FRAIL Scale and the SARC-F, self-reported
screening instruments for frailty and sarcopenia respectively
 determine the relationship between frailty status and health-state utility and to
determine a minimally important difference for frailty measures.
Research from this doctoral thesis has confirmed that frailty is common among community 
dwelling older adults in Australia and it is associated with a range of health and socioeconomic 
determinants. Findings have also demonstrated that improvement in frailty classification is 
possible and that remaining stable is common. The dynamic nature of frailty was further 
highlighted in our findings, which demonstrated the importance of repeated frailty measurement 
for improved mortality prediction. Additionally, frailty and sarcopenia in combination result in 
worse survival outcomes.  
xiii 
We have also demonstrated the predictive validity of self-reported screening instruments for both 
frailty and sarcopenia, and that frailty is associated with lower health-state utility. In terms of 
conducting assessments for frailty, we have identified values for minimally important differences 
for both methods of frailty measurement.  
These findings have important clinical implications for both the identification and management of 
frail individuals, and for promoting healthy ageing through offering preventative strategies. A key 
message from this thesis for health practitioners and older adults is that despite frailty being 
common, it can be either prevented, reversed, or delayed, and that a regular review of frailty 
status is important for targeting interventions as required, and maximising quality of life. 




As the Australian and global population ages, there is a responsibility among health 
practitioners and policy makers to promote opportunities for healthy ageing (World Health 
Organization, 2015). These strategies should focus beyond merely extending life, to 
enhancing wellbeing, function and participation, and quality of life. While ageing is a 
universal and inevitable part of the life course, there is large variability seen in the health and 
functional status of older adults, which reflects the multifactorial nature of survival into old 
age (Prince et al., 2015; Steves, Spector, & Jackson, 2012).  
Frailty may be a contributor to this variability in the wellbeing of older adults (Clegg, Young, 
Iliffe, Rikkert, & Rockwood, 2013). Understanding frailty and its course, therefore, is an 
important component in promoting healthy ageing locally and globally. This is particularly 
relevant as there are interventions available to potentially prevent or delay the onset 
and progression of frailty, including strength-based exercise, and promoting adequate 
dietary intake, especially of protein (Puts et al., 2017). Much of the identification and 
management of frailty is ideally suited to primary care and community-based services 
(Lacas & Rockwood, 2012), and strengthening the evidence base for addressing frailty in 
these settings is critical. 
Frailty is a state of decreased physiological reserve and resilience in which individuals are 
more vulnerable to stressors and at greater risk of adverse health events, such as falls, 
fractures, hospitalisation and loss of independence (Clegg et al., 2013). This decreased reserve 
results from a cumulative decline across multiple physiological systems (Mitnitski, Mogilner, 
& Rockwood, 2001), and a frail individual may be viewed as a complex system on the 
threshold of breakdown, with higher order functions usually compromised first: balance, 
mobility, cognitive function (Nowak & Hubbard, 2009). Frailty may also result from severe 
disease or comorbidity, or from the physiologic changes of ageing that are not related to 
disease, such as sarcopenia (Fried et al., 2001). 
Frailty also shares common features with sarcopenia, a syndrome of lean muscle mass and 
function loss (Cesari, Landi, Vellas, Bernabei, & Marzetti, 2014). Despite their shared 
characteristics, there has been no study which has examined the association between the 
combined presence of frailty and sarcopenia with mortality. A better understanding of how 
these two conditions interact would provide useful information on prognosis and prioritising 
treatment for individuals with either or both conditions. This is important, as there are 
interventions available that may delay the development and progression of frailty, such as 
exercise focused on strength training, increasing nutritional intake, particularly protein, 
reducing polypharmacy, and increasing vitamin D levels (Clegg et al., 2013; Puts et al., 2017), 
and which are also likely to be useful in the management of sarcopenia (Yoshimura et al, 2017).
1
1.1.1 The prevalence of frailty 
There are two approaches commonly used to describe frailty: the frailty phenotype (FP) and the 
cumulative deficits approach. The former views frailty as a physiologic syndrome which is 
manifested when three or more of the following deficits are present: unintentional weight loss, 
self-reported exhaustion, slow walk speed, weakness, and low physical activity (Fried et al., 
2001). The deficits approach defines frailty as a multi-dimensional risk state based on the 
proportion of potential deficits present in the individual, with a higher proportion representing a 
higher level of frailty (Mitnitski et al., 2001). This proportion of deficits is referred to as a frailty 
index (FI). 
Frailty is common among community-dwelling adults and its prevalence has been estimated 
internationally at 9.9% (weighted mean, range 4% to 17%) based on FP measurement, and at 
13.6% (weighted mean, range 4% to 59%) according to the FI (≥65 years) (Collard, Boter, 
Schoevers, & Oude Voshaar, 2012). 
Australia’s population is ageing, with the proportion of individuals aged 65 years and 
older expected to increase from a current 16% to an estimated 19% of the population by 2031, 
and to a possible 25% in 2061, with the largest proportional growth expected in those aged 
85+ years (Australian Bureau of Statistics, 2013). Understanding frailty prevalence in 
Australia will be important for planning health and social services to promote the healthy 
ageing and wellbeing of this cohort. To date there have been several Australian 
population-level studies that have investigated frailty prevalence (Blyth et al., 2008; Dent, 
Hoon et al., 2016; Widagdo, Pratt, Russell, & Roughead, 2015; Wong, McCaul, Yeap, 
Hankey, & Flicker, 2013). However, none of these has examined frailty and factors associated 
with frailty using both forms of measurement in the one cohort. This is necessary to 
examine whether the FP and FI share common characteristics in terms of prevalence, 
distribution of scores, association between measures, and actors associated with frailty. 
Regardless of the approach used in measurement, it is important to note that frailty is a 
dynamic process where individuals are capable of improving and transitioning to lesser states 
of frailty, particularly those who are pre-frail (Fallah et al., 2011; Gill, Gahbauer, Allore, & 
Han, 2006). Internationally, frailty state transitions and associated factors have been 
examined from the perspective of the FP and FI separately in different cohorts (Kojima, 
Taniguchi, Iliffe, Jivraj, & Walters, 2019); however, the performance of both measures 
longitudinally in the same cohort is yet to be examined. It is important to understand how 
the different forms of frailty measurement compare in terms of frailty state change over time. 
2
1.1.2 Recognising and managing frailty 
The primary care setting has been identified as playing a crucial role in the recognition and 
management of frailty, as well as the promotion of healthy ageing through integrated and patient 
centred care (Cesari et al., 2016; Theou & Rockwood, 2012). A range of frailty screening and 
assessment instruments is available. The instruments are quick to administer and can be self-
reported by patients (Dent, Kowal, & Hoogendijk, 2016). However, there has not been a 
comprehensive review of self-reported tests for frailty identification or an examination of their 
diagnostic test accuracy (DTA) against the reference standards of either the FP or FI.  
While the case is clearly made for assessing frailty status at the beginning of ageing care (Theou 
& Rockwood, 2012), the review of frailty status requires just as much attention, taking into 
account the changeable nature of frailty. However, the predictive ability of repeated frailty 
measurements on mortality is yet to be determined. 
Self-reporting instruments and utility. The FRAIL Scale (Morley, Malmstrom, & Miller, 
2012) and SARC-F (Malmstrom, Miller, Simonsick, Ferrucci, & Morley, 2016) are two self-
reporting instruments for the screening of frailty and sarcopenia respectively, which have been 
proposed for use in primary care settings (Burgess & Hercus, 2017; Morley & Malmstrom, 
2014). The FRAIL Scale has preliminary evidence in favour of its predictive validity for 
mortality (Kojima, 2018), and there are similar emerging findings for the SARC-F (Malmstrom 
et al., 2016; Woo, Leung, & Morley, 2014). Further information about the predictive validity and 
DTA of both instruments is required, particularly for their use in the Australian population. 
Understanding the preference-based value (utility) that individuals place on health states is an 
important component in the evaluation of interventions (Drummond, Sculpher, Torrance, 
O'Brien, & Stoddart, 2005; Neumann, Goldie, & Weinstein, 2000). While frailty is known to be 
associated with reduced quality of life (Kojima, Iliffe, Jivraj, & Walters, 2016), the utility of 
frailty states is less well understood. Minimally important difference (MID) also provides 
valuable information regarding the smallest change in a treatment outcome which an individual 
would perceive as being important. Likewise, MID values are unknown for both forms of frailty 
measurement.  
1.2   Aims of the research 
The research that resulted in this thesis by publication focused on frailty at a population level in 
the Australian context. The research aims were to: 
 identify the prevalence of frailty at a population level and describe associated factors
(Chapters 4 and 5)
 examine the transitions between frailty states and describe the characteristics
associated with frailty status improving, remaining stable, or worsening (Chapter 6)
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 identify the diagnostic test accuracy (DTA) of self-reported screening instruments
against a frailty reference standard for community dwelling older adults in a
systematic review (Chapter 7)
 determine the predictive ability of frailty classification, and the effect of recency of
frailty measurement, on mortality prediction (Chapter 8)
 also examine the predictive ability of sarcopenia alone and sarcopenia in combination
with frailty on mortality (Chapter 9)
 examine the predictive validity of the FRAIL Scale and the SARC-F, self-reported
screening instruments for frailty and sarcopenia respectively (Chapter 10)
 determine the relationship between frailty status and health-state utility and to
determine a minimally important difference for frailty measures (Chapter 11).
1.3  The context of the research 
The distribution of frailty and associated factors were examined using Australian population 
cohorts in the studies comprising this thesis. The use of randomly selected population data is 
important in epidemiological research in order to produce a representative sample of the 
population and to minimise systematic sampling errors (Fletcher, Fletcher, & Fletcher, 2014).  
The majority of studies in this thesis (Chapters 5, 6, 8, 9, 10, and 11) were a secondary analysis of 
data from the North West Adelaide Health Study (NWAHS), a population representative 
longitudinal study of men and women (Grant et al., 2009). Participants in the study were 
randomly selected from households in the North West of metropolitan Adelaide. We included 
participants aged ≥65 years. Stage 2 data (2004-06) were used as baseline for all studies, and 
Stage 3 (2008-10) for follow-up. 
Chapter 4 was a secondary cross-sectional analysis of data from the Dynamic Analyses to 
Optimise Ageing Project (DYNOPTA), a pooled dataset of nine Australian longitudinal studies 
of ageing, and the NWAHS (Anstey et al., 2010; Grant et al., 2009). Three cohorts from 
DYNOPTA with data available from 2004 and 2006 were using in conjunction with NWAHS 
Stage 2 (2004-06). This combined data set offered a large sample of participants aged ≥65 years 
(n = 8804) and enabled frailty prevalence findings to be more generalisable across the Australian 
population. 
The characteristics of both NWAHS and DYNOPTA cohorts are discussed in detail in Chapter 3. 
4
1.4 The organisation of the thesis 
The remaining chapters of this thesis are ordered as follows: 
 Chapter 2 provides a background to frailty definitions, prevalence, associated factors,
associated outcomes, screening and assessment methods, and interventions that might
reverse or delay frailty. Additionally, gaps in the scientific literature regarding frailty
are discussed. The chapter is an expanded version of a published manuscript designed to
raise general practitioner awareness about the public health issues of frailty
(Appendix A).
 Chapter 3 describes the research cohorts used as the data source for studies included in
this thesis. The North West Adelaide Health Study (NWAHS) cohort was used for
studies discussed in Chapters 5, 6, 8, 9, 10, and 11. However, NWAHS data were also
used in combination with Dynamic Analyses to Optimise Ageing Project
(DYNOPTA) in Chapter 4.
 Chapter 4
Published work in this chapter: Frailty prevalence in Australia: Findings from four
pooled Australian cohort studies
The paper presented in this chapter reports on the prevalence of frailty from an analysis
of four pooled Australian cohort studies from the Dynamic Analyses to Optimise
Ageing Project (DYNOPTA) and North West Adelaide Health Study
(NWAHS). Frailty was measured using a modified frailty phenotype (FP).
 Chapter 5
Published work in this chapter: Frailty prevalence and factors associated with the
frailty phenotype and frailty index. Findings from the North West Adelaide Health
Study (NWAHS)
The paper presented in this chapter reports on the prevalence of frailty and associated
factors in the North West Adelaide Health Study (NWAHS) using both the frailty
phenotype (FP) and frailty index (FI). Frailty prevalence was reported, together with
agreement between each form of frailty measurement, as well as factors associated with
frailty.
 Chapter 6
Published work in this chapter: Frailty state transitions and associated factors in
South Australian older adults
The paper presented in this chapter examines frailty state transitions and factors
associated with improvement or worsening frailty status as revealed in the data from the
North West Adelaide Health Study (NWAHS). Frailty was measured using the FP and
FI, with repeated measures at 4.5 years follow-up.
 Chapter 7
Published work in this chapter (as second author): Diagnostic test accuracy of self-
reported screening instruments in identifying frailty in community-dwelling older
people: A systematic review
This paper is a systematic review examining the diagnostic test accuracy of self-reported
and/or self-administered frailty screening instruments against two frailty reference
standards, the frailty phenotype (FP) and the frailty index (FI) within community-
dwelling older adult populations. (The protocol for this systematic review is also
included in Appendix B).
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 Chapter 8
Published work in this chapter: Recurrent measurement of frailty is important for
mortality prediction: Findings from the North West Adelaide Health Study
The paper presented in this chapter examines the relationship between frailty status (at
baseline and follow-up) and mortality using both the frailty phenotype (FP) and frailty
index (FI) in the North West Adelaide Health Study (NWAHS). Frailty was measured
at baseline for all participants, while a returning sample had frailty measurement at two
time points, with a mean 4.5 years between baseline and follow-up. 10 years of survival
data were available for all participants.
 Chapter 9
Paper submitted for publication and under review: The combination of frailty and
sarcopenia is an important mortality predictor: North West Adelaide Health
Study findings
This study examined the predictive ability of frailty and sarcopenia classification on
mortality in the North West Adelaide Health Study (NWAHS). Frailty was measured
using the frailty phenotype (FP) and frailty index (FI), and sarcopenia using the revised
European consensus definition. The relationship between classification as frail and / or
sarcopenic with mortality was examined.
 Chapter 10
Paper submitted for publication and under review: FRAIL Scale: Predictive validity
and diagnostic test accuracy
is a study that examines the predictive validity of the FRAIL Scale against mortality as
well as diagnostic test accuracy (DTA) against reference standards of the FP and FI for
frailty, for 668 community-dwelling adults aged ≥ 65 years from the North West
Adelaide Health Study (NWAHS). 10 years of survival data were available for all
participants.
 Chapter 11
Paper submitted for publication and is under review: Frailty state utility and
minimally important difference: Findings from the North West Adelaide Health
Study
This study describes Frailty State Utility and Minimally Important Difference (MID)
for both the frailty phenotype (FP) and frailty index (FI) in the North West Adelaide
Health Study (NWAHS). Utility (which is a preference-based valuation of a health
state) was measured using the six-dimensional health survey (SF-6D) Health Survey.
Two methods were used to measure MID for frailty, namely anchor-based (against self-
reported health status) and distribution-based (using 1/2 SD of mean frailty scores).
 Chapter 12 presents a summative discussion of the key findings which were identified
in research conducted that formed that basis of this thesis as well as recommendations
for further research.
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1.5 Summary and going forward 
This chapter has provided a brief introduction to the concept of frailty and the research aims of 
this thesis. It is anticipated that the findings reported in this thesis will contribute to the evidence 
base informing both policy and practice in promoting the health of older adults. In particular, 
highlighting that frailty is common, that regular review of frailty status is important to take into 
account the dynamic nature of the condition, that there are simple screening instruments available 
to support this process, that sarcopenia should be considered in combination with frailty, and that 
change to frailty status is important to older adults and can improve their quality of life. The 
following chapter is a literature review which provides a detailed background to frailty, the gaps 
in the scientific literature, and the rationale for the studies included in this thesis. 
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Australia’s population is ageing, with the proportion of individuals aged 65 years and older 
expected to increase from a current 16% to an estimated 19% of the population by 2031 and 
to a possible 25% by 2061, with the largest proportional growth expected in those aged 85+ 
years (Australian Bureau of Statistics, 2013). Understanding physical issues that will 
affect people in this age group is critical in order to care effectively for this expanding 
cohort. Therefore, knowledge of frailty, a condition common among older adults, is a priority 
(Cesari et al., 2016). Furthermore, the primary care setting has been identified as playing a 
crucial role in the recognition and management of frailty, as well as the promotion of healthy 
ageing through integrated and patient centred care (Cesari et al., 2016). 
This chapter provides an overview of frailty, its trajectory and complications, as well as 
describing strategies for identification and management. The second half of the chapter 
describes gaps in the scientific literature around frailty, and the rationale for the projects 
conducted as part of this thesis. More detailed reviews on frailty have been recently published 
(Dent et al., 2019; Hoogendijk et al., 2019). 
Aspects of this background review were published in Australian Doctor. A copy of the 
published article is provided in the Appendix. 
2.1 Frailty 
Frailty is due to a decline across a range of physiological systems resulting in 
decreased physiological reserve that results in vulnerability to a range of adverse health 
outcomes such as disability, hospitalisation, entry to residential care, and death when faced 
with stressors such as illness (Andrew Clegg, Young, Iliffe, Rikkert, & Rockwood, 
2013; Morley et al., 2013). Frailty is a useful concept for explaining the diversity in health 
and function seen in older people, where some individuals of the same age remain 
robust and active while others experience substantial deterioration in their health with 
loss of independence. Frailty is distinct from multi-morbidity and disability, but all three 
may be present concurrently in some older adults (Fried, Ferrucci, Darer, Williamson, & 
Anderson, 2004). 
2.1.1 Frailty measurement 
The two main approaches to defining frailty among researchers are the phenotypic model 
and the cumulative deficit model (Fried et al., 2001; Mitnitski, Mogilner, & 
Rockwood, 2001).  
Frailty phenotype approach. The frailty phenotype approach (FP) defines individuals as 
frail where three or more deficits are identified from amongst a range of five physical 
criteria: unintentional weight loss, exhaustion, low physical activity level, slow walk speed, 
and weak grip strength (Fried et al., 2001). The physical function variables of weakness 
and slowness are shared characteristics of sarcopenia (Cesari, Landi, Vellas, Bernabei, & 
Marzetti, 2014), a separate skeletal muscle disorder that can co-exist with frailty and worsen 
frailty.  
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Cumulative deficit approach represented as a frailty index (FI). The cumulative 
deficit approach counts the proportion of deficits present in an individual across a range of 
physical and psychological variables which can be evaluated through a comprehensive 
assessment or drawn from pre-existing medical records or databases, to calculate a frailty 
index (FI) (Mitnitski et al., 2001). The cumulative deficit model is mathematically 
based, and frailty is the proportion of deficits present in an individual (Mitnitski et al., 
2001; Searle, Mitnitski, Gahbauer, Gill, & Rockwood, 2008). For example, if an individual 
is found to have 25 deficits out of 100 variables evaluated, then their FI would be 0.25. A 
higher FI represents a higher level of frailty, and those with a score of > 0.21 are classified 
as frail (Hoover, Rotermann, Sanmartin, & Bernier, 2013). 
Despite differences, the FP and FI are moderately correlated (Rockwood, Andrew, 
& Mitnitski, 2007). Frailty increases non-linearly with age, is predictive of mortality, 
and is higher for women (Theou, Brothers, Pena, Mitnitski, & Rockwood, 2014). 
Studies which report on frailty using the FI tend to report a greater prevalence in 
comparison with the FP (Blodgett, Theou, Kirkland, Andreou, & Rockwood, 2015; 
Collard, Boter, Schoevers, & Oude Voshaar, 2012). Therefore, some individuals classified 
as non-frail by the FP can be categorised as frail by the FI. While the FP was designed, and 
is most commonly used as a categorical measure, it has also been used as a continuous 
measure to examine the association of frailty with adverse outcomes, and for comparison 
with other frailty measures (Blodgett et al., 2015; Bouillon et al., 2013; Andrew Clegg et 
al., 2013; Sanders et al., 2011; Theou, Brothers, Mitnitski, & Rockwood, 2013; Theou et 
al., 2014). Furthermore, using a continuous FP may result in improved predictive validity of 
the measure (Sanders et al., 2011). 
2.1.2 Frailty screening and instruments 
The timely identification and management of frailty in the primary care setting is 
important as this condition is associated with a range of adverse health outcomes, 
including geriatric syndromes such as falls and delirium, hospitalisation, decreased 
quality of life, cognitive impairment, disability, admission to residential aged care, and 
mortality (Cesari et al., 2016; Andrew Clegg et al., 2013). The phenotypic method (FP) has 
been popular for its brevity but in population groups where frailty is common and where an 
electronic health record system exists, the FI is being increasingly utilised. Since July 2017 
in the English NHS, primary care practices have used an Electronic Frailty Index to 
identify patients aged 65 years and older who are living with frailty (British Medical 
Association, 2018; A. Clegg et al., 2016).  
The use of frailty screening tools is one potential approach to identifying frailty in 
the primary care setting, particularly using instruments which can be self-reported; 
however, there are many from which to choose such as the FRAIL scale, Kihon 
checklist, Groningen Frailty Indicator, etc. (Dent, Kowal, & Hoogendijk, 2016), with 
research underway to determine the best tool for Australian general practice 
(Ambagtsheer et al., 2017; Dent, Kowal, et al., 2016). Figure 2.1 illustrates one quick and 
easy way to administer a frailty screening tool, the Clinical Frailty Scale (Rockwood et 


















































































































































Many of these screening tools have proven to be reliable and valid measures of frailty within 
different contexts (Dent, Kowal, et al., 2016). However, only some of these are suitable for use 
as self-administered instruments, which must take the form of either a postal survey or a self-
completed questionnaire.  
Several systematic reviews have examined the utility of frailty screening within community 
settings, from the perspective of both self-report and test-based measurements (Apostolo et al., 
2017; Drubbel et al., 2014; Sutton et al., 2016; Vermeulen, Neyens, van Rossum, 
Spreeuwenberg, & de Witte, 2011). Two systematic reviews have reported on the diagnostic 
test accuracy (DTA) of frailty screening instruments against a reference standard (Clegg, 
Rogers, & Young, 2015; Pialoux, Goyard, & Lesourd, 2012). A complicating factor in these 
reviews of frailty screening instruments is a lack of consensus on a definition of frailty, which 
is reflected in two separate reference standards, together with a large number of potential index 
tests (Apostolo et al., 2017). Furthermore, while some screening instruments are useful when 
identifying frailty risk, they are perhaps less helpful in guiding intervention to reverse or delay 
frailty (Walston, Buta, & Xue, 2018). 
The FRAIL Scale. The Fatigue, Resistance, Ambulation, Illnesses, and Loss of weight 
(FRAIL) scale (Table 2.1), was developed by Morley and colleagues (2012) in order to screen 
for frailty using a self-reported instrument that did not require a face-to-face clinical 
examination. This scale is a short and easy to administer tool which has been identified as 
practical for use in screening for frailty in the general practice setting, and has been 
recommended as a preferred instrument in the Australian primary care setting (Burgess & 
Hercus, 2017). The FRAIL Scale has demonstrated preliminary evidence in favour of its 
predictive validity for mortality (Kojima, 2018). Individuals registering three or more FRAIL 
characteristics are classified as frail, while those with one or two characteristics are pre-frail, 
and those with no characteristics are non-frail (Morley et al., 2012).  
Table 2.1: FRAIL Scale – modified from (Morley et al., 2012, p. 608) 
Fatigue: Do you feel tired all or most of the time?  
Resistance: Do you have any difficulty walking up 10 steps without resting? 
Ambulation: Do you have any difficulty walking several hundred metres?  
Illnesses: More than five illnesses from the following: hypertension, diabetes, cancer (not minor skin 
cancer), chronic lung disease, heart attack, congestive heart failure, angina, asthma, arthritis, stroke, 
and kidney disease.  
Loss of weight: Unintentional weight loss of more than 5% over the last 12 months 
Scoring: 
For each question: no = 0, yes = 1 
0: Non-frail 
1-2: Pre-frail 
3 or more: Frail 
Administration time: several minutes 
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Two studies have examined the diagnostic test accuracy (DTA) of the FRAIL Scale against the 
FP, the first by Braun and colleagues (2018) (Sensitivity: 50.0%, Specificity: 92.0%) and the 
other by Mijnarends et al. (2015) (Sensitivity: 68.4%, Specificity: 96.2%). The studies
indicated that in these contexts the FRAIL Scale performed well at ruling out the presence 
of frailty because of its high specificity, but failed to correctly identify a substantial 
number of those who were frail because of its lower sensitivity. The implication of the low 
FRAIL Scale sensitivity is that a number of true cases of frailty based on FP are likely to be 
missed. 
2.3 Frailty prevalence  
Frailty is common among community-dwelling adults and its prevalence has been estimated 
internationally at 9.9% (weighted mean, range 4% to 17%) based on FP measurement, and at 
13.6% (weighted mean, range 4% to 59%) according to the FI (≥65 years) (Collard et al., 
2012). Frailty prevalencehas been investigated in four Australian cohort studies (Blyth et al., 
2008; Dent, Hoon, et al., 2016; Widagdo, Pratt, Russell, & Roughead, 2015; Wong, 
McCaul, Yeap, Hankey, & Flicker, 2013).  
One South Australian study using 1992 data compared frailty using both the FP and FI, where 
frailty prevalence was reported at 9% (FP) and 18% (FI) (mean age 78.2 [6.7]) (Widagdo et al., 
2015). Two other male studies reported a prevalence of 9% (FP; New South Wales; mean age 
76.9 [5.5]) and 16% (FRAIL Scale; Western Australia; mean age 76.9 [3.8]) (Blyth et al., 
2008; Wong et al., 2013). One recent rural South Australian study looked at individuals ≥65 
years and found a frailty prevalence of 25% (FI; mean age 75.9 [7.9]) (Dent, Hoon, et al., 
2016). The true prevalence of frailty is likely to be higher as  these  studies 
excluded  residents of aged care facilities.  
2.4 Factors associated with frailty
In a systematic review by Feng and colleagues (2017), a range of  sociodemographic, physical 
and psychological factors were found to be associated with frailty in older adults 
across 23 longitudinal studies. Sociodemographic variables associated with frailty included: 
older age, female sex, lower education and lower income. Physical factors included: 
being underweight, obese and demonstrating a higher allostatic load (dysregulation 
across physiological systems). The presence of depression, cognitive impairment 
and poor self-rated health were other key variables associated with increased frailty. The  
largest study included in the review, with 40,657 female participants, by Woods and colleagues 
(2005) identified that older age, the presence of chronic conditions, smoking, depressive 
symptoms, and being underweight and overweight / obese were significantly associated with 
incident frailty (FP), while higher income, moderate alcohol use, living alone, and self-reported 
health were protective factors.
2.5 Trajectory of frailty 
Frailty is a dynamic process and there is growing interest in how frailty changes over time, and 
the factors that are associated with early versus late stage frailty that may be amenable 
to intervention (Espinoza, Jung, & Hazuda, 2012; Fallah et al., 2011; Gill, Gahbauer, 
Allore, & Han, 2006; Lee, Auyeung, Leung, Kwok, & Woo, 2014; Trevisan et al., 
2016). Improvement is possible, with rates of improvement in frailty status ranging from 
6% to 25% (Espinoza et al., 2012; Gill et al., 2006; Lee et al., 2014; Trevisan et 
al., 2016). Improvement typically is a single-step transition to an adjacent state, such as 
from pre-frail to non-frail (Espinoza et al., 2012; Gill et al., 2006; Lee et al., 2014; Trevisan 
et al., 2016). 
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Even so, transition to a worse frailty level is more common than improvement 
(Espinoza et al., 2012; Gill et al., 2006; Trevisan et al., 2016), and remaining in a 
stable frailty state is the most common outcome in longitudinal studies (Gill et al., 
2006; Lee et al., 2014). It is important to note that there are interventions currently 
available to reverse or delay frailty (Puts et al., 2017).  
A range of socioeconomic, clinical, and behavioural factors influences frailty transitions. 
Increased age, cognitive impairment, obesity, the presence of multi-morbidity, lower 
education level, and hospitalisation are risk factors for worsening frailty status (Espinoza et 
al., 2012; Gill, Gahbauer, Han, & Allore, 2011; Lee et al., 2014; Peterson et al., 2009; 
Trevisan et al., 2016), while increased levels of physical activity, female gender, being 
overweight, low alcohol consumption, higher educational level, living alone and fewer 
baseline deficits increase the likelihood of improved frailty (Hubbard, Fallah, Searle, 
Mitnitski, & Rockwood, 2009; Lee et al., 2014; Peterson et al., 2009; Trevisan et al., 2016) 
2.6 Frailty outcomes 
2.6.1 Mortality 
The relationship of frailty with mortality has been examined in a number of systematic 
reviews of longitudinal studies, which have determined that those classified as frail by 
either the FP or FI have a greater risk of mortality when compared to non-frail 
individuals (Chang & Lin, 2015; Kojima, Iliffe, & Walters, 2018; Shamliyan, Talley, 
Ramakrishnan, & Kane, 2013; Vermeiren et al., 2016). Pooled odds ratios for increased 
mortality risk range between 2.58 for the FP and 1.85 for the FI (Vermeiren et al., 2016). 
Frailty has thus been identified as a significant long-term predictor of mortality. However, 
predictive strength is best over a short period of follow-up (Shamliyan et al., 2013), 
potentially due to the dynamic nature of frailty where change is likely over time 
(Kojima et al., 2018). Furthermore, there is a cumulative effect where the presence of 
an increased number of deficits is associated with greater mortality risk (Kane et al., 2012). 
2.6.2 Other outcomes 
Frailty has also been associated with a range of other adverse outcomes. Frail individuals 
have a greater likelihood for incident disability in activities of daily living (Kojima, 
2017; Vermeiren et al., 2016), increased rates of hospitalisation and nursing home 
admission (Vermeiren et al., 2016; Wang, Shamliyan, Talley, Ramakrishnan, & Kane, 
2013), a greater risk of future falls (Kojima, 2015), and an inverse association with 
quality of life (QOL) (Crocker et al., 2019; Kojima, Iliffe, Jivraj, & Walters, 2016). 
2.7 Frailty and sarcopenia 
Sarcopenia is a skeletal muscle disorder characterized by loss of muscle mass and function 
(Cruz-Jentoft & Sayer, 2019). Increasingly, frailty and sarcopenia are being examined together, 
as these conditions share features in common, in particular in relation to lower lean mass and 
physical function (Cesari et al., 2014). Internationally, sarcopenia prevalence has been 
estimated at 10% in adults aged ≥60 years (Shafiee et al., 2017), and individuals with 
sarcopenia have significantly higher mortality risk compared with their healthy counterparts 
(Liu et al., 2017). The prevalence of sarcopenia has been previously reported at 6.2% for men 
and 9% for women aged ≥ 65 years in a community-dwelling cohort of older adults (Yu et al., 
2014). 
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While there are various approaches to the measurement and definition of frailty, the European 
consensus definition is most commonly used (Cruz-Jentoft & Sayer, 2019). Using this 
approach, individuals are classified as sarcopenic if both of the following criteria are 
present: weakness and low skeletal muscle mass (SMI). Weakness is defined by either 
gripstrength measured using a hand-held dynamometer and stratified by sex and BMI, 
or through chair rise testing. Low SMI may be calculated using appendicular skeletal 
muscle mass (ASM) measured using dual energy x-ray absorptiometry (DXA), or 
whole body skeletal muscle mass using bioelectrical impedance analysis (BIA) 
(Cruz-Jentoft et al., 2019).  
The prevalence of frailty and sarcopenia in combination has been explored in a small number 
of studies. Mori et al (2019) identified 3.6% of participants in a population of 
Japanese community-dwelling adults (n=331; mean age 71.5 [SD 5.1] years; 72% female) as 
being both frail (using FP approach) and sarcopenic, while Yoshimura and colleagues 
(2019) identified 2.1% as being both frail (FP) and sarcopenic in a Japanese community-
dwelling cohort (n=963; mean age 72.2 [SD 7.6] years; 67% female). This proportion was 
higher (18%, FP) for a Spanish sample of older adults either hospitalised or 
attending a geriatric outpatient clinic (n=444; mean age 77.3 [SD 8.4] years; 45% 
female) (Bernabeu-Wittel et al., 2019), and for a sample of participants attending a 
Dutch geriatric outpatient clinic (n = 299; mean age 82.4; [SD 7.1] years; 65% female) at 
42% FP and 25% FI (Reijnierse et al., 2016). 
2.8 Comprehensive assessment and management of frailty 
A comprehensive assessment should be used to confirm an individual’s frailty level, identify 
remediable factors, undertake investigations and then institute an appropriate management 
plan (e.g., chronic disease or mental health plan) in collaboration with both the individual and 
their carers. It is possible for some components to be assessed through self-report or via 
other healthcare professionals (e.g., practice nurse) and, as previously mentioned, 
aspects of these assessments can be computed to produce a frailty index score (Theou et al., 
2015).  
Domains that could be regularly assessed in a comprehensive assessment include: 
 Medications
 Continence
 Falls, osteoporosis and fractures
 Syncope or dizziness
 Gait, walk speed, and balance




 Body mass index (BMI), anorexia and nutritional status
 Sensory ability (vision and hearing)
 Presence of pain
 Physical activity level
 Presence of chronic diseases (e.g., arthritis, cerebrovascular disease, cardiovascular
disease, diabetes, respiratory disease, renal disease, anaemia)
 Blood pressure (i.e., postural hypotension or hypertension), heart rate and rhythm (i.e.,
atrial fibrillation)
 Immunisation status
 Social support and transport
 Advance care directives 16
2.8.1 Comprehensive geriatric assessment (CGA) 
The comprehensive geriatric assessment (CGA) is a multidimensional holistic assessment 
of the health and wellbeing of the older person, which results in a management plan to 
address issues that have been identified (British Geriatrics Society, 2019). Typically, this 
covers the assessment domains of physical function, social and physical environment, 
psychological components, and medication review. In addition, the goals and preferences of 
the individual are taken into account to ensure that the management plan is personalised 
and person-centred. CGA has been found to benefit older adults in terms of minimising 
adverse outcomes when applied across both community and acute care settings (Ellis, 
Whitehead, Robinson, O’Neill, & Langhorne, 2011; Garrard, Cox, Dodds, Roberts, & Sayer, 
2019). 
2.8.2 75+ Health Assessment 
In the Australian context, the Medicare Benefits Schedule (MBS)-funded 75+ Health 
Assessment is an ideal framework in which to comprehensively assess an individual’s 
frailty status in the primary care setting (Department of Health, 2019b). A range of 
MBS item numbers can be used to comprehensively assess an individual, confirm their 
frailty level, identify remediable factors, undertake investigations, and then institute 
an appropriate management plan (e.g., chronic disease or mental health plan) in 
collaboration with patients and carers. These items include:  
 75+ health assessment (MBS items: 705 / 707)
 GP management plan and review (MBS item: 721)
 coordination of team care arrangements (MBS item: 721)
 medication review (MBS item: 900)
 referral for geriatrician assessment (MBS item: 141)
Another source of comprehensive assessment of older adults in Australia is through the 
Aged Care Assessment Program (Department of Health, 2019a). One of the aims of this 
program is to assess older adults’ support needs and eligibility for access to subsidised aged 
care services, as well as to locate and access these services. The assessments are designed to 
be holistic, and incorporate physical, medical, psychological, cultural, social, 
environmental and wellness dimensions of ageing. 
2.9  Frailty intervention 
Two systematic reviews which examined interventions aimed at reversing frailty, by Puts et al 
(2017) (12 RCTs and 2 cohort studies) and Apostolo et al (2018) (21 RCTs) respectively, 
identified the strongest evidence in favour of exercise and nutrition interventions. While 
findings for comprehensive geriatric assessment (CGA) have been mixed, the landmark 
Australian Frailty Intervention Trial (FIT) of Cameron and colleagues (2013), which used 
CGA principles to underpin assessment and intervention, demonstrated a 14.7% lower 
prevalence in the intervention group. The intervention, delivered over 12 months, was both 
multidisciplinary and multifactorial (nutrition, exercise, psychological treatment, social 
linkage, and equipment) and was tailored to frailty (FP) characteristics identified at baseline.  
A tailored approach to monitoring and intervention is recommended depending on the 
stage of frailty progression (Sternberg, Wershof Schwartz, Karunananthan, Bergman, & 
Mark Clarfield, 2011). Robust individuals would benefit from prevention strategies  
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focused on minimising risk factors such as hypertension, smoking, cholesterol, and 
ensuring vaccinations are up-to-date; while pre-frail individuals may require prevention 
strategies, such as chronic disease management, geriatric assessment, falls prevention; 
and for frail individuals, rehabilitation, geriatric management, symptom management, 
and strategies to maintain function and quality of life, including rehabilitation 
(Sternberg et al., 2011). Some of these strategies will involve linking patients to 
relevant allied health and support services, local gyms, pharmacy, geriatricians, and 
geriatric outpatient services. For frail patients who are approaching end of life, a 
discussion on the goals of care is also required, considering advanced care directives, 
supportive and palliative care, and a transition from active treatment to comfort care 
(Cardona-Morrell et al., 2017).  
When planning frailty interventions, older adults should be engaged in setting goals based on 
the needs that are most important to them (Theou & Rockwood, 2012). As most 
frailty interventions require some form of behaviour change, using the principles of 
motivational interviewing and working collaboratively with patients is critical for success 
(Rollnick, Miller, & Butler, 2008). 
It is important to note that a number of the interventions described to treat frailty are likely 
to have a complementary benefit for sarcopenia, particularly exercise in combination with 
other strategies, such as protein supplementation (Dent et al., 2018; Puts et al., 2017). 
2.9.1 Physical activity and nutritional status 
Exercise and nutritional strategies (especially increasing protein intake) are critical in 
the prevention and treatment of frailty (Puts et al., 2017). Older people are keen to know 
more about exercise, but, importantly, have expressed a desire to be kept informed and 
encouraged by their GP (Jadczak, Dollard, Mahajan, & Visvanathan, 2017). Exercise 
interventions, in addition to improving frailty status, also have positive effects on falls 
reduction, balance, mobility, mood, and functional ability (de Labra, Guimaraes-Pinheiro, 
Maseda, Lorenzo, & Millan-Calenti, 2015).  
Group exercise programs can provide opportunities for socialisation, which has its 
own beneficial effects, as well as contributing to exercise adherence (Farrance, Tsofliou, & 
Clark, 2016). Exercise programs for addressing frailty should ideally be multi-component, 
involving a combination of resistance, balance, and flexibility (Jadczak, Makwana, 
Luscombe-Marsh, Visvanathan, & Schultz, 2018). Strength training is emphasised as a key 
component of exercise (Puts et al., 2017). Online exercise prescribing resources are available 
to aid decision making (Exercise is Medicine Australia, 2018). 
As nutrition is an important factor in the pathophysiology of frailty, it also has a role in 
its treatment (Cruz-Jentoft, Kiesswetter, Drey, & Sieber, 2017). It is recommended that 
the optimal daily protein intake for older people should be at least 1.0-1.2 g/kg/day (Baum, 
Kim, & Wolfe, 2016), with an increase to 1.2-1.5g/kg/day in those who are unwell or have a 
chronic disease (including dialysis) (Bauer et al., 2013). Protein intake should be <0.8g/kg/
day and for those with moderate kidney disease, however, protein intake can be > 0.8 g/kg/day 
with regular monitoring of glomerular filtration rate (GFR) required for those with GFR 
>30 but <60 mL/min/1.73m2 (Bauer et al., 2013). There is evidence to recommend protein 
supplementation in combination with exercise to reduce the progression of frailty (Kim & 
Lee, 2013), and to improve frailty status, muscle strength and mobility in older adults (Liao et 
al., 2018). The Asia Pacific clinical practice guidelines for the management of 
frailty support protein supplementation, particularly in combination with physical 
activity, for frail individuals demonstrating unintentional weight loss (Dent et al., 2017). 
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2.9.2 Medication regime 
Strategies to minimise polypharmacy are an important component of the medical management 
of older adults who are both frail or at risk of becoming frail, and medications with an 
anticholinergic effect (e.g., antihistamines, tricyclic antidepressants, major tranquilisers, old 
and atypical antipsychotics, and antimuscarinics for urinary incontinence) have been 
specifically highlighted as being associated with frailty after adjusting for polypharmacy in 
general (Gnjidic et al., 2012, Page et al., 2016).  
The Asia-Pacific Clinical Practice Guidelines for the Management of Frailty (Dent et al., 2017) 
strongly recommend that polypharmacy be addressed by reducing or de-prescribing any 
inappropriate and / or superfluous medications. Guidelines for depresribing, such as the 
Screening Tool of Older Person’s Prescriptions (STOPP) criteria (Hamilton et al., 2011), and 
the 2015 updated Beers Criteria can be used to support this strategy. 
2.10 Gaps in scientific knowledge on frailty and rationale for this thesis 
This section describes gaps in the scientific literature on frailty and the rationale for each of 
the studies included as chapters in this thesis. Internationally, there is a large and growing 
body of research focused on frailty prevalence and outcomes (Collard et al., 2012; 
Shamliyan et al., 2013; Vermeulen et al., 2011). However, at the time of commencement of 
this PhD, there were a limited number of population-level studies that had investigated 
frailty in the Australian context (Blyth et al., 2008; Dent, Hoon, et al., 2016; Widagdo et al., 
2015; Wong et al., 2013). Frailty prevalence was the focus of the research reported in Chapters 
4 and 5. 
2.10.1 Frailty measurement 
While there has been some comparison of the two dominant approaches to frailty 
measurement internationally (Blodgett et al., 2015), to date there has been no examination of 
the FP and FI together in an Australian cohort. Likewise, the dynamic nature of frailty has 
been examined in several international and Australian cohorts, which used single measures 
to examine frailty state transitions (Kojima, Taniguchi, Iliffe, Jivraj, & Walters, 2019). 
However, no study has compared frailty state transitions and factors associated with 
transition for both the FP and FI in the same cohort. Given the lack of consensus as to 
which assessment method is the gold standard, the research in this PhD describes findings 
according to both forms of measurement. These topics are the focus of research reported in 
Chapters 5 and 6. Understanding which factors pose different risks for frailty transition at 
different stages of the frailty process, for each model of frailty measurement, can support a 
tailored approach in targeting intervention to vulnerable individuals.
Repeated assessment. Clinicians and policy makers increasingly recognise the need for 
assessing the frailty status of their older patients (Theou & Rockwood, 2012), while 
balancing this against the burden to clinicians and consumers of repeated assessment. The 
dynamic nature of frailty means that a single assessment of frailty status may not reflect the 
changing frailty risk profile of individuals over time, and that regular review would be of 
benefit in order to offer appropriate interventions. While both approaches to frailty 
measurement have strong predictive validity for mortality, disability and other adverse health 
outcomes (Shamliyan et al., 2013; Vermeulen et al., 2011), the predictive ability of 
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repeated frailty measurement on mortality is yet to be determined and therefore, the benefit 
of a regular review of frailty status over time is yet to be established. This observation has 
been addressed through the research described in Chapter 8. 
2.10.2  Screening for frailty 
Primary care is a key setting for frailty identification as it is typically the first point of contact 
for older adults with the health system (Cesari et al., 2016; Dent, Kowal, et al., 2016; Morley et 
al., 2013). In the time-poor environment of clinic and general practice, there is a need for 
screening tools that are accurate and quick to administer. Screening for frailty using self-report 
instruments is a potential strategy for reducing the clinical resources required to screen for this 
condition (Pialoux et al., 2012). There is a wide range of potential screening instruments (Dent, 
Kowal, et al., 2016), a number of which have diagnostic test accuracy (DTA) estimates 
reported. However, at the beginning of the research reported here, there was yet to be a 
systematic review to examine the DTA of self-reported screening instruments for frailty against 
the FP or FI reference standard. Chapter 7 presents the results of such a review conducted for 
this study. 
In light of a call for the use of the FRAIL Scale as a screening instrument in Australia (Burgess 
& Hercus, 2017), it must be remembered that no study has yet reported on this instrument’s 
predictive validity for mortality in an Australian cohort of both men and women. A recent 
systematic review of the FRAIL Scale reported that while there is preliminary evidence for the 
predictive validity for mortality of the instrument, more studies are warranted to examine the 
properties of this tool (Kojima, 2018). Further research is required into the applicability of this 
instrument in the Australian context, which is why this topic was addressed in this research, as 
reported in Chapter 10. 
2.10.3 Sarcopenia 
Frailty may also be occur with sarcopenia (Cesari et al., 2014). The two conditions share 
similar features and both are associated with increased mortality risk (Liu et al., 
2017; Shamliyan et al., 2013). The relationship between the two conditions has been 
examined in a limited number of studies internationally, particularly at population level 
(Mori & Tokuda, 2019; Yoshimura et al., 2019). Despite their shared characteristics, and 
individually each being associated with increased mortality, there has been no study which has 
examined the combined presence of frailty and sarcopenia and association with mortality.  
A better understanding of how these two conditions interact would provide useful information 
on prognosis and prioritising treatment for individuals with either or both conditions. This is 
important as there are interventions available that may delay the development and progression 
of frailty, such as exercise focused on strength training, increasing nutritional intake, 
particularly protein, reducing polypharmacy, and increasing vitamin D levels (Andrew Clegg et 
al., 2013; Puts et al., 2017). The relationship between frailty and sarcopenia is examined in 
Chapter 9. 
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2.10.4  Health-state utility of frailty 
Frailty is associated with lower quality of life (QOL) (Crocker et al., 2019; Kojima et al., 
2016). QOL can be represented in terms of preference-based health-state utilities, which reflect 
preferences that individuals or groups place on a set of health outcomes (Drummond, Sculpher, 
Torrance, O'Brien, & Stoddart, 2005). Health-state utilities range between 1 (perfect health) 
and 0 (death) and are used in evaluating the comparative effectiveness of health interventions 
(Drummond et al., 2005). Despite a range of studies describing the association between frailty 
and QOL at a population level (Crocker et al., 2019; Kojima et al., 2016), there have been no 
population level estimates using preference-based measures of health-state utility, which can be 
used in health economic evaluation of frailty interventions (Neumann, Goldie, & Weinstein, 
2000). Drawing utility data from a range of sources, particularly cohort surveys, is an 
important component of economic evaluation, particularly when coupled with health-state 
transition data as it improves the reliability and generalisability of estimates (Drummond et al., 
2005; Neumann et al., 2000). Chapter 11 addresses the topic of frailty health-state utility. 
2.10.5  Frailty: Minimally important difference 
A challenge remains for clinicians and researchers in interpreting statistically significant 
improvement in frailty status when examining frailty interventions; namely, what level of 
incremental change in condition is sufficient to be considered clinically meaningful? 
Minimally important difference (MID) is the smallest change in a treatment outcome which an 
individual would perceive as being important, and can assist with the understanding of how 
much change associated with an intervention is important to health consumers (Wyrwich et al., 
2005). At the beginning of this research, no studies had yet published frailty MID findings for 
either the frailty phenotype (FP) or frailty index (FI). MID may be useful in providing a patient 
perspective that informs clinical decision making regarding the effectiveness of frailty 
interventions (Sloan, Cella, & Hays, 2005). Frailty MID estimates are the focus of Chapter 11. 
2.11 Summary 
In summary, frailty is common among older adults, and despite being associated with adverse 
health outcomes, is a dynamic condition where interventions are available to prevent, delay or 
slow its progression. The primary care setting is ideally suited to the identification and 
management of frailty, and a range of quick and easy to administer screening instruments is 
available as the starting point in a stepwise process of more detailed assessment which may 
result in comprehensive management. However, a challenge facing clinicians is the differing 
approaches to frailty measurement (the FP and FI), and the wide variety of frailty screening 
instruments available. When assessing for frailty, it is important to also consider the presence 
of sarcopenia which has shared features with frailty, particularly weakness and slowness. 
Efforts to improve frailty status or maintain healthy ageing are likely to result in improved 
quality of life.  
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Chapter 3 
Research cohort profile 
This chapter provides background information on the research cohorts used in the studies that 
are described in the chapters that follow.   
3.1  North West Adelaide Health Study (NWAHS) 
The studies comprising each chapter of this thesis (with the exception of Chapters 1, 2 and 12, 
and Chapter 4, which included additional population cohorts) were a secondary analysis of 
data from the North West Adelaide Health Study (NWAHS), a population representative 
longitudinal study of 4060 men and women aged ≥18 years (Grant et al., 2009).  
All households in the North West of metropolitan Adelaide (see Figure 3.1, reproduced from 
Melaku et al [2019]) with a listing in the Electronic White Pages telephone directory were 
eligible for study selection. Households were randomly selected, and within each household the 
person who had the most recent birthday and was aged ≥18 years was invited to participate. 
Participants were interviewed by phone, attended a clinic for a biomedical examination, and 
completed a written questionnaire. Individuals unable to answer questions in English at the 
initial recruitment stage were excluded from the study, as were individuals living in residential 
institutions, such as nursing homes. For Stage 1 4060 males and females aged ≥18 years were 
recruited to the study (51% female). 
Figure 3.1  Map of the NWAHS study area  (Reproduced from Melaku et al. 2019, p.2) 
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The data collection for Stage 1 occurred between 1999-2003. For Stage 2 data were collected 
between 2004-2006, and for Stage 3 between 2008 and 2010. A phone interview, 
clinic examination, and written questionnaire were repeated for each stage. The probability of 
selection was known, which allowed for weighting of data to the area population. For each stage of 
the study, participants were contacted in approximately the same order to maintain a four year 
follow up time. 
Stage 2 data were used as baseline for all studies included in this thesis to construct both frailty 
measures: the frailty phenotype (FP) and frailty index (FI). Stage 1 weight was used to 
calculate weight loss over four years preceding Stage 2, and likewise Stage 2 weight for weight 
loss over four years preceding Stage 3. Detailed discussion on the method of frailty measurement 
occurs in subsequent chapters. 
Stage 3 data were used to construct both the FP and FI in order to measure the change in frailty 
at follow up. The mean time between baseline and follow up was 4.5 (SD 0.45) years. Information 
on participant mortality was drawn from data matching to official death records. The 
follow-up window for mortality was to a censoring date of 30/9/2016. (There was a minimum of 
10 years of mortality data for all participants.) 
In summary, the NWAHS data collected during Stage 2 (baseline for studies in this thesis) 
included:  
 phone interview:
demographic information; health conditions; health care utilisation; joint pain; falls and
injury; and Centre for Epidemiological Studies Depression Scale (CES-D)
 written questionnaire:
36-Item Short Form Survey (SF-36); exercise; family history of health conditions;
osteoporosis and sequelae; sunlight exposure; diabetes and sequelae; respiratory
function and sequelae; alcohol consumption; smoking; mental health and wellbeing –
General Health Questionnaire-12 (GHQ-12); and demographics.
 clinic measurement:
height and weight; blood pressure; spirometry; grip strength; dual-energy X-ray
absorptiometry (DEXA); and blood and urine analysis.
Data collected during Stage 3 (follow-up for studies in this thesis) included: 
 phone interview:
demographics; health conditions; falls and injury; joint pain; health care utilisation;
exercise; Assessment of Quality of Life (AQOL) instrument; cardiovascular disease and
health literacy; self-reported body measurements; household food habits; household
environment; other members of the household; and early learning
 written questionnaire:
36-Item Short Form Survey (SF-36); carers; family history; diabetes and sequelae;
respiratory function and sequelae; Asthma Control Questionnaire (ACQ); Chronic Lung
Disease (CLD) severity index; alcohol consumption; smoking; sleep quality; Centre for
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Epidemiological Studies Depression Scale (CES-D); Pearlin Mastery Scale; joint pain; 
and cardiovascular disease questionnaire 
 clinic measurement:
height and weight; blood pressure; spirometry; grip strength; and blood and urine
analysis.
Frailty was examined in the NWAHS cohort as it was a local population study that included a 
comprehensive range of assessments that allowed both frailty measures to be quantified together 
with other outcomes of interest such as sarcopenia, quality of life, and mortality. Stage 2 was used 
as baseline rather than Stage 1 as weight loss between these stages was used as a FP variable. 
3.2 DYNOPTA 
The study described in Chapter 4 of this thesis was a secondary cross-sectional analysis of data 
from the Dynamic Analyses to Optimise Ageing Project (DYNOPTA) and the NWAHS. 
DYNOPTA is a pooled dataset of nine Australian longitudinal studies of ageing consisting of: the 
Australian Longitudinal Study of Ageing (ALSA); Australian Longitudinal Study on Women's 
Health (ALSWH); Australian Diabetes and Obesity Survey (AusDiab); Blue Mountains Eye Study 
(BMES); Canberra Longitudinal Study (CLS); Household, Income and Labour Dynamics of 
Australia (HILDA); Melbourne Longitudinal Study Healthy Ageing (MELSHA); Personality and 
Total Health through life (PATH); and the Sydney Older Person's study (SOPS) (Anstey et al., 
2010) (Figure 2). 
DYNOPTA included 50,652 baseline participants (wave 1 of each study between 1990 and 
2001). Of these, 39 085 (77.2%) were female. The pooled DYNOPTA dataset consisted of :
 demographic information








For DYNOPTA studies to be included in the Chapter 4 analysis, the single phases of each study 
had to have been conducted between 2004 and 2006, with variables available to construct the FP. 
There were three studies in DYNOPTA which met the criteria for inclusion–the Australian 
Longitudinal Study of Women’s Health Old Cohort (ALSHW-old) (Lee et al., 2005); Australian 
Diabetes and Obesity Lifestyle Study (AusDiab) (Dunstan et al., 2002); and the Blue Mountains 
Eye Study (BMES) (Attebo, Mitchell, & Smith, 1996; Mitchell et al., 1998). 
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Figure 3.2  Locations of contributing Australian Longitudinal Ageing Studies, 
Reproduced from Anstey et al (2009) p4. 
Participants included in our secondary analysis were community-dwelling, aged ≥65 years, and had 
at least three valid responses to the five potential frailty variables. Participants from DYNOPTA 
studies living in residential care facilities and those with missing information regarding 
community or residential status were excluded from this study. Frailty was not measured directly 
in any of the cohorts; however, it was operationalised using a modification of the FP and is 
descriibed in detail in chapter 4. All data was collected regardless of age.
We decided to examine frailty in DYNOPTA as the combination of population level studies 
from across Australia was useful for reporting frailty prevalence in Australia. The cohort 
profiles included DYNOPTA studies are discussed below. 
3.2.1  Australian Longitudinal Study of Women’s Health Old Cohort 
(ALSHW-old) 
The ALSHW-old is a national population-based sample of women aged 70-75 years living 
in both the community and residential care (Lee et al., 2005). Participants were randomly 
selected from the database of the Health Insurance Commission (HIC) that runs Medicare, 
the national health insurance scheme. Sampling from the population was random; however, 
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women living in rural  and remote areas were sampled at twice the rate of those living in urban 
areas. Surveys were posted to potential participants with information packs inviting participation. 
The postal survey measured:  
 36-Item Short Form Survey (SF-36)
 Center for Epidemiologic Studies Depression Scale (CES-D)
 measures of social support and neighbourhood satisfaction
 demographics
 health behaviours
 diagnoses and symptoms
 health service utilisation
 stress
 life events.
3.2.2  Australian Diabetes and Obesity Lifestyle Study (AusDiab) 
The AusDiab is a national population-based sample of community-dwelling men and women aged 
≥25 years; (Dunstan et al., 2002). A cluster sampling method was used based on a random 
selection of six census collector districts, which are the smallest geographic units defined by the 
Australian Bureau of Statistics at each census, consisting of an average of 225 dwellings each. All 
private dwellings within the cluster received a letter inviting participation. An interviewer visited 
each household and conducted an interview with every resident who met the eligibility 
requirements. The interviewer collected information on demographics and any history of diabetes.  
Participants then attended a local testing site for a biomedical examination of individuals’ physical 
features, including height, weight, blood pressure, ECG; fasting blood measurements; and urine 
measurement. Participants also completed a self-administered questionnaire, consisting of a 36-
Item Short Form Survey (SF-36) and questions about general health and wellbeing. For the 
purposes of this study, we only included participants aged ≥65 years. 
3.2.3  Blue Mountains Eye Study (BMES) 
The BMES is a population-based sample of community-dwelling men and women in New South 
Wales aged ≥49 years (Attebo et al., 1996; Mitchell et al., 1998). Participants living in two 
postcode areas to the west of Sydney (Katoomba, Leura, Medlow Bath (postcode 2780) and 
Wentworth Falls (postcode 2782) were recruited through a door-to-door census. All permanent 
residents who were not living in residential care were invited to attend a clinic examination. The 
examination consisted of an assessment of eye conditions, and general health status, diet, family 
history, fasting blood tests, hearing assessment, tests of memory and cognition (mini mental state 
examination), and quality of life (the 36-Item Short Form Survey [SF-36]).  
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Chapter 4 
Frailty prevalence in Australia:  
Findings from four pooled Australian cohort studies 
Frailty prevalence in Australia: Findings from four pooled Australian cohort studies was 
published in the Australasian Journal of Gerontology. The statement of authorship and paper (.pdf) 
follow over the page. 
This article, together with the article in Chapter 5, were the subject of an invited commentary on 
frailty in the same journal issue by Vasikaran Naganathan (2018). The results from this study were 
used as the basis for analysis in a publication by Taylor and colleagues (2019) which examined 
geospatial modelling of the prevalence and changing distribution of frailty in Australia.
4.1 Summary of the study 
Objectives: To examine the prevalence of frailty in Australian older adults. 
Methods: Frailty was measured using a modified Fried frailty phenotype (FFP) in a combined 
cohort of 8804 Australian adults aged ≥65 years (female 85.6%, median age 80 [79-82] years) 
from the Dynamic Analyses to Optimise Ageing Project (DYNOPTA) and the North West 
Adelaide Health Study (NWAHS). 
Results: Using the FFP, 20.5% of participants were identified as frail, while a further 47.9% 
were pre-frail. Chi square testing of frailty among four age groups (65-69, 70-74, 75-79, and 
80-84 years) for sex and marital status revealed that frailty was significantly higher for females
(approximately double that of men), increased significantly with advancing age for both sexes,
and was significantly higher for women who were widowed, divorced or never married.
Conclusions: If frailty could be prevented or reversed it would have an impact on a larger 
number of older people. 
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Objective: To examine frailty prevalence in Australian
older adults.
Methods: Frailty was measured using a modified Fried
Frailty Phenotype (FFP) in a combined cohort of 8804
Australian adults aged ≥65 years (female 86%, median age
80 (79–82) years) from the Dynamic Analyses to Optimise
Ageing Project and the North West Adelaide Health Study.
Results: Using the FFP, 21% of participants were frail
while a further 48% were prefrail. Chi-squared testing of
frailty among four age groups (65–69, 70–74, 75–79 and
80–84 years) for sex, and marital status revealed that
frailty was significantly higher for women (approximately
double that of men), increased significantly with advancing
age for both sexes, and was significantly higher for women
who were widowed, divorced or never married.
Conclusion: If frailty could be prevented or reversed, it
would have an impact on a larger number of older people.
Policy Impact: Population studies show a high
prevalence of frailty. The challenge for researchers in
this field is to find effective and practical interventions
that can reverse and/or prevent frailty.
Key words: Australia, cohort studies, epidemiologic
measurements, frail older adults, prevalence.
Introduction
Frailty is a state of decreased physiological reserve in
which individuals are more vulnerable to stressors and at
greater risk of adverse health outcomes such as falls,
fracture, hospitalisation and loss of independence [1].
There are two approaches commonly used to describe
frailty: The Fried Frailty Phenotype (FFP) and the cumu-
lative deficits approach. The former views frailty as a
physiologic syndrome which is present when three or
more of the following deficits are present: Unintentional
weight loss, self-reported exhaustion, slow walk speed
and low physical activity [2]. The latter approach defines
frailty as a multidimensional risk state based on the pro-
portion of potential deficits present in the individual,
with a higher proportion representing a higher level of
frailty [3]. Both approaches have been shown to have
strong predictive validity for mortality, disability and
other adverse health outcomes [4,5]. Individuals classified
as prefrail also have an elevated but intermediate risk of
adverse outcomes [2]. Regardless of the approach used in
measurement, it is important to note that frailty is a
dynamic process where individuals are capable of transi-
tioning to lesser states of frailty, particularly those who
are prefrail [6,7]. Furthermore, interventions such as
exercise in combination with other strategies may delay
the development and progression of frailty; however,
there is not yet consensus among researchers on the ideal
approach [1,8].
Internationally, pooled measurements of frailty prevalence
for both men and women have been identified at
between 10 and 14% using the FFP [4,9]. Frailty preva-
lence is known to increase with age, is higher among
women, and is associated with social vulnerability [4,10].
Frailty has been examined in Australia using various
frailty methods [11,12]; however, the FFP is the most
commonly used frailty scale internationally [13]. No Aus-
tralian study has pooled data from Australian cohort
study data sets to determine frailty prevalence in men
and women.
The aim of this study was to examine frailty point preva-
lence using the FFP in Australian adults aged ≥65 years
from the Dynamic Analyses to Optimise Ageing Project
(DYNOPTA) and the North West Adelaide Health Study
(NWAHS).
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This study was a secondary cross-sectional analysis of data
from the DYNOPTA, a pooled data set of nine Australian
longitudinal studies of ageing (data from three studies
used), and the NWAHS, a population-based sample of
community-dwelling adults aged ≥18 years living in the
north-western metropolitan area of Adelaide [14,15]. The
studies contributing to the DYNOPTA data set for this
study included the following: The Australian Longitudinal
Study of Women’s Health Old Cohort (ALSWH-old), a
national population-based sample of women aged 70–
75 years living in both the community and residential care;
the Australian Diabetes and Obesity Lifestyle Study (Aus-
Diab), a national population-based sample of community-
dwelling men and women aged ≥25 years; and the Blue
Mountains Eye Study (BMES), a population-based sample
of community-dwelling men and women in New South
Wales aged ≥49 years [14].
Data were drawn from single phases of each study con-
ducted between 2004 and 2006. In this secondary analysis,
participants included in the study were community-dwelling,
aged ≥65 years and had at least three valid responses to the
five potential frailty variables. Data from six DYNOPTA
studies were not able to be included in our analysis as vari-
ables were not measured to construct the FFP or data collec-
tion was out of the date range. Frailty was not measured
directly in any of the cohorts; however, it was opera-
tionalised using a modification of the FFP (Table 1) [2]. The
recruitment and follow-up of participants are described else-
where [14,15]. Participants from DYNOPTA studies living
in residential care facilities (n = 99) and those with missing
information regarding community or residential status (n =
67) were excluded from this study.
Individuals with three or more criteria were classified as
frail, those with one and two criteria as prefrail, while
those with no deficits were considered not frail [2]. It is
common for studies to make more than one modification
to the FFP, particularly when using existing data to opera-
tionalise frailty and to use only self-reported items [16].
Approximately 88% of studies which use the FFP modify
at least one criterion [16]. The modified frailty criteria used
in this study were developed according to the availability
of variables across the multiple data sets and that the mod-
ifications had been used previously in other published stud-
ies [16].
Data were analysed using IBM SPSS Statistics 23 software.
Descriptive characteristics were reported as percentages.
Subgroup analysis of frailty prevalence was determined for
sex, age groups (65–69, 70–74, 75–79 and 80–84 years)
and marital status, due to the known association between
these factors and frailty [4,10]. Chi-squared testing of sta-
tistical significance between subgroups was measured using
an alpha value of 0.05. Weighting of results was not per-
formed due to the combination of multiple cohorts.
Results
This study included 8804 participants aged ≥65 years (me-
dian age 80 (79–82) years, female = 86%). The breakdown
of participants by individual studies was as follows:
NWAHS (n = 944, mean age 74.0 (6.4), female 51%);
ALSWH-old (n = 6131, mean age 80.8 (1.4), female
100%); AusDiab (n = 1634, mean age 73.0 (6.0), female
52%), and BMES (n = 95, mean age 76.3 (7.1), female
68%).
Frailty prevalence is reported in Table 2. Using the FFP,
21% of participants were classified as frail while a further
48% were prefrail. Frailty prevalence ranged from 6% in
AusDiab to 26% in ALSWH–old. Frailty was significantly
higher for women (P < 0.001), increased significantly with
Table 1: Fried Frailty Phenotype: Comparison of original and modified version used in Dynamic Analyses to Optimise
Ageing Project and North West Adelaide Health Study
Item Original phenotype Modified phenotype
Weight loss Unintentional weight loss of ≥10 pounds in prior year or at
follow-up, of ≥5% of body weight in prior year (by direct
measurement of weight)
BMI <21 kg/m2. Clinic measurement
Weakness Grip strength (kg) measured using dynamometer in the lowest
20% at baseline adjusted for sex and BMI. Cut points stratified by sex
and BMI
Reporting health limits lifting or carrying groceries ‘a lot’ from
the SF36
Exhaustion Two questions used from the CES–D Scale. How often in the last week
did you feel:
(i) I felt that everything I did was an effort; and (ii) I could not get going
Scoring: Rarely or none (0), some or a little (1), moderate (2), most (3).
Deficit present when answering ‘2’ or ‘3’ to either question
Responding to the question ‘during the past four weeks did you
feel worn out?’ with ‘good bit, most or all’
Slowness The slowest 20% of the population based on time to walk 15 feet,
adjusting for sex and height
Reporting that health limits walking 100 m either ‘a little’ or ‘a
lot’ from the SF36
Low activity Minnesota Leisure Time Activity Questionnaire. Kilocalories per week
stratified by sex. Men <383 kcal per week, women <270 kcal per week
Reporting no walking for sport, recreation or fitness in the last
two weeks
BMI, body mass index; CES-D, Centre for Epidemiologic Studies Depression; SF36, 36-item Short Form Survey.
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older age groups (P < 0.001), and was significantly higher
for those widowed, divorced or never married (P < 0.001).
When stratified by sex, frailty was significantly associated
with older age groups for both men (P < 0.001) and
women (P < 0.001); however, being widowed, divorced or
never married was associated with higher frailty prevalence
for women only (P = 0.008). For those classified as frail
(n = 1807), the most common deficits present were slow-
ness (n = 1693, 94%), followed by low physical activity (n
= 1645, 91%), weakness (n = 1120, 62%), exhaustion (n =
661, 37%) and weight loss (n = 351, 19%).
Discussion
Based on our study of pooled data from four Australian
longitudinal studies on ageing, 21% of participants were
identified as frail, with a further 48% as prefrail. The
prevalence of frailty in women was approximately double
that seen in men across all age groups, and as expected,
the prevalence of frailty increased significantly with
increasing age. The prevalence of frailty in this sample is
substantially higher than has been reported previously in
Australian studies [17,18]. Frailty was significantly higher
in our study for women who were divorced, widowed or
never married compared to their married or de facto coun-
terparts. A range of social vulnerability variables, including
being divorced or widowed, have been previously identified
with increased frailty [10].
The higher prevalence in this study is most likely due to
the large proportion of female participants, who are known
to have higher rates of frailty than men [9]. Also, using a
modified FFP consisting of self-report items may have con-
tributed to a prediction of frailty prevalence 4% higher
than using original criteria [16]. Frailty prevalence in our
study was similar to a systematic review of 24 international
studies where frailty prevalence was 7% for men and 13%
for women, with frailty by age group in women ranging
from 3% for those aged 65–70 years to 31% for those
aged 85–90 [4].
Table 2: Frailty prevalence using the Fried Frailty Phenotype (FFP) and association with demographic variables
Total, n (%) Phenotype categories P-value
Not frail, n (%) Prefrail, n (%) Frail, n (%)
Whole sample 8804 2780 (32) 4217 (48) 1807 (21) —
Study
NWAHS 944 (11) 402 (43) 418 (44) 124 (13) —
ALSWH-old 6131 (70) 1492 (24) 3074 (50) 1565 (26) —
AusDiab 1634 (19) 856 (52) 674 (41) 104 (6) —
BMES 95 (1) 30 (32) 51 (54) 14 (15) —
Sex
Male 1272 (14) 666 (52) 527 (41) 79 (6) <0.001*
Female 7532 (86) 2114 (28) 3690 (49) 1728 (23) —
Age, mean (SD) 78.6 (5) 76.7 (6) 79.0 (5) 80.4 (3) —
Age, median (IQR) 80 (79–82) 79 (72–81) 80 (79–82) 81 (79–82) —
Age groups, years†
65–69 905 (10) 521 (58) 343 (38) 41 (5) <0.001*
70–74 696 (8) 362 (52) 286 (41) 48 (7) —
75–79 2076 (24) 659 (32) 1044 (50) 373 (18) —
80–84 4990 (57) 1205 (24) 2468 (50) 1317 (26) —
Marital status‡
Married/De facto 4042 (46) 1436 (36) 1895 (47) 711 (18) <0.001*
Divorced/Widowed/Never married 4702 (53) 1329 (28) 2287 (49) 1086 (23) —
Stratified by sex
Age groups (male), years†
65–69 427 (34) 256 (60) 159 (37) 12 (3) <0.001*
70–74 331 (26) 188 (57) 130 (39) 13 (4) —
75–79 274 (22) 123 (45) 129 (47) 22 (8) —
80–84 172 (14) 76 (44) 72 (42) 24 (14) —
Age groups (female), years†
65–69 478 (6) 265 (55) 184 (39) 29 (6) <0.001*
70–74 365 (5) 174 (48) 156 (43) 35 (10) —
75–79 1802 (24) 536 (30) 915 (51) 351 (20) —
80–84 4818 (64) 1129 (23) 2396 (50) 1293 (27) —
Marital status (male)‡
Married/De facto 990 (78) 528 (53) 408 (41) 54 (6) 0.174
Divorced/Widowed/Never married 259 (20) 130 (50) 107 (41) 22 (9) —
Marital status (female)‡
Married/De facto 3052 (41) 908 (30) 1487 (49) 657 (22) 0.008*
Divorced/Widowed/Never married 4443 (59) 1199 (27) 2180 (49) 1064 (24) —
*P < 0.05 (chi-squared test; main effects only reported). †Participants aged ≥85 years excluded from age group analysis due to small sample size (males n = 70, females n = 75). ‡Not
stated or missing not included. Fried Frailty Phenotype cut points for number of deficits: 0 = not frail, –, Not reported; 1–2 = prefrail, ≥3 = frail. —, Not reported; ALSWH-old, Australian
Longitudinal Study of Women’s Health Old Cohort; AusDiab, Australian Diabetes and Obesity Lifestyle Study; BMES, Blue Mountains Eye Study; IQR, interquartile range; NWAHS, North West
Adelaide Health Study; SD, standard deviation.
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Modifications to the FFP are common across studies in
order to make use of available variables, but can result in
substantial differences to frailty prevalence [16]. The modi-
fication of the five phenotype variables was a limitation of
this study, and the findings should be considered in this
light. These specific five criteria used in combination have
not been validated. The prevalence reported here is likely
an underestimate of frailty in the total population as older
adults living in residential aged care or those unable to par-
ticipate in clinic assessments were not included. The use of
the phenotypic method rather than the deficit accumulation
method is also likely to have resulted in a lower prevalence
[1]. As our study was a secondary analysis of four pooled
studies, we were unable to report on other descriptive char-
acteristics of the sample due to differences in measurement
of these variables between each study. Despite the limita-
tions outlined above, this is the largest study to examine
frailty prevalence in Australia to date.
Conclusion
Currently, with more than 3 million Australian adults aged
65 and over, at least 700 000 may be frail and a further
1.6 million prefrail. By 2031, 5.7 million Australians will
be aged 65 years and older [19]. By then, the number
of frail older adults may be 1.2 million with a further 2.7
million prefrail if the prevalence is unchanged. If an inter-
vention was to reduce the onset of frailty by just 5% [8],
there could be 370 000 less frail older people in our society
by 2031, thus potentially reducing the health and aged care
cost burden [20].
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Chapter 5 
Frailty prevalence and factors associated with the frailty phenotype and 
frailty index. Findings from the North West Adelaide Health Study 
Frailty prevalence and factors associated with the frailty phenotype and frailty index. 
Findings from the North West Adelaide Health Study was published in the Australasian 
Journal of Gerontology. This article, together with the article which comprises Chapter 4, were the 
subject of an invited commentary on frailty in the same journal issue by Vasikaran Naganathan 
(2018). The statement of authorship and paper (.pdf) follow over the page. 
Additional table(s) and/or figure(s) are provided in the Supplementary material for Chapter 5. 
5.1 Summary 
Objectives: To determine the prevalence of frailty and associated factors in the North West 
Adelaide Health Study (2004-06) using the frailty phenotype (FP) and frailty index (FI). 
Methods: Frailty was measured in 909 community dwelling participants aged ≥65 using the FP 
and FI. 
Results: The FP classified 18% of participants as frail, and the FI 48%. The measures were 
strongly correlated (r = 0.76, p < 0.001) and had a kappa agreement of 0.38 for frailty 
classification, with 37% of participants classified as non-frail by the FP being classified as frail 
by the FI. Being older, a current smoker, and having multimorbidity and polypharmacy were 
associated with higher frailty levels by both tools. Female, low income, obesity, and living 
alone were associated with the FI. 
Conclusions: Frailty prevalence was higher when assessed using the FI. Socioeconomic factors 
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Objective: To determine the prevalence of frailty and
associated factors in the North West Adelaide Health
Study (2004–2006) using the Frailty Phenotype (FP) and
Frailty Index (FI).
Methods: Frailty was measured in 909 community-
dwelling participants aged ≥65 years using the FP and FI.
Results: The FP classified 18% of participants as frail and
the FI 48%. The measures were strongly correlated (r =
0.76, P < 0.001) and had a kappa agreement of 0.38 for
frailty classification, with 37% of participants classified as
non-frail by the FP being classified as frail by the FI. Being
older, a current smoker, and having multimorbidity and
polypharmacy were associated with higher frailty levels by
both tools. Female, low income, obesity and living alone
were associated with the FI.
Conclusion: Frailty prevalence was higher when assessed
using the FI. Socioeconomic factors and other health
determinants contribute to higher frailty levels.
Practice Impact: It is important to be aware that there
is only modest agreement between two of the most
common measures used to determine frailty. Factors
associated with frailty included older age, multimorbidity,
polypharmacy, being female, low income, living alone,
obesity and smoking.
Key words: Australia, cohort studies, epidemiologic mea-
surements, frail older adults, prevalence.
Introduction
Frailty is a state of decreased physiological reserve in
which individuals are vulnerable to stressor events result-
ing in adverse health outcomes such as falls, disability
and death [1]. There are two main approaches to defining
frailty. The Frailty Phenotype (FP) focuses on physical
manifestations, and frailty is present when three of more
of the following criteria are met: unintentional weight
loss, weak grip strength, self-reported exhaustion, slow-
ness and low physical activity level [2]. The cumulative
deficits model is mathematically based, where frailty is
the proportion of deficits present in an individual and this
proportion is represented as a Frailty Index (FI) [3,4].
Despite differences, both approaches are moderately corre-
lated [5]. Frailty increases nonlinearly with age, is predic-
tive of mortality and is higher for women [6]. Studies
which report on frailty using established FI cut-points
tend to report higher frailty prevalence in comparison
with the FP [7]. While the FP was designed and is most
commonly used as a categorical measure, it has also been
used as a continuous measure to examine the association
of frailty with adverse outcomes, and for comparison with
other frailty measures [1,6,8–11]. Furthermore, using a
continuous FP may result in improved predictive validity
of the measure [11].
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Frailty has been investigated in four Australian cohort stud-
ies [12–15]. One South Australian study using 1992 data
compared frailty using both the FP and FI, where frailty
prevalence was reported at 9% (FP) and 18% (FI) (mean age
78.2 (6.7)) respectively [12]. Two other male studies
reported a prevalence of 9% (FP; New South Wales; mean
age 76.9 (5.5)) and 16% (FRAIL Scale; Western Australia,
mean age 76.9 (3.8)) [13,14]. One very recent rural South
Australian study looked at individuals ≥65 years and found
a frailty prevalence of 25% (FI; mean age 75.9 (7.9)) [15].
The aims of this study were to determine the prevalence of
frailty in the North West Adelaide Health Study (NWAHS)
using two measures of frailty (FP and FI) and to determine fac-
tors associated with both of these measures. A novel feature of
our study is the examination of factors associated with frailty
in Australian men and women using both the FP and FI.
Methods
Sample and study design
This is a secondary analysis of data from NWAHS, a popula-
tion representative longitudinal study of 4060 men and
women aged ≥18 years [16]. Participants in the study were
randomly selected from households in the north-west of
metropolitan Adelaide and were interviewed by phone,
attended a clinic for biomedical examination and completed a
questionnaire. Probability of selection was known and allowed
for weighting of data to the area population. Individuals living
in residential care facilities were excluded from NWAHS.
Participants included in this secondary analysis were those
aged ≥65 years who attended the clinic assessment at Stage
2 (2004–2006). Stage 1 weight was used to calculate base-
line weight loss over four years preceding Stage 2. Vari-
ables within the data set were used to construct both the
FP and FI measures [17]. Participants were excluded if they
had a FP score with <3 valid responses or a FI with <27
valid responses (20% missing). We used Stage 2 data for
this study, as future analysis will examine frailty state tran-
sitions and associations with quality of life and survival in
Stage 3 (2008–2010). SA Health Human Research Ethics
Committee (TQEH/LMH/MH) (Reference number HREC/
15/TQEH/61) provided ethics approval.
Construction of the Frailty Phenotype
Data were available for the original phenotype criteria (ex-
haustion and weakness), and modified variables were used
for the remaining three (weight loss, slow walking and low
physical activity) [18] (Table 1). The FP is typically presented
as three categories (non-frail, prefrail and frail). In this article,
we have used a dichotomous FP, non-frail (0–2 deficits, com-
bining non-frail and prefrail categories) and frail (3+ deficits)
to examine association with cohort characteristics. Results
for the FP were reported as both categorical (non-frail and
frail) and continuous (proportion of deficits).
Construction of the FI
At least 30 age-related health deficits are required to calculate
a FI [4]. We developed a 34-item FI based on a standard
methodology [4] and excluded outcomes of interest for fur-
ther analysis such as variables used in the Short Form 6D
quality of life measure. Included variables were recoded to
provide a score between 0, for no deficit, and 1, for maximal
expression of deficit. The FI may be reported as a continuous
measure between zero (extremely robust) and one (extremely
frail) [3] and is also typically presented as four categories
(non-frail, prefrail, frail and most frail) with a frail cut-point
of 0.21 representing elevated risk of adverse health outcomes
[19]. In this article, we have used a dichotomous FI: non-frail
(0 to ≤0.21, combining non-frail and prefrail categories) or
frail (>0.21, combining frail and most frail categories) to
examine the association with cohort characteristics. The 34
variables included in the FI are reported in Table 1.
Statistical analysis
SPSS version 23 was used for all statistical analyses. Case
weights for the cohort were used in analysis procedures,
reporting mean scores and percentages to ensure that the
sample was representative of the north-western population
of Adelaide. Statistical significance was determined by an
alpha value of 0.05. FP and FI scores were compared using
one-way ANOVA in relation to descriptive characteristics
of the sample. The 99th percentile was also calculated for
both frailty measures. Regression models were used to test
the best fit of association between age and frailty. Agree-
ment between the two frailty scales was measured using
the kappa statistic. Univariate and multivariate logistic
regression analyses were used to examine the association
between individual cohort characteristics and frailty. A 24-
item FI was also constructed excluding chronic conditions
to examine the association of frailty with multimorbidity.
Results
A total of 909 older participants (mean age 74.4 (6.2), 55%
female) were included in this study. The 36 participants
who were excluded (missing more than 20% of FI variables)
were older (mean age 81.5 (6.5), P < 0.001) and were more
likely to be female (84%, P = 0.002) than those included.
Using the FP criteria, 18% were classified as frail, compared
to 48% using the FI (Table 2). See Table S1 (Supporting
information) for three category frailty status classification.
The kappa statistic for agreement between scales in classify-
ing individuals was 0.38 (SE = 0.03, P < 0.001). Of those
participants who were classified as frail by the FP, 91%
were also classified as frail by the FI. However, among
those classified as non-frail by the FP, more than one-third
(37%) were classified as frail by the FI (Table 3). Categori-
cal FP and FI prevalence is presented in Table S2 (Support-
ing information) for agreement between three category
frailty measures. The participants who were classified as
non-frail by the FP but frail by the FI had significantly
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higher (P < 0.05) rates of multimorbidity (2+ chronic condi-
tions) (odds ratio (OR) 5.7, 95% confidence interval (CI)
4.1–7.9); polypharmacy (5+ medications) (OR 3.3, 95% CI
2.4–4.5); 2 + falls (OR 6.0, 95% CI 3.7–9.7); a hospital
emergency admission in last 12 months (OR 2.5, 95% CI
1.5–4.2); physical function limitations: climbing one flight
of stairs (OR 38.9, 95% CI 19.3–78.4), walking more than
1 km (OR 36.1, 95% CI 20.5–63.6), bending, kneeling or
stooping (OR 23.8, 95% CI 13.1–43.2); emotional prob-
lems: feel full of life (OR 28.6, 95% CI 12.7–64.4), feel
tired (OR 33.4, 95% CI 13.4–83.6), felt calm and peaceful
(OR 8.9, 95% CI 4.1–19.5); and poor self-reported health
(OR 24.5, 95% CI 13.9–43.1) than those classified as non-
frail in both measures (data not shown).
Frailty Phenotype scores ranged from zero to five deficits
(mean 1.32 (1.17)) with only one individual scoring five.
The FI ranged from zero to 0.78 (mean 0.23 (0.15)). None
of the measures showed a ceiling effect. The 99th per-
centile score for the FP was 4.0, and for the FI, it was
0.61. The FP demonstrated a floor effect with 29% of par-
ticipants scoring zero, which was considerably greater than
the 1% of participants scoring zero with the FI.
There was a strong correlation between mean FI scores and
proportion of FP deficits present (r = 0.76, P < 0.001) (Fig-
ure 1a). The scores for both frailty measures as a proportion
of the total deficits demonstrated a right skewed distribution
(Figure 1b). Frequencies and histograms for each FP and FI
variable are available in Table S3 (Supporting information).
Mean frailty scores were significantly higher in both measures
for women, older age, lower income, obesity, and living alone
and in the FP only for lower education and being widowed
(Table 2). An exponential model best described the relation-
ship between frailty and age, with a 4% natural log increase
per year of age for the mean FP and a 3% natural log increase
per year for the mean FI. For women, the log increase per year
of age for frailty was 4% for the FP and 3% for the FI. For
men, the rate was 3% per year of age for the FP (Figure 2a) and
Table 1: Frailty Phenotype and Frailty Index variables
Item NWAHS phenotype Original phenotype†
Frailty Phenotype
Weight loss >10% weight loss over four years
(clinic measurement: Phase 1 and Phase 2)
Unintentional weight loss of ≥10 pounds in prior year or at follow-up,
of ≥5% of body weight in prior year (by direct measurement of weight)
Weakness Original method used Grip strength (kg) measured using dynamometer in the lowest 20% at
baseline adjusted for sex and body mass index. Cut-points stratified
by sex and BMI
Exhaustion Original method used Two questions used from the CES-D. How often in the
last week did you feel:
• I felt that everything I did was an effort
• I could not get going
Scoring: rarely or none (0), some or a little (1), moderate (2), most (3).
Deficit present when answering ‘2’ or ‘3’ to either question
Slowness Self-report to the question: Health limits
you a lot walking 100 m (SF36 q11)
The slowest 20% of the population based on time to walk 15 feet,
adjusting for sex and height
Low activity Australian Bureau of Statistics National
Health Survey, METs per week based
on previously published
cut-points for this cohort (<100 METs) [29]
Minnesota Leisure Time Activity questionnaire. Kilocalories per week
stratified by sex. Men <383 kcal per week, women <270 kcal per week
34-item Frailty Index
Angina Self-reported health
Heart attack Health limits lifting or carrying groceries
Osteoporosis Health limits climbing several flights of stairs
Osteoarthritis Health limits climbing one flight of stairs
Rheumatoid and any other arthritis Health limits bending, kneeling or stooping
Stroke or TIA Health limits walking more than 1 km
Diabetes Health limits walking 100 m
Any mental health problem Felt lonely
10% weight loss over four years Felt that could not get going
Systolic blood pressure Difficulty keeping mind on what you were doing
Diastolic blood pressure Felt everything was an effort
FEV1/FVC postratio Physical and emotional problems interfered with social activities
Weak grip strength Felt full of life
Falls Felt calm and peaceful
Hospital emergency admission Felt worn out
Low activity level (<100 METs per week) Felt tired
Healthy as anybody I know
Health is excellent
†Exhaustion and weakness. BMI, body mass index; CES-D, Center for Epidemiologic Studies Depression Scale; FEV1/FVC, forced expiratory volume/forced vital capacity; METs, metabolic
equivalent of task; NWAHS, North West Adelaide Health Study; TIA, transient ischaemic attack.
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2% for the FI (Figure 2b). See Figure S1 (Supporting informa-
tion) for log increase per year based on frailty classification.
Being older, a current smoker, and having multimorbidity and
polypharmacy were significantly associated with both the FP
and FI. Table 2 shows the results of multivariate analysis where
frailty status was dichotomised as either non-frail or frail. Being
female, low income, obesity and living alone were significantly
associated with only the FI. Being widowed was positively asso-
ciated with frailty in the univariate analysis but negatively asso-
ciated in the multivariate analysis for both frailty measures.
This is probably because being widowed is more likely for older
women who live alone than for other population groups. When
the 24-item FI, without the chronic conditions, was used in the
multivariate analysis, all variables remained significantly associ-
ated with frailty, including multimorbidity (OR 2.61, 95% CI
1.80–3.79, P < 0.001) (data not shown).
Discussion
In this study, there was only modest agreement between
the two measures when classifying individuals as either
non-frail or frail, which has implications for the clinical
setting. As frailty is a potentially reversible state, correct
identification is necessary for individuals to be offered
timely and appropriate interventions [20].
Frailty prevalence (FP: 18%, FI: 48%) was substantially
higher than in a previous South Australian study which
measured frailty prevalence in men and women using both
measures (FP: 9%, FI: 18%, mean age 78.2 (6.7) years)
[12]. In that study, exclusively self-report FI variables and
a higher cut-point of 0.25 were used, which is likely to
have contributed in part to the lower prevalence [19,21].
The use of self-report data was also the case for the study
by Dent et al. [15] (FI: 18%, mean age 75.9 (7.9) years).
Our FI used a combination of self-report and test-based
health measures, and had a cut-point of 0.21, as combining
both forms of measurement has been identified as best pre-
dicting adverse health outcomes [19,21]. Furthermore,
when comparing our findings, using data from 2004 to
2006, with the findings by Widagdo et al. [12] who used
data from 1992, there may be a cohort effect. The compar-
atively lower socioeconomic status (SES) of the NWAHS
region might also have contributed to a higher frailty
prevalence [22]. Frailty for men in the NWAHS cohort
(FP: 13%) was slightly higher than the New South Wales
study (FP: 9%, mean age 76.9 (5.5) years) [13]. The exclu-
sion of individuals living in residential care from this and a
number of other studies as well as the potential non-parti-
cipation of home-bound older people is likely to result in
an underestimation of the true prevalence of frailty [23].
Multivariate analysis of cohort characteristics identified
that being older, a current smoker, and having multimor-
bidity and polypharmacy were associated with higher
frailty levels by both frailty measures. The association with
multimorbidity for the FI was maintained when health con-
ditions contributing to multimorbidity status were excluded
from the FI. Being female, a low income earner, obesity
and living alone were associated with only the FI.
Our findings for the FI are consistent with other studies
which have identified women as having significantly higher
frailty than men, and for both measures, that frailty increases
significantly with age in a nonlinear pattern [3,6,24,25]. The
significant association of lower household income with the
FI in this population is also similar to other studies [2,25].
(a) (b)
Figure 1: Characteristics of the Frailty Phenotype (FP) and Frailty Index (FI). (a) Relationship between the FP (number
of deficits) and the FI (mean score). The error bars represent the 95% confidence interval of the estimate of the mean
FI. Error bar not shown for five phenotype deficits as only one participant had this score. (b) Distribution of FP and FI
scores as a proportion of deficits present. ( ) Frailty Index; ( ) Frailty Phenotype.
Table 3: Proportion of participants within the Frailty
Phenotype and Frailty Index categories
Frailty Index, n (%) Total, n (%)
Non-frail Frail
Frailty Phenotype, n (%)
Non-frail 494 (63) 265 (37) 759 (82)
Frail 2 (2) 148 (98) 150 (18)
496 (52) 413 (48) 909 (100)
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Likewise, multimorbidity has been identified elsewhere as a
significant contributor to the development of frailty and was
also a significant factor for both measures in our study
[11,13,26]. Additionally, being a current smoker has been
previously identified as a significant factor associated with
frailty and is consistent with our findings [11]. These health
and social determinants of frailty may be useful triggers for
alerting clinicians to vulnerable older adults who might bene-
fit from a screening, comprehensive assessment and individu-
alised remediation or treatment of risk.
In this study, both frailty measures demonstrated a strong
significant correlation in continuous scores but only a modest
kappa score of 0.38 in their ability to classify individuals as
either non-frail or frail, with the FI classifying a larger num-
ber of participants as frail. Agreement between measures was
potentially strengthened by the use of all five FP variables in
the FI as they met FI inclusion criteria [4]. Of note, over a
third of individuals classified as non-frail by the FP were clas-
sified as frail by the FI. These participants had significantly
higher rates of multimorbidity, polypharmacy, physical func-
tional limitations, emotional problems and poor self-
reported health than those classified as non-frail by both
measures. The agreement between the FP and FI has been
identified elsewhere as ranging from slight to moderate, with
the FI classifying more people as frail with better discrimina-
tive ability at the lower and middle end of the frailty contin-
uum than the FP [9,10]. The literature suggests that the FI
may be a suitable scale that captures the multidimensionality
of frailty and has high predictive ability of adverse outcomes
[9,27]. The advantage of the FP is that it is shorter and relies
on less items; however, grip strength and gait speed used in
the FP are not standard components of a clinical geriatric
assessment, although these measurements might potentially
be considered as markers of an accumulation of deficits [27].
The main strength of this study was the use of population-
based data to measure frailty using both the FP and the FI.
Limitations of the study were the availability of general popu-
lation variables rather than ageing-specific variables such as
cognitive impairment or gait speed. Inclusion of cognitive
impairment has been highlighted as an important variable in
the measurement of frailty [28]. Some researchers may dis-
agree with using the continuous FP as this scale was originally
developed to be used as a categorical variable. Even so, a
number of studies have used it in continuous form, and for
the purpose of this study, we decided to report both continu-
ous and categorical findings [8–11]. However, in 2011 in a
study in which Fried was a co-author, the researchers
acknowledge that there is a floor effect when using the contin-
uous 5-point FP and instead recommended a recalibrated 10-
point scale to better differentiate individuals [11]. Even so,
the most commonly used FP scales in the literature use either
5- or 3-point categorisation [18]. Another limitation of the
study was the use of a modified FP which is recognised as hav-
ing a potential impact on frailty prevalence [18]. The rate of
physical inactivity in our sample is high (43%) compared to
the originally published FP proportion (22%) [2] and may be
a result of the low SES of the NWAHS population rather than
due to modification per se [22]. However, our selection of a
previously published threshold for physical inactivity in this
cohort is likely to reflect an accurate proportion of physical
inactivity that in turn presents an increased risk of frailty
[29]. Reporting the association between frailty and multimor-
bidity using a FI which contains nine health conditions is
another limitation of this study; we addressed this with a sub-
analysis using a 24-item FI which excluded these conditions.
The association was weaker in this subanalysis; however, it
still remained significant.
Conclusion
In this study, we successfully measured frailty prevalence in
a sample of South Australian older adults using the FP and
the FI. Socio-economic and other health determinants con-
tributed to higher risk of frailty. There was only a modest
(a) (b)
Figure 2: Relationship between average frailty scores (proportion of deficits present) and age stratified according to
sex, using the (a) Frailty Phenotype and (b) Frailty Index. Male; Female.
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agreement between both measures in classifying individuals
as either non-frail or frail, with the FI classifying a greater
number of individuals as frail. This difference in sensitivity
of frailty measures has clinical implications, where the
choice of tool may impact the accurate identification of
frailty. A FI consisting of at least 30 self-report and clinical
measurements may be more appropriate to use in the clini-
cal setting due to its sensitivity in identifying at-risk indi-
viduals, and the emergence of electronic health records
may facilitate the generation of an automated FI score
[30]. Further research is required to refine the process of
frailty screening and assessment.
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Chapter 6 
Frailty state transitions and associated factors in South Australian 
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6.1 Summary 
Aim: Frailty is a state of decreased physiological reserve and vulnerability to stressors. 
Understanding the characteristics of those most at risk of worsening, or likely to improve their 
frailty status, are key elements in addressing this condition. This study measured frailty state 
transitions and factors associated with improvement or worsening frailty status in the North 
West Adelaide Health Study. 
Methods: Frailty was measured using the frailty phenotype (FP) and a 34-item frailty index 
(FI) for 696 community dwelling participants aged ≥65 years, with repeated measures at 4.5 
years follow-up. 
Results: Improvement in frailty state was common for both tools (FP 15.5%; FI 7.9%). The 
majority remained stable (FP 44.4%; FI 52.6%), and many transitioned to a worse level of 
frailty (FP 40.1%; FI 39.5%). For both measures, multimorbidity was associated with 
worsening frailty among non-frail participants. Among pre-frail participants, normal waist 
circumference was associated with improvement, whereas older age was associated with 
worsening of frailty status. Among frail individuals, younger age was associated with 
improvement, and male sex and older age were associated with worsening frailty status. 
Conclusions: Frailty is a dynamic process where improvement is possible. Multimorbidity, 
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Aim: Frailty is a state of decreased physiological reserve and vulnerability to stressors.
Understanding the characteristics of those most at risk of worsening, or likely to improve their
frailty status, are key elements in addressing this condition. The present study measured
frailty state transitions and factors associated with improvement or worsening frailty status in
the North West Adelaide Health Study.
Methods: Frailty was measured using the frailty phenotype (FP) and a 34-item frailty index
(FI) for 696 community-dwelling participants aged ≥65 years, with repeated measures at
4.5-year follow up.
Results: Improvement in frailty state was common for both tools (FP 15.5%; FI 7.9%). The
majority remained stable (FP 44.4%; FI 52.6%), and many transitioned to a worse level of
frailty (FP 40.1%; FI 39.5%). For both measures, multimorbidity was associated with worsen-
ing frailty among non-frail participants. Among pre-frail participants, normal waist circumfer-
ence was associated with improvement, whereas older age was associated with worsening of
frailty status. Among frail individuals, younger age was associated with improvement, and
male sex and older age were associated with worsening frailty status.
Conclusions: Frailty is a dynamic process where improvement is possible. Multimorbidity,
obesity, age and sex were associated with frailty transitions for both tools. Geriatr Gerontol
Int 2018; 18: 1549–1555.
Keywords: aged, Australia, cohort studies, epidemiology, frailty.
Introduction
Frailty represents a decline across multiple physiological systems,
making individuals more vulnerable to stressor events and at a
greater risk of adverse health outcomes, such as disability, hospitali-
zation, entry to residential care and death.1–4 Frailty is common
among older adults, and the prevalence has been measured at 14%
using the frailty phenotype (FP) and 24% using the frailty index
(FI),2 which are the two main approaches to the measurement of
frailty. Prevalence is typically higher when measured using the FI.5,6
There is growing interest in how frailty changes over time, and
the factors that are associated with early versus late stage frailty for
possible intervention.7–11 Frailty is a dynamic process where
improvement is possible, with rates of improvement in frailty sta-
tus ranging from 6% to 25%.7–10 Improvement typically is a
single-step transition to an adjacent state, such as from pre-frail to
non-frail.7–10 Even so, transition to a worse frailty level is more
common than improvement,7,8,10 and remaining in a stable frailty
state is the most common outcome.8,9
A range of socioeconomic, clinical and behavioral factors influ-
ence frailty transitions. Increased age, cognitive impairment, obesity,
the presence of multimorbidity, lower education level and hospitaliza-
tion are risk factors for worsening frailty status,7,9,10,12,13 whereas
increased levels of physical activity, female sex, being overweight, low
alcohol consumption, higher educational level, living alone and fewer
baseline deficits increase the likelihood of improved frailty.9,10,12,14
The aims of the present study were to examine the transitions
between frailty states for a cohort of older Australian adults using
both the FP and FI, and to describe the characteristics associated
with frailty status improving, remaining stable or worsening.
Although frailty state transitions have been examined
internationally,7–10 and in two Australian studies using the FP15 and
the FRAIL scale16 respectively, to the best of our knowledge this is the
1549|© 2018 Japan Geriatrics Society
DOI: 10.1111/ggi.13522
55
first study to report on frailty state transitions using both the FP and FI,
and to describe a range of factors associated with transitions for both.
Understanding the natural course of frailty and the characteristics
of those most at risk of worsening or likely to improve their frailty sta-
tus might be considered key elements in maximizing the health, func-
tioning and well-being of individuals in our aging populations.1,17
Methods
Sample and study design
The present study was a secondary analysis for data from the North
West Adelaide Health Study, a population-based longitudinal
study of community-dwelling adults living in the North West of
Adelaide, South Australia.18 As the probability of selection was
known, data were weighted to the area population. Stage 2
(2004–2006) was the baseline for the present study, and only par-
ticipants aged ≥65 years at the time of attending clinic stage 2 were
included. Follow up of participants for stage 3 occurred in
2008–2010 (4.5 years [0.45 SD] mean follow up). Information on
participant mortality was drawn from data matching to official
death records. Participants were excluded from this analysis if there
were missing three or more FP variables or ≥20% of FI variables at
either stage, if English comprehension was inadequate and if they
were lost to follow up (Fig. S1). Ethics approval for this study was
granted by SA Health Human Research Ethics Committee.
FP
A modified FP was used to measure frailty status at baseline and
follow up. Individuals with three or more deficits were classified as
frail, while those with one or two deficits were classified as pre-
frail and those with no deficits present were non-frail.19 The FP
criteria used in the present study are described in Table 1. The
characteristics of the modified FP in the North West Adelaide
Health Study cohort have been described previously.6
FI
We developed a 34-item FI following a standard methodology.20
Based on the proportion of deficits, individuals scoring >0.21 were
classified as frail, while those with scores ranging between 0.10 and
0.21 were pre-frail, and <0.10 were considered non-frail.21 FI vari-
ables are outlined in Table 1, and the characteristics of this FI have
been described previously.6 A 24-item FI, which excluded 10 chronic
conditions, was also constructed to examine the relationship
between multimorbidity and FI frailty state transitions (Table 1).
Statistical analysis
SPSS version 23 (IBM Corporation, Armonk, NY, USA) was used for
statistical analyses. Case weights for the cohort were used in analysis
procedures, reporting mean scores and percentages to ensure that
the sample was representative of the population. Statistical signifi-
cance was determined by an alpha value of 0.05. The number and
proportion of participants classified as non-frail, pre-frail or frail
using both measures were reported according to cohort characteris-
tics. The number and proportion of those in each frailty category
who remained stable, improved or worsened was also reported.
Transition directions included: (i) non-frail at baseline and worse at
follow up (pre-frail, frail or dead); (ii) pre-frail at baseline and
improved at follow up to a non-frail state; (iii) pre-frail at baseline
worsening to a frail or dead state; (iv) frail at baseline improving to
pre-frail or non-frail; and (v) frail at baseline worsening to dead.
Univariate logistic regression was carried out as a first step in the
purposeful selection process for identifying candidate variables for
multivariate analysis (Supporting Information Tables 4,5). Any vari-
able with P-value of <0.25 was included. An iterative process of vari-
able selection was then used for multivariate logistic regression
using backwards elimination of non-significant variables from the
model. Covariates that were significant for only one frailty measure
were included in the model for analysis of both measures. At the
end of this process of deleting and verifying, the model contained
significant covariates and confounders associated with frailty state
transitions that were included in the final multivariate analysis.
Table 1 Frailty phenotype and frailty index variables
Frailty phenotype 34-Item frailty index
Weight loss: >10% weight loss over
4 years (clinic measurement)
Angina† Self-reported health
Heart attack† Health limits lifting or carrying groceries
Osteoporosis† Health limits climbing several flights of
stairs
Osteoarthritis† Health limits climbing one flight of
stairs
Weakness: Original method used Rheumatoid and any other arthritis† Health limits bending, kneeling or
stooping
Exhaustion: Original method used Stroke or TIA† Health limits walking more than 1 km
Diabetes† Health limits walking 100 m
Slowness: Self-report to the question
“Health limits you a lot walking
100 m.” (SF36 q11)
Any mental health problem† Felt lonely
Systolic blood pressure† Felt that could not get going
Diastolic blood pressure† Difficulty keeping mind on what you
were doing
10% weight loss over 4 years Felt everything was an effort
Low activity: Australian Bureau of
Statistics National Health Survey.
(<100 METs per week)
FEV1/FVC post ratio Physical and emotional problems
interfered with social activities
Weak grip strength Felt full of life
Falls Felt calm and peaceful
Hospital emergency admission Felt worn out
Low activity level (<100 METs per
week)
Felt tired
Healthy as anybody I know
Health is excellent
†Variable excluded from 24-item frailty index. BMI, body mass index; METs, metabolic equivalent of task; SF36, 36-Item Short Form Health
Survey.
MQ Thompson et al.
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Covariates included: sex, age group (65–74 years and ≥75 years), the
presence of multimorbidity (≥2 chronic conditions), obesity (waist
circumference men >102 cm, women >88 cm), polypharmacy (≥5
medications) and living arrangements (alone or with others). Covari-
ates that were tested but not included were: education level, income
group, smoking status and alcohol consumption. As the length of
time between the baseline and follow-up clinics varied for each par-
ticipant, we also included time between clinics as a covariate.
Results
Study participants
In the present analysis, we included 696 participants (mean age
73.4 years [6.1], 53.1% women). We excluded 93 participants due
to insufficient FI or FP variables at phase 3, and 120 were lost to
follow up. Baseline descriptive characteristics of participants based
on the FP and FI frailty categories are presented in Table 2. At
baseline, 16.3% of participants were classified as frail according to
the FP, whereas 45.6% were frail based on the FI. The
213 excluded participants were more likely to be older (mean age
75.8 years [6.7]), and frail as classified by the FP (20.7%) and the
FI (52.1%) at baseline, compared with those included in analysis.
Frailty state transitions
The majority of participants in this cohort either improved or
remained stable over 4.5 years (FP 59.9%, FI 60.5%). Figure 1
shows the frailty state at follow up according to baseline frailty states
for both measures (see also Supporting Information Tables 1–3). A
number of participants improved their frailty state: FP – 23.1% of
pre-frail and 21.6% of frail individuals; FI – 13.6% of pre-frail and
8.4% of frail individuals. Remaining stable was the most common
frailty state transition for both the FP (47.7% of non-frail, 44.7% of
pre-frail and 36.9% of frail) and the FI (54.4% of non-frail, 38.0%
of pre-frail and 61.5% of frail). The next most likely state transition
was to a worse frailty state (FP 40.1% and FI 39.5%), which also
included death (19%). When participants transitioned to a different
frailty state (improved, worsened or dead), this was most typically to
a state adjacent their baseline classification.
Table 2 Baseline frailty categories for the frailty phenotype and frailty index (34-item) based on descriptive characteristics















Total 696 233 (32.0) 357 (51.7) 106 (16.3) 175 (23.2) 219 (31.2) 302 (45.6)
Sex
Male 353 (46.9) 127 (35.7) 179 (50.5) 47 (13.8) 98 (27.3) 115 (33.2) 140 (39.5)
Female 343 (53.1) 106 (28.5) 178 (52.9) 59 (18.6) 77 (19.4) 104 (29.4) 162 (51.2)
Age groups
65–74 years 442 (59.9) 171 (37.3) 234 (53.3) 37 (9.4) 129 (28.6) 152 (33.7) 161 (37.7)
≥75 years 254 (40.5) 62 (24.0) 123 (49.5) 69 (26.5) 46 (15.2) 67 (27.5) 141 (57.2)
Education level†
Up to secondary 427 (61.6) 125 (28.6) 229 (53.0) 73 (18.4) 89 (19.1) 144 (34.4) 194 (46.5)
Trade/certificate/diploma 229 (32.6) 97 (38.7) 104 (48.2) 28 (13.1) 75 (30.2) 64 (25.7) 90 (44.1)
Bachelor degree or higher 19 (2.5) 9 (52.9) 8 (35.3) 2 (11.8) 8 (41.2) 6 (35.3) 5 (23.5)
Income groups†
Up to $20k 345 (45.6) 92 (24.8) 187 (54.5) 66 (20.6) 65 (16.5) 111 (32.6) 169 (51.0)
$20–$40k 223 (35.1) 96 (42.4) 103 (45.8) 24 (11.8) 77 (32.2) 71 (30.5) 75 (37.2)
$40–$60k 48 (7.0) 24 (41.7) 20 (50.0) 4 (8.3) 17 (34.0) 13 (27.7) 18 (38.3)
>$60k 23 (2.8) 12 (52.6) 10 (42.1) 1 (5.3) 10 (36.8) 9 (42.1) 4 (21.1)
Smoking status†
Never smoked 326 (49.6) 107 (29.3) 174 (54.7) 45 (16.0) 84 (23.1) 107 (32.0) 135 (44.8)
Former smoker 327 (45.1) 116 (35.9) 159 (48.0) 52 (16.0) 80 (22.8) 99 (30.3) 148 (46.9)
Current smoker 42 (5.2) 10 (25.0) 23 (52.8) 9 (22.2) 11 (25.7) 13 (31.4) 18 (42.9)
Alcohol consumption†,‡
Not at risk 593 (85.0) 201 (31.8) 299 (51.2) 93 (17.0) 146 (22.5) 190 (31.7) 257 (45.8)
Excess 75 (10.0) 22 (27.9) 42 (57.4) 11 (14.7) 21 (27.9) 22 (29.4) 32 (42.6)
Waist circumference†,§
Normal 328 (45.7) 140 (40.5) 151 (46.0) 37 (13.5) 113 (30.9) 103 (32.8) 112 (37.7)
Obese 364 (53.6) 92 (24.9) 204 (56.4) 68 (18.6) 62 (16.7) 114 (28.2) 188 (56.7)
Multimorbidity†
0–1 health conditions 486 (68.9) 184 (36.7) 248 (51.4) 54 (11.9) 169 (32.4) 174 (35.4) 143 (32.2)
≥2 health conditions 210 (31.1) 49 (21.7) 109 (52.4) 52 (25.9) 6 (2.8) 45 (21.8) 159 (75.4)
Polypharmacy†
0–4 medication 371 (53.2) 138 (36.2) 200 (53.6) 33 (10.2) 126 (30.9) 133 (36.4) 112 (32.8)
≥5 medications 319 (46.1) 92 (26.5) 154 (49.8) 73 (23.6) 45 (13.4) 84 (25.2) 190 (61.3)
Living arrangements†
Lives with others 418 (67.6) 154 (33.9) 206 (51.3) 58 (14.8) 104 (23.4) 142 (33.6) 172 (43.0)
Lives alone 257 (29.1) 74 (28.3) 137 (51.5) 46 (20.2) 65 (22.7) 71 (24.7) 121 (52.5)
Marital status†
Married/de facto 386 (63.6) 145 (34.7) 189 (50.9) 52 (14.4) 102 (24.7) 126 (32.8) 158 (42.5)
Separated/divorced 87 (8.1) 32 (36.4) 46 (52.7) 9 (10.9) 29 (32.1) 24 (28.6) 34 (39.3)
Widowed 198 (25.6) 50 (24.6) 108 (53.1) 40 (22.3) 40 (17.8) 63 (28.2) 95 (54.0)
Never married 18 (1.8) 5 (30.8) 10 (53.8) 3 (15.4) 3 (16.7) 6 (41.7) 9 (41.7)
Frailty phenotype cut points (number of deficits): 0,not frail; 1–2, pre-frail; and ≥3, frail. Frailty index cut points (proportion of deficits): 0 to ≤0.10,
not frail; >0.10 to ≤0.21, vulnerable; and >0.21, frail. †Not stated or missing not included. ‡Excess alcohol consumption was measured as >14 drinks
per week and/or more than four drinks per session. §Waist circumference in men >102 cm and in women >88 cm is considered obesity.
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Factors associated with frailty state transitions
Tables 3 and 4 examine the relationship between frailty state tran-
sitions and covariates. The reference category of “same” was used
for comparison of “better” and “worse” states. Baseline frailty cat-
egory and frailty state transition proportions were similar for both
the 34-item and 24-item FI, which excluded chronic conditions
(see supplementary file).
Improved at follow up
Pre-frail at baseline
Obese individuals were significantly less likely to improve accord-
ing to both measures (FP: OR 0.37, 95% CI 0.20–0.68, P = 0.001;
FI: OR 0.25, 95% CI 0.09–0.74, P = 0.013), whereas polyphar-
macy was negatively associated with improvement for the FP
(OR 0.42, 95% CI 0.22–0.81, P = 0.009).
Frail at baseline
Older age was negatively associated with improving for the FI
(OR 0.13, 95% CI 0.03–0.65, P = 0.013), as was multimorbidity
(OR 0.11, 95% CI 0.02–0.67, P = 0.016).
Worsened at follow up
Non-frail at baseline
Multimorbidity was associated with worsening according to both
measures (FP: OR 4.20, 95% CI 1.78–9.89, P = 0.001; FI: OR
5.74, 95% CI 1.21–27.09, P = 0.027). In addition, for the FI, obe-
sity was associated with worsening (OR 2.24, 95% CI 1.06–4.76,
P = 0.035), while people living alone were less likely to worsen
(OR 0.37, 95% CI 0.15–0.93, P = 0.035). Stratified by sex, women
living alone were significantly less likely to worsen (OR 0.19, 95%
CI 0.05–0.67, P = 0.010) than women living with others, whereas
there was no difference for men in terms of living arrangements
and worsening.
Pre-frail at baseline
Older age (≥75 years) was associated with worsening state for both
measures (FP: OR 3.06, 95% CI 1.72–5.47, P < 0.001; FI: OR
3.55, 95% CI 1.56–8.05, P = 0.002), whereas obese individuals
were less likely to worsen for the FP (OR 0.54, 95% CI 0.30–0.97,
P = 0.038).
Frail at baseline
Male sex was significantly associated with worsening for both
measures (FP: OR 3.91 95% CI 1.01–15.14, P = 0.048; FI: OR
3.22, 95% CI 1.50–6.92, P = 0.003), as was older age (≥75 years;
FP: OR 6.74, 95% CI 1.66–27.33, P = 0.008; FI: OR 6.40, 95% CI
2.95–13.86, P < 0.001). Living alone was significantly associated
with worsening for the FI (OR 2.70, 95% CI 1.23–5.92,
P = 0.013).
Discussion
Frailty, in the present study of community-dwelling Australian
older adults, was identified as a dynamic condition where approxi-
mately 60% of participants either improved or remained stable
over the course of 4.5 years; however, deterioration to a worse
frailty state was more likely than improvement. This finding was
similar to other studies that have examined frailty state
transitions.8,9
The pattern was similar for both the FP and FI, with the FI
identifying higher baseline frailty prevalence and a lower rate of
improvement; however, the pattern of movement assessed by each
instrument provides corroboration of the nature of changes.
Improvement to a lesser frailty state occurred for a number of
pre-frail and frail individuals, as measured by both the FP and
FI. Improvement in the FP for 16% of participants was slightly
higher than that of other randomly sampled cohorts of similar
follow-up periods where 12% and 6% of participants improved,
respectively.7,10 Improvement in the present cohort, as measured
by the FI, at 8% was half that of the FP. Even so, the potential for
improvement was evident for both pre-frail and frail individuals.
Normal waist circumference was a significant factor for the
improvement of pre-frail individuals for both measures, whereas
polypharmacy was negatively associated with improvement for the
FP. In other studies, normal weight has been identified as a signifi-
cant protective factor for survival,22 and polypharmacy has been
associated with increased risk of mortality.10,15 Improvement of
frail participants was significantly associated with younger age and
with having less than two chronic conditions for the FI.
Worsening was most common to an adjacent frailty state.
Gradual worsening to an adjacent frailty state has been identified
as a common feature of frailty across a number of studies that
have used a FP method.7–10 A pattern of gradual decline has also
been identified in a study that examined change in mean FI
score.11 Despite worsening of frailty level being the most common
transition in this cohort, interventions exist that might prevent
worsening.1,23
The worsening of non-frail individuals was significantly associ-
ated with the presence of multimorbidity for both measures, and
Figure 1 Frailty state transitions between baseline and follow
up (4.5 years mean) for the (a) frailty phenotype and (b) frailty
index. ( ) Non-frail, ( ) pre-frail, ( ) frail and ( ) dead.
MQ Thompson et al.
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with obesity and living with others for the FI. Chronic conditions
are recognized as having an impact on physiological systems that
might lead to the development of frailty.9,10,24 The present find-
ings on the association between obesity and the development of
frailty are consistent with those of others who identified that obe-
sity and overweight increased the risk of non-frail individuals tran-
sitioning to a worse frailty state.10,22,25 The mechanisms by which
obesity has a potential impact on frailty status include inflamma-
tory dysregulation and sarcopenic obesity, where a mismatch
exists between fat mass and muscle mass.26 Non-frail women liv-
ing alone in the present study were significantly less likely to
worsen than those living with others; however, this scenario was
not the case for non-frail men. This finding is similar to another
study that identified a positive effect of living alone on frailty for
women.27 The protective effects of non-frail women living alone
might be linked to carer stress, which was not measured in the
North West Adelaide Health Study.
Being older was associated with the worsening of pre-frail indi-
viduals for both measures, while obesity was protective for the
FP. Advanced age has been identified as being associated with
frailty previously in this cohort,6 and in other studies internation-
ally.2 Previous studies that have reported older age being signifi-
cantly associated with the worsening of any frailty characteristic,7
the worsening of frailty in men,9 becoming frail and dying,10 and
the worsening of a continuous FI score.11 The protective effect of
obesity has been described elsewhere as potentially associated with
Table 3 Multivariate logistic regression examining transitions in frailty phenotype states over 4.5 years
Odds ratio (95% confidence interval)
Baseline frailty status Non-frail Pre-frail Pre-frail Frail Frail
Follow-up status Worse† Improved‡ Worse† Improved‡ Worse†
Sex
Female 1 1 1 1 1
Male 0.76 (0.41, 1.42) 0.91 (0.49, 1.69) 1.03 (0.58, 1.85) 1.06 (0.31, 3.56) 3.91 (1.01, 15.14)*
Age group
65–74 years 1 1 1 1 1
≥75 years 1.89 (0.97, 3.68) 0.49 (0.24, 1.00) 3.06 (1.72, 5.47)* 0.59 (0.17, 2.09) 6.74 (1.66, 27.33)*
Waist circumference§
Normal 1 1 1 1 1
Obese 1.50 (0.81, 2.78) 0.37 (0.20, 0.68)* 0.54 (0.30, 0.97)* 2.60 (0.71, 9.57) 0.92 (0.26, 3.29)
Multimorbidity
0–1 conditions 1 1 1 1 1
≥2 conditions 4.20 (1.78, 9.89)* 1.03 (0.51, 2.07) 1.58 (0.84, 2.96) 0.70 (0.21, 2.38) 0.77 (0.20, 2.91)
Polypharmacy
0–4 medication 1 1 1 1 1
≥5 medications 0.85 (0.45, 1.60) 0.42 (0.22, 0.81)* 0.89 (0.49, 1.61) 0.35 (0.09, 1.37) 0.41 (0.10, 1.68)
Living arrangements
Lives with others 1 1 1 1 1
Lives alone 0.92 (0.45, 1.89) 0.50 (0.24, 1.02) 1.01 (0.54, 1.90) 0.46 (0.11, 1.92) 3.35 (0.85, 13.18)
Adjusted for time between clinic measurements. Frailty phenotype cut points (number of deficits): 0, not frail; 1–2, pre-frail; and ≥3, frail. *P < 0.05.
†A more severe frailty state, including death, compared with baseline state. ‡A less severe frailty state compared with baseline state. §Waist circumfer-
ence in men >102 cm and in women >88 cm is considered obesity.
Table 4 Multivariate logistic regression examining transitions in frailty index (24-item) states over 4.5 years
Odds ratio (95% confidence interval)
Baseline frailty status Non-frail Pre-frail Pre-frail Frail Frail
Follow-up status Worse† Improved‡ Worse† Improved‡ Worse†
Sex
Female 1 1 1 1 1
Male 0.51 (0.23, 1.12) 0.44 (0.15, 1.28) 0.89 (0.42, 1.89) 1.11 (0.40, 3.08) 3.22 (1.50, 6.92)*
Age group
65–74 years 1 1 1 1 1
≥75 years 2.13 (0.88, 5.12) 0.23 (0.04, 1.18) 3.55 (1.56, 8.05)* 0.13 (0.03, 0.65)* 6.40 (2.95, 13.86)*
Waist circumference§
Normal 1 1 1 1 1
Obese 2.24 (1.06, 4.76)* 0.25 (0.09, 0.74)* 0.52 (0.24, 1.12) 0.43 (0.16, 1.15) 0.85 (0.41, 1.77)
Multimorbidity
0–1 conditions 1 1 1 1 1
≥2 conditions 5.74 (1.21, 27.09)* 1.12 (0.30, 4.14) 1.68 (0.69, 4.08) 0.11 (0.02, 0.67)* 0.50 (0.23, 1.09)
Polypharmacy
0–4 medication 1 1 1 1 1
≥5 medications 1.39 (0.62, 3.12) 0.82 (0.28, 2.44) 1.59 (0.74, 3.40) 0.42 (0.14, 1.31) 1.60 (0.73, 3.50)
Living arrangements
Lives with others 1 1 1 1 1
Lives alone 0.37 (0.15, 0.93)* 0.64 (0.17, 2.46) 1.41 (0.57, 3.47) 0.99 (0.29, 3.43) 2.70 (1.23, 5.92)*
Adjusted for time between clinic measurements. Frailty index cut points (proportion of deficits): 0 to ≤0.10, not frail; >0.10 to ≤0.21, pre-frail; and
>0.21, frail. *P < 0.05. †A more severe frailty state, including death, compared with baseline state. ‡A less severe frailty state compared with baseline
state. §Waist circumference in men >102 cm and in women >88 cm is considered obesity.
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being a target of increased medical care and benefiting from
higher metabolic reserves.22
Male sex and older age were associated with the worsening
(transition to dead) of frail individuals for both measures, while
living alone was significant for the FI only. Although women have
higher frailty levels in this cohort,6 their reduced mortality risk
might reflect the male–female health-survival paradox, in which
women have a survival advantage over men despite having a sig-
nificantly higher number of disabling health conditions, including
frailty.28 For older age, the likelihood of worsening for frail indi-
viduals was sixfold that of those classified as frail in the younger
age group for both measures, suggesting that advancing age has a
greater impact on mortality risk in the later stages of frailty. Living
alone has been described as increasing the vulnerability for frailty
through mechanisms, such as undernutrition.19
The covariates associated with improvement or worsening
frailty status presented different risks based on the stage of frailty
progression. Each of these factors have a potential role in trigger-
ing or accelerating frailty through either the physiological changes
of aging or by means of a pathway of disease or comorbidity.19
However, for individuals already pre-frail and frail at baseline,
frailty itself plays a more important role in influencing later-stage
frailty transitions.
The two frailty measures showed similar patterns of frailty state
transitions over the 4.5-year mean follow-up period. Their key
differences included higher baseline frailty prevalence for the FI
(45.6%) compared with the FP (16.3%), and a smaller proportion
of individuals improving in frailty status for the FI (7.9%) com-
pared with the FP (15.5%). The higher baseline prevalence for the
FI has been reported elsewhere.5,6
Aging-specific variables, such as cognition and gait speed, were
not available for the present cohort. Accordingly, we used a modi-
fied FP, which might have impacted the estimate of frailty preva-
lence.29 The North West region of Adelaide has a lower
socioeconomic status compared with the broader metropolitan
area; therefore, the present findings might not be representative of
the Australian population.6 The exclusion of individuals living in
residential care from the present study is likely to result in under-
representing the baseline prevalence of frailty. A further limitation
of this study was the use of FI categories to measure frailty state
transitions. It is possible that smaller changes might be clinically
significant, but this is yet to be determined using continuous
frailty scores. Furthermore, the loss to follow up of 213 partici-
pants who were significantly older and had higher frailty preva-
lence based on the baseline frailty classification is likely to have
impacted our findings, potentially resulting in an underestimation
of frail individuals remaining stable or improving.
Frailty was identified as a dynamic process in which many
individuals improved over a 4.5-year follow-up period. Most
individuals improved or remained stable. For both improvement
and worsening, transition to an adjacent frailty state was most
likely. Among the factors that were identified as associated with
frailty transitions, age and sex are non-modifiable, but multimor-
bidity, obesity, polypharmacy and living status might be targeted.
These factors pose different risks for frailty transition at different
stages of the frailty process, as does frailty classification itself
and, hence, suggests a tailored approach in targeting vulnerable
individuals. These findings have implications for clinicians and
policymakers. Identifying individuals who are at risk of becoming
frail and recognizing that there is potential for improvement of
those who are already pre-frail or frail will be an important fea-
ture of maintaining healthy aging populations. This is particularly
prescient, as interventions exist that might prevent, delay or
reverse frailty.1,23
Acknowledgements
The authors would acknowledge the contribution of the North
West Adelaide Health Study participants and clinic staff. This
work was supported by the Resthaven GTRAC research
grant to OT.
Disclosure statement
The authors declare no conflict of interest.
References
1 Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly
people. Lancet 2013; 381 (9868): 752–762.
2 Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of
frailty with survival: a systematic literature review. Ageing Res Rev 2013;
12 (2): 719–736.
3 Mitnitski A, Song X, Skoog I et al. Relative fitness and frailty of elderly
men and women in developed countries and their relationship with
mortality. J Am Geriatr Soc 2005; 53 (12): 2184–2189.
4 Vermeulen J, Neyens JC, van Rossum E, Spreeuwenberg MD, de
Witte LP. Predicting ADL disability in community-dwelling elderly peo-
ple using physical frailty indicators: a systematic review. BMC Geriatr
2011; 11: 33.
5 Blodgett J, Theou O, Kirkland S, Andreou P, Rockwood K. Frailty in
NHANES: comparing the frailty index and phenotype. Arch Gerontol
Geriatr 2015; 60 (3): 464–470.
6 Thompson MQ, Theou O, Yu S, Adams RJ, Tucker GR,
Visvanathan R. Frailty prevalence and factors associated with the frailty
phenotype and frailty index: findings from the North West Adelaide
Health Study. Australas J Ageing 2018; 37 (2): 120–126.
7 Espinoza SE, Jung I, Hazuda H. Frailty transitions in the San Antonio
Longitudinal Study of Aging. J Am Geriatr Soc 2012; 60 (4): 652–660.
8 Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty
states among community-living older persons. Arch Intern Med 2006;
166 (4): 418–423.
9 Lee JS, Auyeung TW, Leung J, Kwok T, Woo J. Transitions in frailty
states among community-living older adults and their associated factors.
J Am Med Dir Assoc 2014; 15 (4): 281–286.
10 Trevisan C, Veronese N, Maggi S et al. Factors influencing transitions
between frailty states in elderly adults: the Progetto Veneto Anziani
Longitudinal Study. J Am Geriatr Soc 2016; 65 (1): 179–184.
11 Fallah N, Mitnitski A, Searle SD, Gahbauer EA, Gill TM, Rockwood K.
Transitions in frailty status in older adults in relation to mobility: a mul-
tistate modeling approach employing a deficit count. J Am Geriatr Soc
2011; 59 (3): 524–529.
12 Peterson MJ, Giuliani C, Morey MC et al. Physical activity as a preventa-
tive factor for frailty: the health, aging, and body composition study. J
Gerontol A Biol Sci Med Sci 2009; 64 (1): 61–68.
13 Gill TM, Gahbauer EA, Han L, Allore HG. The relationship between
intervening hospitalizations and transitions between frailty states. Geron-
tol A Biol Sci Med Sci 2011; 66A (11): 1238–1243.
14 Hubbard RE, Fallah N, Searle SD, Mitnitski A, Rockwood K. Impact of
exercise in community-dwelling older adults. PLoS One 2009; 4 (7):
e6174.
15 Jamsen KM, Bell JS, Hilmer SN et al. Effects of changes in number of
medications and drug burden index exposure on transitions between
frailty states and death: The Concord Health and Ageing in Men Project
Cohort Study. J Am Geriatr Soc 2016; 64 (1): 89–95.
16 Gardiner PA, Mishra GD, Dobson AJ. Validity and responsiveness of
the FRAIL scale in a longitudinal cohort study of older Australian
women. J Am Med Dir Assoc 2015; 16 (9): 781–783.
17 Xue QL. The frailty syndrome: definition and natural history. Clin Ger-
iatr Med 2011; 27 (1): 1–15.
18 Grant JF, Taylor AW, Ruffin RE et al. Cohort profile: the North West
Adelaide Health Study (NWAHS). Int J Epidemiol 2009; 38 (6):
1479–1486.
19 Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence
for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56 (3): M146–M156.
20 Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A stan-
dard procedure for creating a frailty index. BMC Geriatr 2008; 8: 24.
21 Hoover M, Rotermann M, Sanmartin C, Bernier J. Validation of an
index to estimate the prevalence of frailty among community-dwelling
seniors. Health Rep 2013; 24 (9): 10–17.
22 Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause
mortality with overweight and obesity using standard body mass index
categories: a systematic review and meta-analysis. JAMA 2013; 309 (1):
71–82.
23 Puts MT, Toubasi S, Andrew MK et al. Interventions to prevent or
reduce the level of frailty in community-dwelling older adults: a scoping
review of the literature and international policies. Age Ageing 2017; 46
(3): 383–392.
24 Weiss CO. Frailty and chronic diseases in older adults. Clin Geriatr Med
2011; 27 (1): 39–52.
25 Stenholm S, Strandberg TE, Pitkala K, Sainio P, Heliovaara M,
Koskinen S. Midlife obesity and risk of frailty in old age during a
MQ Thompson et al.
1554 | © 2018 Japan Geriatrics Society60
22-year follow-up in men and women: the Mini-Finland Follow-up
Survey. J Gerontol A Biol Sci Med Sci 2014; 69 (1): 73–78.
26 Blaum CS, Xue QL, Michelon E, Semba RD, Fried LP. The associa-
tion between obesity and the frailty syndrome in older women: the
Women’s Health and Aging Studies. J Am Geriatr Soc 2005; 53 (6):
927–934.
27 Trevisan C, Veronese N, Maggi S et al. Marital status and frailty in older
people: gender differences in the Progetto Veneto Anziani Longitudinal
Study. J Womens Health (Larchmt) 2016; 25 (6): 630–637.
28 Alberts SC, Archie EA, Gesquiere JA, Vaupel JW, Christensen K. The
male-female health-survival paradox: a comparative perspective on sex
differences in aging and mortality. In: Weinstein M, Lane MA, eds. Soci-
ality, Hierarchy, Health: Comparative Biodemography: a Collection of Papers.
Washington, DC: The National Academies Press, 2014.
29 Theou O, Cann L, Blodgett J, Wallace LM, Brothers TD, Rockwood K.
Modifications to the frailty phenotype criteria: systematic review of the
current literature and investigation of 262 frailty phenotypes in the Sur-
vey of Health, Ageing, and Retirement in Europe. Ageing Res Rev 2015;
21: 78–94.
Supporting information
Additional supporting information may be found in the online
version of this article at the publisher’s website: .
Figure S1 Flow diagram of participants.
Table S1 Frailty category and death status at 4.5 years mean fol-
low up according to baseline frailty category. Percentage by base-
line frailty status.
Table S2 Frailty category and death status at 4.5 years mean fol-
low up according to baseline frailty category. Percentage of whole
sample.
Table S3 Frailty state transitions: better, same and worse (worse
includes dead) at 4.5 years mean follow up according to baseline
frailty category.
Table S4 Univariate logistic regression for variables associated
with frailty phenotype transitions in frailty states over 4.5 years,
adjusted for time between clinic appointments. Reference category
is “same.”
Table S5 Univariate logistic regression for variables associated
with frailty index transitions in frailty states over 4.5 years,
adjusted for time between clinic appointments. Reference category
is “same.”
How to cite this article: Thompson MQ, Theou O,
Adams RJ, Tucker GR, Visvanathan R. Frailty state transi-
tions and associated factors in South Australian older
adults. Geriatr. Gerontol. Int. 2018;18:1549–1555. https://
doi.org/10.1111/ggi.13522
Frailty state transitions
© 2018 Japan Geriatrics Society | 155561
Chapter 7 
Diagnostic test accuracy of self-reported screening instruments in 
identifying frailty in community-dwelling older people:  
A systematic review 
Diagnostic test accuracy of self-reported screening instruments in identifying frailty 
in community-dwelling older people: A systematic review was published in the journal 
Geriatrics and Gerontology International. The statement of authorship and paper (.pdf) follow 
over the page. 
Additional table(s) and/or figure(s) are provided in the Supplementary material for Chapter 7. 
A copy of the systematic review protocol published in the JBI Database of Systematic Reviews 
and Implementation Reports is included as Appendix B. 
This publication also appeared as a chapter in the doctoral thesis of Rachel C Ambagtsheer 
(lead author), with Mark Q Thompson as secondary author. The contribution of each author is 
specified in the following statement of authorship.
7.1 Summary 
Background: Against a backdrop of ageing populations worldwide, it has become increasingly 
important to identify frailty screening instruments suitable for community settings. 
Self-reported and/or administered instruments may offer significant simplicity and 
efficiency advantages over clinician-administered instruments but their comparative 
diagnostic test accuracy has yet to be systematically examined. 
Aims: The aim of this systematic review was to determine the diagnostic test accuracy of 
self-reported and/or self-administered frailty screening instruments against two widely 
accepted frailty reference standards (the Frailty Phenotype and the Frailty Index) within 
community-dwelling older adult populations. 
Methods: We conducted a systematic search of the Embase, CINAHL, MEDLINE, PubMed, 
Web of Science, PEDro, PsycINFO, ProQuest Dissertations, Open Grey and GreyLit 
databases up to April 2017 (with an updated search conducted over May-July 2018) to 
identify studies reporting comparison of self-reported and/or self-administered frailty 
screening instruments against an appropriate reference standard, with a minimum 
sensitivity threshold of 80% and specificity threshold of 60%. 
Results: We identified 24 studies that met our selection criteria. Four self-reported 
screening instruments across three studies met minimum sensitivity and specificity thresholds.  
However, in most cases, study design considerations limited the reliability and 
generalisability of the results. Additionally, meta-analysis was not conducted because no 
more than three studies were available for any of the unique combinations of index tests and 
reference standards. 
Conclusions: Although our study has demonstrated that a number of self-reported frailty 
screening instruments reported sensitivity and specificity within a desirable range 
for community application, additional diagnostic test accuracy studies are needed. 
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Against a backdrop of aging populations worldwide, it has become increasingly important to
identify frailty screening instruments suitable for community settings. Self-reported and/or
administered instruments might offer significant simplicity and efficiency advantages over
clinician-administered instruments, but their comparative diagnostic test accuracy has yet to
be systematically examined. The aim of this systematic review was to determine the diagnostic
test accuracy of self-reported and/or self-administered frailty screening instruments against
two widely accepted frailty reference standards (the frailty phenotype and the Frailty Index)
within community-dwelling older adult populations. We carried out a systematic search of
the Embase, CINAHL, MEDLINE, PubMed, Web of Science, PEDro, PsycINFO, ProQuest
Dissertations, Open Grey and GreyLit databases up to April 2017 (with an updated search
carried out over May–July 2018) to identify studies reporting comparison of self-reported
and/or self-administered frailty screening instruments against an appropriate reference stan-
dard, with a minimum sensitivity threshold of 80% and specificity threshold of 60%. We
identified 24 studies that met our selection criteria. Four self-reported screening instruments
across three studies met minimum sensitivity and specificity thresholds. However, in most
cases, study design considerations limited the reliability and generalizability of the results.
Additionally, meta-analysis was not carried out, because no more than three studies were
available for any of the unique combinations of index tests and reference standards. Although
the present study has shown that a number of self-reported frailty screening instruments
reported sensitivity and specificity within a desirable range for community application, addi-
tional diagnostic test accuracy studies are required. Geriatr Gerontol Int 2019; ••: ••–••.
Keywords: aged 80 and over, frailty, geriatric assessment, primary healthcare.
Introduction
Frailty has been identified as a global public health priority in soci-
eties with aging populations.1 Frailty is a state of decreased physio-
logical reserve and increased vulnerability to stressor events,
resulting in increased risk of adverse health outcomes, such dis-
ability, hospitalization, institutionalization and mortality.2–4 Frailty
is a dynamic condition where improvement is possible5,6 and
interventions exist that can delay or reverse frailty.7 Identifying
individuals who would benefit from timely identification and inter-
vention, therefore, is a key priority in the management of frailty
within the community.8,9
There are currently a large number of different frailty screening
instruments in existence, many of which have proven to be reli-
able and valid measures of frailty within different contexts.10
However, only some of these are suitable contenders to be consid-
ered within the scope of self-administered instruments, taking the
form of either a postal survey or a self-completed questionnaire.
Several systematic reviews have examined the utility of frailty
screening within community settings, from the perspective of both
self-report and test-based measurement.4,9,11–13
Two systematic reviews have reported on the diagnostic test
accuracy (DTA) of frailty screening instruments against a refer-
ence standard.14,15 A number of publications have examined the
DTA of self-reported instruments for the identification of frailty
since these reviews were published, hence the need for the present
review. One of the key complexities identified in these reviews
regarding frailty screening is a lack of consensus on a definition of
frailty, which is reflected in two separate reference standards and a
large number of potential index tests.9
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The aim of the present review was to identify the DTA of self-
reported screening instruments against a frailty reference standard
for community-dwelling older adults. Specifically, our review
questions were:
• How accurate are self-reported screening instruments against
agreed reference standards?
• How does the accuracy of self-reported instruments vary
according to whether the test is self-reported or self-administered?
Methods
We consulted the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement16 and the Joanna
Briggs Institute (JBI) Critical Appraisal Checklist for Diagnostic
Test Accuracy Studies tool17 in developing the study design. The
study protocol has been published previously, and the study is
registered with both the PROSPERO (ID: CRD42017081379) and
the JBI databases.18
We diverged from our original protocol with respect to the fol-
lowing points:
• We focused on frailty alone rather than including pre-frailty for
purposes of clarity.
• We excluded Comprehensive Geriatric Assessment as a refer-
ence standard for frailty due to a lack of standardization in
terms of its administration between studies and the absence of
a widely recognized threshold for frailty. We have, however
included studies where the Frailty Index (FI) was derived from
Comprehensive Geriatric Assessment.
• We excluded studies carried out in hospital settings and emer-
gency departments, along with patients with specific conditions;
for example, cancer.
• We included studies from inception of the databases rather
than studies published after 1 January 2001.
• Due to significant overlap between JBI and quality assessment
of diagnostic accuracy studies (QUADAS) and time limitations,
we critically appraised against the JBI framework only.
• Meta-analysis and subgroup analysis were not carried out due
to substantial heterogeneity in the results.
• We excluded consideration of feasibility from our review given
that our search strategy, which is focused on diagnostic accu-
racy, is likely to have omitted a high proportion of papers
focused specifically on the feasibility of individual instruments.
Selection criteria
Types of studies
We included observational studies published in English and car-
ried out in community settings.
Participants
The participants in our included studies were community-
dwelling older adults with a minimum mean age of 65 years, or
where at least half of the study participants were aged ≥65 years.
Studies of participants living in residential care settings were
excluded. Studies that addressed a specific diagnosis or that were
carried out in an acute setting (e.g. cancer patients, surgical
patients or emergency department patients) were excluded.
Index tests
Any index test purporting to measure frailty that was entirely self-
reported (i.e. administered by an investigator, but including no
clinical or physical measurements), or that was self-administered
was included. Tests that were partially self-reported were
excluded, unless test results for the self-reported items were pres-
ented independently of the non-self-reported items. We included
studies in which the self-report frailty instrument was completed
by a proxy, as well as studies where the older person self-
completed the instrument. Studies using a self-reported FI were
excluded, as any FI (self-report, test-based or combination) that
meets the criteria of Searle et al. might be considered to be a refer-
ence standard.19
Reference standards
Studies were included if they applied either of two frailty reference
standards: the frailty phenotype (FP; Fried et al.20) or the FI
(Mitnitski et al. 2001).21 Studies applying no reference standard or a
reference standard other than those specified above were excluded.
Diagnosis of interest
The diagnosis of interest was frailty.
Search strategy
To identify published studies, we searched the databases MEDLINE/
PubMed, PEDro, Embase, PsycINFO, CINAHL, Scopus and Web
of Science from inception. The initial search was carried out between
March and April of 2017, and updated in July 2018. Our search strat-
egy was developed in consultation with an academic librarian with a
specialty in medicine.
The search strategy was developed in a scaffolded manner, com-
mencing with a CINAHL and PubMed search to inform specified
keyword analysis, including MeSH terms, for subsequent database
searching. We then used truncated and expanded keyword varia-
tions of the terms relating to frailty, self-report and screening, along
with specific self-report screening tools (e.g. Kihon Checklist).
To identify unpublished and grey literature, we searched
ProQuest, OpenGrey, The Grey Literature Report database and
consulted websites of key gerontological research centers with a
focus on frailty.
We also reviewed the reference lists of all included studies to
identify additional studies of interest.
The search strategy syntax for individual databases is provided
in Table S1.
Study selection
All studies of interest were exported from the respective databases
and imported into Zotero Reference Manager version 4.0.29.17.
Zotero was selected for this process because of its compatibility
with the various data extraction formats from the electronic data-
bases, its low cost, and an internal capability that made it relatively
easy to identify and remove duplicates. Duplicates were identified
using the inbuilt feature and manually checked before deletion by
one researcher (RA).
The resulting unique records were exported into a Microsoft
Excel 2016 (Redmond, WA, USA) worksheet before being
assessed for title and abstract relevancy by two independent
reviewers (RA and MT). We consulted a third reviewer (TS) over
any differences in opinion regarding the inclusion of individual
articles.
Agreed articles were extracted in full text format by one
reviewer (RA), and reviewed independently by the same reviewers
RC Ambagtsheer et al.
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(RA and MT) with recourse to the third reviewer (TS) to achieve
consensus. The reason for exclusion was retained for all articles
reviewed after the initial title/abstract screen.
Quality review
Two reviewers (RA and MT) subjected the included full-text arti-
cles to an initial assessment against the inclusion criteria, and a
number of studies were excluded at this point. The reasons for
exclusion were retained.
Included studies were assessed against the JBI Checklist for
Diagnostic Test Accuracy Studies.17 This Checklist is based on
the QUADAS 2 signaling questions and relate to the design and
conduct of the study (see Box 1).22
Two reviewers (RA and MT) then assessed included studies
independently against the JBI criteria. We recorded a value of
“Yes,” “No” or “Unclear” against each criterion, and made addi-
tional notes where appropriate.
Data extraction
We developed an initial data extraction template, which was based
on the JBI Data Extraction tool17 and was finalized in consultation
with the research team. We extracted country of origin, sample
size, mean age of participants, percentage male/female, index test
and reference standard, test thresholds, and self-report or self-
administration status. Data was extracted independently by two
reviewers (RA and MT) and then discussed to achieve consensus.
Where necessary, we sought additional clarification or data from
study authors, especially with respect to 2 × 2 data to allow calcu-
lation of diagnostic characteristics.
Statistical analysis
We used Microsoft Excel and SPSS version 25 (IBM Corporation,
Armonk, NY, USA)23 to carry out descriptive analysis of the data.
We calculated sensitivity, specificity, positive predictive value, neg-
ative predictive value and likelihood ratios along with their associ-
ated 95% confidence intervals within the Review Manager
(RevMan) version 5.3 software (The Nordic Cochrane Center,
Cochrane Collaboration, Copenhagen, Denmark). We used
Revman to construct forest plots of the data to show heterogeneity.
For the purposes of the present study, we adopted 80% as a
minimum sensitivity threshold9,24,25 and 60% as a minimum
specificity threshold24 as being acceptable. Although good screen-
ing tests have both high sensitivity and specificity (i.e. results close
to 1), in practice there is often a trade-off in favor of one over the
other.26 In the case of frailty screening within community settings,
high sensitivity and low specificity tends to be the more preferable
scenario where identification of as many frail individuals as possi-
ble is a priority.27 Following this logic, it might be more desirable
to have a higher number of false positives than false negatives, sig-
nifying that there is a greater chance of potentially identifying as
frail people who are not frail rather than missing those who are.
Additionally, we used Microsoft Excel to construct the Youden
Index (sensitivity + specificity-1). The Youden Index is a single
summary measure reflecting how closely the DTA result matches
the ideal of no false positives or false negatives.28 Although the
Youden Index adds additional interpretive information (as a kind of
balancing mechanism across the sensitivity and specificity values), it
is not appropriate to consider it in isolation, especially in the context
of the present study. For example, the Youden Index, as a single sta-
tistic, does not take into consideration decisions such as prioritiza-
tion of high sensitivity over high specificity into account.
The “metandi” command in Stata (StataCorp, College Station,
TX, USA) requires a minimum of four studies for meta-analysis
of DTA studies.29 However, the present review did not identify
more than three studies comparing the same index test and refer-
ence standard. Consequently, we did not carry out meta-analysis,
and have synthesized results in tabular and narrative formats.
Results
All results presented below are descriptive in nature. Across all
possible comparisons of index and reference tests, the highest
number of included studies per comparison was just three. In this
single instance, a comparison of the Tilburg Frailty Indicator (index
test) versus FP, the bivariate model was not calculated as the num-
ber of studies was below the minimum required (n = 4). Therefore,
as meta-analysis was not possible, all comparisons are presented in
tabular and graphical format, along with a narrative synthesis.
Search results and study characteristics
The search results (including the updated search) returned 18 034
results in total. The large number of results returned was due to a
number of factors, including carrying out the search from the
inception of the databases, the large number of databases
searched, extensive duplication between databases and the need to
allow for numerous combinations of the search term “self” in rela-
tion to screening. Study results are shown in the flow diagram in
Figure 1. Of the total records identified, 10 579 duplicates were
identified and removed, leaving 7455 records to be screened by
title and abstract. Initial agreement between reviewers was 77.8%;
where assessments differed, these were resolved through discus-
sion or occasionally referred to the third reviewer.
After title and abstract screening, 7164 articles were excluded
due to lack of relevance or because they could not be sourced in
full text format. In all, 291 studies were assessed in full-text format
Box 1 JBI CRITERIA.
1. Recruitment: Was a consecutive or random
sample of patients enrolled?
2. Case–control: Was a case–control design
avoided?
3. Exclusions: Did the study avoid inappropriate
exclusions?
4. Index test interpretation: Were the index test
results interpreted without knowledge of the results
of the reference standard?
5. Threshold: If a threshold was used, was it pre-
specified?
6. Reference standard: Is the reference standard
likely to correctly classify the target condition?
7. Reference standard interpretation: Were the
reference standard results interpreted without
knowledge of the results of the index test?
8. Interval: Was there an appropriate interval
between index test and reference standard?
9. Same reference standard: Did all patients
receive the same reference standard?
10. All patients: Were all patients included in the
analysis?
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against the inclusion/exclusion criteria. Of these, 267 were subse-
quently excluded. Key reasons for exclusion included not having a
reference standard or an inappropriate reference standard applied
(28.1%), focus on a specific disease (18.1%), being a non-DTA or
observational study (16.9%), using non-self-reported instruments
(9.4%) and not meeting the age criteria (7.9%). Ultimately,
24 studies were deemed to have met the inclusion/exclusion
criteria and underwent JBI critical appraisal.
Included studies
Across the 24 included studies, the sample size ranged from 52 to
27 527, with a total of 84 984 participants. The characteristics of
included studies are summarized in Table 1. The mean age of par-
ticipants, where stated, ranged from 65.3 years up to 85.7 years.
In all, there were 31 instances of screening instruments com-
pared against a frailty reference standard across the included stud-
ies, with some studies having more than one combination of
index test and reference standard. The most frequently
implemented instruments were the fatigue, resistance, ambulation,
illnesses, and loss of weight (FRAIL) scale (22.6% of instances),
the Groningen Frailty Indicator (12.9%) and Self-Reported Health
(12.9%), representing a mix of multidimensional and unidimen-
sional indicators.
Almost two-thirds (64.5%) of all comparisons were made
against the FP alone as a reference standard, 19.4% against both
the FP and the FI, and 16.1% against the FI alone.
The most common mode of administration was self-reporting
to an external interviewer (54.8% of instances). Approximately
one-quarter of cases involved self-administration of the instru-
ment (25.8%). Finally, 19.4% of instances did not specify the
mode of administration.
Methodological quality
We assessed the 24 included articles against the JBI quality criteria.
The results of the methodological quality assessment against the
JBI criteria for included studies are shown in Table 2.
Figure 1 Study flow diagram. DTA, diagnostic test accuracy.
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Methodological quality of studies ranged from a low of 30% up to
90%, with almost 90% of included studies meeting ≥50% of qual-
ity criteria. The JBI criteria were designed for DTA-specific stud-
ies; however, in the present review, we have also applied them to
population studies. Quality should therefore be interpreted in light
of the study design. We encourage readers to refer to Table 1 for
context-specific information regarding study setting and design
when interpreting the DTA results.
Test accuracy
We were able to obtain sufficient data to calculate diagnostic test
accuracy from 14 of the included studies (Tables 3,S2, S3; Fig. S1).
The sensitivity and specificity of frailty screening instruments
against the two reference standards varied widely between
included studies that provided DTA data (Table 3).
Self-reported screening instruments meeting the minimum
sensitivity and specificity thresholds included the PRISMA-7
against the FP (two studies; sensitivity 100.0%, specificity 80.0%49
and sensitivity 93.3%, specificity 78.2%34), the GFI against the FP
(sensitivity 100.0%, specificity 80.0%49); Self-Rated Health against
the FP (sensitivity: 85%, specificity:73%34); and Self-Reported
Physical Activity against the FP (sensitivity:80.6%, specific-
ity:84.2%30) (Table 4). All instruments scoring high sensitivity also
returned a Youden index value above 0.5.
Of the results reported above, most (5 of 6) were based on
self-reported rather than self-administered instruments. Only the
Groningen Frailty Indicator against the FP (sensitivity 100.0%,
specificity 80.0%), as reported in the study by Braun et al., was
self-administered.49 However, as the sample size was small
(n = 52), this result should be interpreted with caution.
Discussion
We did not find strong and reliable evidence in support of the DTA
of self-reported instruments for the identification of frailty included
within the present study. Two candidates (the PRISMA-7 and the
Groningen Frailty Indicator) developed specifically for the identifica-
tion of frailty met our minimum sensitivity and specificity require-
ments against the FP,34,49 as did Self-Reported Health (Hoogendijk
et al.34). However, the studies from which they were drawn were
characterized by wide confidence intervals and relatively small sam-
ple sizes, and in the case of one study (Hoogendijk et al.34), a higher
prevalence of frailty than would be expected to be found within the
community due to study design. Only Self-Reported Physical Activ-
ity, not a frailty screening instrument per se, but rather a single self-
reported criterion of the FP, simultaneously met our sensitivity and
specificity criteria, and was based on a relatively large sample size
(n = 4000).30 However, none of the studies described above met the
JBI criterion for random or consecutive recruitment and/or were
deliberately structured to achieve an overrepresentation of frail indi-
viduals, limiting their reliability and generalizability.
The present review found very high heterogeneity with respect
to DTA, study design, index test and reference standard between
the included studies. This is an important consideration, because
study methodology, sample size, setting, and selection of both
index test and reference standard are all likely to have influenced
DTA results. Very few studies compared the same index test and
reference standard, making a meta-analysis statistically unviable.
In this respect, the present results were consistent with other studies
in finding substantial variability for the DTA of frailty screening
instruments.11,14,15
In the included studies, the reference standard was commonly
modified, which complicates interpretation of the present results.
The majority of studies that used the FP as a reference standard in
this review included variables that differed from the original for-
mulation specified by Fried et al.20 The FP is commonly modified
due to the availability of variables or ease of data collection across
studies, and the modification of variables has implications for
frailty prevalence, and thus also DTA findings.53 Furthermore, we
observed considerable variation in terms of the threshold for
frailty used for the FI across a number of studies, which ranged
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make definitive recommendations regarding the DTA of various
self-reported instruments in their ability to identify frailty, and this
also impacts healthcare providers and policymakers in determin-
ing whether a particular instrument is sufficiently accurate to
apply for population level or clinic in frailty screening.
No conclusive statement can be made regarding the accuracy
of self-reported versus self-administered tests. In the present
review, the screening tests were interviewer-administered in the
majority of instances (54.8%), a much smaller proportion were
self-administered (25.8%) and 19.4% had an unknown mode of
administration. In a number of studies, screening tests were either
interviewer or self-administered concurrent to a broader assess-
ment, which included a range of questions covering geriatric syn-
dromes, health conditions and disability. Different methods of
questionnaire administration have been identified as impacting the
quality of data collected, with differences most marked between
interview and self-administration.54 Factors, such as cognitive bur-
den of questionnaires, control over pace of interview, rapport
between interviewer and respondent, and social desirability bias,
are recognized as contributing to potential differences in
responses.54 Therefore, the accuracy of using self-reported, but
not self-administered, frailty screening tools within community-
based frailty screening, particularly in populations with low levels
of education or literacy, is unclear.
The key strength of the present review is to deliver the first
(to our knowledge) comprehensive appraisal of the DTA of self-
reported and/or self-administered screening instruments for the
identification of frailty. Consequently, we anticipate that the data
presented within this review will be particularly relevant to those
seeking to implement surveys carried out by post, online or in
waiting room-type environments. It has also greatly expanded the
number of studies and instruments included in previous reviews.
Furthermore, we have calculated and reported comprehensive
DTA statistics for each of the included studies. For a number of
studies, these data were not reported in the original publications,
and have been sourced through direct communication with
authors.
The present review also identified a number of novel measures
that might be further explored in future DTA studies of instru-
ments for the identification of frailty; for example, the inclusion of
instruments not specific to frailty, such as self-reported health and
self-reported physical exhaustion, both of which returned higher
sensitivity results than some of the instruments designed specifi-
cally to identify frailty. In addition, the present study makes a
range of new contextual and diagnostic information available,
including the Youden Index, which is of potential clinical rele-
vance in making decisions about screening.
There were a number of limitations associated with the present
study. The most significant of these was the heterogeneity charac-
terizing our included studies (particularly with regard to the FI,
where multiple thresholds have been applied), making interpreta-
tion challenging. However, in the absence of consensus within the
field on many aspects of frailty screening, we believe that it
remains important to present the full range of results, so that
policymakers and practitioners can come to their own conclusions
about the appropriateness of various instruments based on their
intended context of use. Additionally, we acknowledge that a
number of the included studies were not explicitly designed as
DTA studies, but rather, might have been designed for another
purpose, such as population-level cohorts. A further limitation is
that we did not include self-reported FI as index tests within our
study. Despite the fact that a self-reported FI can be used for
frailty screening, it also meets the criteria of being a reference
standard for frailty,19 and hence was outside the scope of the
present review. Finally, although we focused this review on older
adults aged ≥65 years, we acknowledge the possibility that a
potential source of the heterogeneity we observed in the results
might be due to differences in functional ability between younger
and older age groups within this cohort.
In order to focus the review, we deliberately excluded studies
focusing on certain populations (cancer and surgical patients) and
settings (residential care, acute care and emergency departments).
Therefore, our findings do not extend beyond community set-
tings. Furthermore, studies that focused on the feasibility of tool
administration and predictive, rather than diagnostic, accuracy
were outside the scope of this review. Where the DTA informa-
tion on the accuracy of screening instruments is limited, it might
be optimal to also consider the predictive accuracy of these instru-
ments (mortality, hospitalization, institutionalization etc.) before
implementing them at a population level or in a clinical setting.
The ability of self-reported instruments to predict adverse out-
comes is an important feature of screening instruments that
should be considered where DTA findings are inconclusive.
Finally, despite the comprehensiveness of our search strategy, it
might be possible that we have inadvertently omitted studies that
were relevant to our review.
There are a number of implications for frailty screening using
self-reported or self-administered instruments that can be drawn
from our results. First, the relatively low accuracy of many of the
formal screening instruments currently in wide use potentially
restricts the field of choice; however, this decision is largely
dependent on the purpose for screening. The appropriate sensitiv-
ity for a self-reported instrument in the identification of frailty
might vary according to the context in which such an instrument
is used. Although a lower sensitivity might be appropriate in a pri-
mary care setting where follow-up investigation can more readily
occur, the presence of a large number of false positive results
might be problematic in larger-scale population-level screening of
frailty. The ethics of frailty screening require follow-up consulta-
tion with a health professional in the event of a positive result;55
therefore, the DTA of a screening instrument has implications in
terms of health resource utilization. Other outcomes, such as pre-
dictive validity, might need to be considered alongside DTA when
considering a self-report instrument for the identification of
frailty.
Alternatively, another option is to consider whether a self-
reported reference standard could be practically applied in
preference to a frailty screening instrument. Frailty screening
instruments are commonly developed as alternatives to reference
standards for purposes of efficiency, but this might come at the
expense of clinical relevance and accuracy.56 A fully self-reported
FI has been identified as having similar characteristics to a test-
based FI.53 Requiring a minimum of 30 variables, this could be
considered as a viable alternative. Otherwise, in contexts where
self-reporting is not possible, and where equipment and space
allow, the FP, a combined test-based and self-report FI or a non-
self-reported instrument (such as gait speed) meeting accuracy
requirements might be able to be administered.
Regardless, any decision on a frailty screening instrument
depends on the purpose for selecting the instrument, and which
approach to frailty best fits the requirements of the health organi-
zation or practitioner recommending the test. It is widely recog-
nized within the frailty literature that the FP and FI approaches to
measuring frailty are essentially different (although complemen-
tary).57 For example, the FP has been proposed as more amenable
to a “first contact” with an individual, as it relies on general signs
and symptoms, and does not readily signify what should be done
by way of therapeutic follow up. In contrast, the FI, as a
RC Ambagtsheer et al.
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multidimensional frailty assessment (often based on a comprehen-
sive assessment), can indicate where clinicians or health service
providers might need to focus their intervention.57 This difference
can influence the motivation for selecting a screening instru-
ment;10 for example, if the instrument is to be used within a large,
population-based study, further investigation will be a priority.
Conversely, if it is to be used for diagnostic screening and assess-
ment, for example, within a primary care context, the ability to
intervene based on information collected will be important.
Although the body of literature on frailty is expanding rapidly, it
appears that there remain an insufficient number of high-quality,
sufficiently-powered DTA studies to enable meaningful conclusions
to be drawn about the performance of individual frailty screening
instruments.58 More studies are required examining the DTA of
self-reported frailty screening instruments for the identification of
frailty in community settings. In the present review, we have com-
bined large population-based studies and smaller clinical studies of
community-dwelling participants. The justification for this choice
was to maximize the available evidence on screening instruments,
and centralize the results to inform research and practice. However,
as the frailty evidence base grows, it might be useful to narrow the
inclusion criteria to DTA studies only in a future review.
The present study has identified several self-reported instru-
ments with potential for application within community settings.
However, despite four screening instruments across three studies
reporting sensitivity and specificity within a desirable range, diag-
nostic accuracy was clouded by study design and sampling issues,
in particular participant selection. The current evidence for the
DTA of many screening instruments does not support their wide-
spread use to identify frailty in community-dwelling adults. Pre-
dictive validity, which was outside the scope of this review, might
be an alternative outcome to inform health policy and practice
decision-making regarding instrument selection for this popula-
tion. Further well-designed DTA studies of self-reported screen-
ing instruments to identify frailty are required.
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Chapter 8 
Recurrent measurement of frailty is important for mortality prediction: 
Findings from the North West Adelaide Health Study. 
Recurrent measurement of frailty is important for mortality prediction: Findings from the 
North West Adelaide Health Study is a paper published in the Journal of the American 
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8.1 Summary
Background: Frailty places individuals at greater risk of adverse health outcomes, however, it 
is a dynamic condition and may not always lead to decline. 
Objectives: To determine the relationship between frailty status (at baseline and follow-up) 
and mortality using both the frailty phenotype (FP) and frailty index (FI). 
Design and setting: Population-based cohort of community-dwelling older adults 
Participants: 909 individuals aged ≥ 65 years (55% female), mean age 74.4 (6.2) years, had 
frailty measurement at baseline. 549 participants had frailty measurement at 2 time points. 
Measurements: Frailty was measured using the FP and FI, with a mean 4.5 years between 
baseline and follow-up. Mortality was matched to official death records with a minimum of 10 
years follow-up. 
Results: For both measures, baseline frailty was a significant predictor of mortality up to 10 
years, with initially good predictive ability (AUC 0.8-0.9) decreasing over time. Repeated 
measurement at follow-up resulted in good prediction compared to lower (AUC: 0.6-0.7) 
discrimination of equivalent baseline frailty status. In a multivariable model, frailty 
measurement at follow-up was a stronger predictor of mortality compared to baseline. Frailty 
change for the Continuous FI was a significant predictor of decreased or increased mortality 
risk based on corresponding improvement or worsening of score (HR = 1.04, 95%CI = 1.02-
1.07, p = .001). 
Conclusions: Frailty measurement is a good predictor of mortality up to 10 years, however, 
recency of frailty measurement is important for improved prediction. A regular review of 





Recurrent Measurement of Frailty Is Important for Mortality
Prediction: Findings from the North West Adelaide Health Study
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OBJECTIVES: Frailty places individuals at greater risk of
adverse health outcomes. However, it is a dynamic condition
and may not always lead to decline. Our objective was to
determine the relationship between frailty status (at baseline
and follow-up) and mortality using both the frailty pheno-
type (FP) and frailty index (FI).
DESIGN: Population-based cohort.
SETTING: Community-dwelling older adults.
PARTICIPANTS: A total of 909 individuals aged 65 years
or older (55% female), mean age 74.4 (SD 6.2) years, had
frailty measurement at baseline. Overall, 549 participants
had frailty measurement at two time points.
MEASUREMENTS: Frailty was measured using the FP and
FI, with a mean 4.5 years between baseline and follow-up.
Mortality was matched to official death records with a min-
imum of 10 years of follow-up.
RESULTS: For both measures, baseline frailty was a signifi-
cant predictor of mortality up to 10 years, with initially good
predictive ability (area under the curve [AUC] = .8-.9) decreas-
ing over time. Repeated measurement at follow-up resulted in
good prediction compared with lower (AUC = .6-.7) discrimi-
nation of equivalent baseline frailty status. In a multivariable
model, frailty measurement at follow-up was a stronger pre-
dictor of mortality compared with baseline. Frailty change for
the Continuous FI was a significant predictor of decreased or
increased mortality risk based on corresponding improvement
or worsening of score (hazard ratio = 1.04; 95% confidence
interval = 1.02-1.07; P = .001).
CONCLUSIONS: Frailty measurement is a good predictor
of mortality up to 10 years; however, recency of frailty
measurement is important for improved prediction. A regu-
lar review of frailty status is required in older adults. J Am
Geriatr Soc 00:1-7, 2019.
Key words: frailty; Australia; mortality; longitudinal
study; older adults
Frailty represents a state of decreased physiologic reservethat places individuals at a greater risk of adverse out-
comes such as disability, institutionalization, and death.1,2
Despite the negative perceptions associated with frailty, it is
possible for frailty status to improve or to remain stable
over time.3,4 This finding is pertinent because interventions
exist that may slow or reverse the frailty process.1,5 The
routine assessment of the frailty status of older adults has
been highlighted as a key activity in primary care so these
interventions might be offered in a timely manner.6-8
The two main approaches to describing frailty are the
frailty phenotype (FP) that defines frailty as a biological
syndrome based on five physical variables,9 and the accu-
mulation of deficit approach that represents the proportion
of deficits present across a range of systems and is represen-
ted as a frailty index (FI).10 A number of studies examined
the relationship between frailty and mortality, and they
identified that when compared with non-frail individuals,
those classified as frail by either the FP or FI have a greater
risk of death.2,11-14 The method of frailty measurement has
an impact on both frailty prevalence and mortality risk, with
the more encompassing definition of the FI generating a
higher prevalence.2 Additionally, there is a cumulative effect
where the presence of an increased number of deficits is asso-
ciated with greater mortality risk.13
Frailty was identified as a significant long-term predictor
of mortality, with predictive strength best over a shorter
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follow-up,2 potentially due to the dynamic nature of frailty
where change is likely over time.12 The relationship between
change in frailty classification and mortality was explored in
single studies for the FP15 and the FI.16 Although clinicians
increasingly recognize the need for assessing frailty status,8
review of frailty status following intervention requires just as
much attention. Understanding the relationship between chang-
ing frailty status and mortality may help provide the evidence
base that clinicians need to be convinced that both assessment
and review of frailty status may be of benefit to their patients.
The aim of this study was to examine the predictive
ability of frailty classification on mortality over 10 years
and the effect of recency of frailty measurement (at follow-
up 4.5 y later) on mortality prediction for both the FP and
FI in the North West Adelaide Health Study (NWAHS).
METHODS
Sample
This study is a secondary analysis of the NWAHS, a longitudi-
nal population survey consisting of community-dwelling adults
randomly selected from households in the northwest region of
metropolitan Adelaide.17 Participants attended a clinic and
completed a written and telephone survey for each study stage.
Because the probability of selection was known, data were
weighted to the area population. The South Australia Health
Human Research Ethics Committee (reference no. HREC/15/
TQEH/61) provided ethics approval for this study.
The baseline cohort of this study included participants
aged 65 years or older who completed stage 2 (2004-2006)
(baseline). We excluded participants who had a FP score with
fewer than three valid responses or a FI with fewer than
27 (20% missing) valid responses at baseline. To examine
the effect of recency of frailty measurement, we analyzed a
returning sample of participants who attended both stage 2
(baseline) and stage 3 (2008-2010) (follow-up) with the same
exclusion criteria for FP and FI valid responses as at baseline.
Participant mortality information was drawn from data mat-
ched to official death records and used to calculate number of
years survived from follow-up, with all participants having a
minimum of 10 years of follow-up from baseline.
Frailty Phenotype
A modified FP was used in this study with identical variables
used at baseline and follow-up (Table S1). Three iterations of
the FP were used: a Continuous FP; a 5-Category FP (0 char-
acteristics, 1 characteristic, 2 characteristics, 3 characteristics,
4-5 characteristics); and a 3-Category FP (individuals with
three or more characteristics were classified as frail; those
with one or two characteristics were classified as pre-frail;
and those with no characteristics present were non-frail).9
The modified FP used in NWAHS was described previ-
ously.18 Although the FP was originally designed as a cate-
gorical variable, it has been used in continuous form.18,19
Frailty Index
We developed a 34-item FI following a standard methodol-
ogy20 (Table S1). Three iterations of the FI were used: a Con-
tinuous FI; a 10% Increment FI (0-10%, 10-20%, 20-30%,
30-40%, 40-50%, and >50% proportion of deficits); and a
3-Category FI (>.21 proportion of deficits = frail; .10 and
.21 = pre-frail; and <.10 non-frail). The FI used in NWAHS
was described previously.18
Data Analysis
We used SPSS v.23 software (IBM Corp, Armonk, NY) for
all statistical analysis. Cohort case weights were used in anal-
ysis and for reporting percentages to ensure the sample was
representative of the population of North West Adelaide.
Weighting was rescaled to sum to the sample size for the
returning sample to adjust for attrition. An α value of .05
was used for determining statistical significance. Participants
in the cohort were matched against death records to deter-
mine the time of death. All-cause mortality was analyzed.
Descriptive characteristics and the number and proportion
of participants classified as non-frail, pre-frail, and frail were
reported according to mortality rate at 1, 2, 4, 6, 8, and
10 years from baseline. State transitions including participants
lost to follow-up were reported. Complex samples procedures
were used in SPSS to allow for the effect of the sample design
on the standard error of estimates. We performed significance
testing of cross-tabs using a Pearson χ2 test and tests for lin-
ear by linear association. Survival was modeled using com-
plex samples Cox regression to allow for the design of the
sample, and we reported the hazard ratio. Multivariable anal-
ysis included combined frailty classification at baseline and
follow-up, sex, age group, education level, and income level.
A predictive probability of surviving 1, 2, 4, 6, 8 and 10 years
from baseline was generated through logistic regression to
generate an area under the curve (AUC) value for frailty clas-
sification at baseline as well as at follow-up.
RESULTS
This study included 909 participants (mean age = 74.4 [SD 6.2]
y; 55% female) at baseline (Table 1). We excluded 36 partici-
pants from analysis at baseline due to insufficient FI or FP
variables. For the returning cohort analysis, we included
549 participants who had frailty measurement at both stages
2 and 3. Of those excluded from the returning cohort,
147 had died between baseline and follow-up, and a further
213 were either lost to follow-up or had insufficient FI or FP
variables. The 360 participants excluded from the returning
cohort were significantly more likely to be older (mean
age = 76.9 [SD 6.2] y), have lower income status, and higher
baseline frailty prevalence (FP = 29.1% frail; FI = 62.0%
frail) than the whole sample (Table S2). All participants at
baseline had a minimum of 10 years of survival data.
Over a 10-year period, 292 (33.8%) participants died,
with men having significantly higher mortality rates (40.1%)
compared with their female counterparts (28.6%) (Table 1,
Figure 1, and Table S3). Likewise, for older age group, 10-year
mortality for those aged 75 years or older (54.3%) was signifi-
cantly higher than for those aged 65 to 74 years (17.8%).
Low-income category was also significantly associated with
mortality at the 10-year mark, at 35.5% for the lowest income
group compared with 11.6% for the higher group.
The 3-Category FP classified 18.3% of participants as
frail at baseline; 48.1% were frail according to the 3-Category
FI. Mortality was significantly higher for increasing levels of
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frailty for both the FP and FI. For the 3-Category FP, 60.2%
of individuals classified as frail had died at 10 years compared
with 26.3% of those who were non-frail. Of those classified
as frail by the 3-Category FI, 45.1% had died at 10 years, in
comparison with 21.4% of non-frail individuals. Frailty state
transitions for this cohort are presented in Table S4 and were
discussed in detail elsewhere.4
FP and FI classification at baseline significantly
predicted the probability of surviving 1, 2, 4, 6, 8, and
10 years from baseline (Table 2) through AUC analysis.
Mortality prediction was strongest at 1 year with good dis-
crimination (AUC = .8-.9) for all iterations of FP and FI
measures: All iterations retained acceptable discrimination
(AUC = .7-.8) at 2 and 4 years and low (AUC: .6-.7) but
significant prediction of mortality at 6, 8, and 10 years.
Repeated frailty measurement at follow-up, for the
returning cohort of 563 participants, resulted in good dis-
criminative ability for all iterations of the FP and FI at 6, 8,
and 10 years from baseline (that equates to approximately
2, 4, and 6 years post follow-up), compared with low dis-
crimination for equivalent baseline measurement (Table 2).
In a multivariable model that included frailty status at
both baseline and follow-up for the returning sample of
563 participants, frailty measurement at follow-up, but not at
baseline, was significantly associated with mortality for all
iterations of the FP and the 3 Category FI; however, both
time points were significant for the Continuous FI and the
10% Increment FI (Table 3). The significant negative coeffi-
cient for the latter measures at baseline is a masked result due
to possible suppression by the stronger predictor at follow-
up. Addressing this by including frailty change (Continuous
FI: follow-up minus baseline) in the model, each 1% improve-
ment or worsening in the Continuous FI was associated
with a corresponding 4% significant increase or decrease,
respectively, in mortality risk (hazard ratio [HR] = 1.04; 95%
confidence interval [CI] = 1.02-1.07; P = .001). The Continu-
ous FI at follow-up remained a significant mortality predictor
in this model. Analysis of the returning sample examining
baseline and follow-up frailty classification separately illus-
trated the stronger association between follow-up frailty mea-
surement and mortality in comparison with baseline
measurement (Tables S5, S6, and S7).
Compared with a reference category of 0 characteristics,
significant elevated mortality risk was identified at three
characteristics for the 5-Category FP at follow-up (HR =
2.97; 95% CI = 1.33-6.63; P = .008). For the 10% incre-
ment FI, with a reference category of 0% to 10%, a margin-
ally significant elevation of mortality risk was observed for a
10% to 20% proportion of deficits at follow-up (HR = 2.55;
95% CI = 1.00-6.46; P = .49), and significant for the 20%
to 30% proportion (HR = 4.82; 95%CI = 1.83-12.69;
P = .002). HRs at higher proportions of characteristics/defi-
cits increased exponentially and were highly significant for
both the FP and FI.
DISCUSSION
Frailty classification was a significant predictor of mortality
up to 10 years in this cohort of community-dwelling
Australian older adults, with predictive ability strongest
immediately after measurement and gradually decreasing
over time. Mortality prediction was improved by repeated
frailty measurement at follow-up.
Approximately one-third of participants died over
10 years, with mortality significantly higher for men, those
in the older age group (≥75 y), and those on the lowest
income group (<$20 000 per annum), consistent with other
studies.2,12,21
Table 1. Descriptive Characteristics of Sample at Baseline and Frailty Status for the Frailty Phenotype and Frailty
Index
Whole sample
3-Category FP, n (%) 3-Category FI, n (%)
n (%) Non-frail Pre-frail Frail Non-frail Pre-frail Frail
909 289 (30.1) 470 (51.6) 150 (18.3) 211 (21.5) 285 (30.4) 413 (48.1)
Sex
Male 453 (45.2) 165 (36.5) 229 (50.2) 59 (13.3)* 124 (27.0) 151 (34.1) 178 (38.9)*
Female 456 (54.8) 124 (24.8) 241 (57.2) 91 (22.5) 87 (16.9) 134 (27.4) 235 (55.7)
Age groups, y
65-74 554 (56.3) 204 (35.7) 295 (53.4) 55 (10.8)* 147 (26.1) 192 (33.9) 215 (40.0)*
≥75 355 (43.7) 85 (22.8) 175 (49.2) 95 (28.0) 64 (15.5) 93 (25.9) 198 (58.5)
Education levela
Up to secondary 569 (63.5) 159 (26.9) 308 (52.9) 102 (20.3)* 110 (17.8) 190 (33.3) 269 (48.9)*
Trade/Certificate/Diploma 288 (30.6) 115 (37.0) 133 (49.0) 40 (14.0) 87 (28.1) 80 (25.3) 121 (46.6)
≥Bachelor’s degree 25 (2.5) 13 (58.2) 10 (32.9) 2 (8.9) 10 (41.6) 10 (38.4) 5 (19.9)
Income groupsa
Up to $20 k 462 (46.5) 117 (23.1) 254 (55.5) 91 (21.4)* 81 (15.6) 144 (30.1) 237 (54.3)*
$20-$40 k 281 (33.5) 117 (41.2) 129 (44.6) 35 (14.2) 87 (29.1) 93 (32.3) 101 (38.6)
$40-$60 k 59 (6.8) 29 (43.6) 24 (45.3) 6 (11.1) 21 (33.1) 17 (30.4) 21 (36.5)
>$60 k 26 (2.6) 13 (47.1) 12 (49.4) 1 (3.5) 11 (36.8) 10 (39.1) 5 (24.2)
Abbreviations: FI, frailty index; FP, frailty phenotype.
Note: n, unweighted; % reported using cohort case weights. The 3-Category FP, no. of characteristics: 0, non-frail; 1-2, pre-frail, ≥3, frail; 3-Category FI, pro-
portion of deficits: 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail.
*P < .05 (main effects reported).
aMissing nor included.
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We examined various iterations of the FP (Continuous,
5-Category, and 3-Category) and the FI (Continuous, 10%
Increment, and 3-Category) with 18.3% of individuals clas-
sified as frail by the 3-Category FP and 48.1% by the
3-Category FI. Both frailty measures in all their iterations
demonstrated significant discriminative ability in predicting
mortality over 10 years, with AUC prediction initially excel-
lent (AUC = .8-.9), decreasing incrementally over time to
low (AUC = .6-.7).22 Frailty measurement for all iterations
of the FP and FI at follow-up had excellent discriminative
ability for mortality, compared with the low AUC of
corresponding baseline measurements. This finding is con-
sistent with the literature, where the strongest association
with mortality is immediately after the frailty measurement,
remaining predictive up to 11 years.2 These findings are
likely due to the dynamic nature of frailty where individuals
are more likely to worsen with increasing age; hence mor-
tality prediction is better over shorter follow-up periods.12
When we examined each iteration of the FP and the FI
in multivariable analysis that included both baseline and
follow-up measurement, frailty measurement at follow-up,
but not at baseline, was significantly associated with mortal-
ity for all iterations of the FP and the 3-Category FI; mea-
surements at both time points were significant for the
Continuous FI and 10% Increment FI. The separate analysis
of the returning sample also illustrated the stronger associa-
tion of follow-up measurement, countering the effect of bias
of being more likely to lose those who were frail at baseline.
Frailty change (between baseline and follow-up) for the
Continuous FI was a significant predictor of decreased or
increased mortality risk in this study based on corresponding
improvement or worsening of frailty, consistent with the
Figure 1. Mortality rates (proportion dead) over 10 years by baseline frailty status for the frailty phenotype (FP) and frailty index
(FI). Proportions reported using cohort case weights. Error bars represent 95% confidence intervals. Note: 3-Category FP, no. of
characteristics present: 0, non-frail; 1-2, pre-frail, ≥3, frail; 5-Category FP, no. of characteristics present: 0, 1, 2, 3, 4-5; 3-Category
FI, proportion of deficits: 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail; 10% Increment FI: 0%-10%, 10%-20%, 20%-
30%, 30%-40%, 40%-50%, >50%.
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findings of Chamberlain and colleagues.16 Although not sig-
nificant in this study, worsening of FP status was identified
elsewhere with increased mortality risk.15 The FI was
described as being more sensitive to change and having more
precise mortality risk prediction compared with the FP due
to its more comprehensive nature.12,16
The findings of our research for the FP were consistent
with those of the original FP study in which three character-
istics was identified as a significant cut point for elevated
mortality risk,9 and furthermore, that each increase in the
number of FP characteristics is associated with elevated
mortality risk.23
However, our finding that those classified as frail by
the 3-Category FP at follow-up had over triple the mortality
risk compared with those who were non-frail was slightly
higher than that of a systematic review by Chang and Lin11
(pooled HR = 2.00) but was within the range of included
studies. The FP has good predictive ability of mortality, and
with only five variables for measurement, this approach is
clinically feasible but limited in terms of the scope of char-
acteristics measured compared with the FI.23
Likewise, our findings for the FI reflected those of other
studies that demonstrated a dose-response relationship
between higher proportions of FI deficits of worse sur-
vival.10,14,24,25 In this study, the 7% increase in mortality
risk for each 1% increase in proportion of deficits at follow-
up for the Continuous FI was higher than the pooled risk of
4% per 1% increase in FI described in a systematic review
by Kojima and colleagues.12 However, it was within the
upper range of studies included in that review. The FI was
described as both pragmatic and flexible in terms of frailty
measurement, and its graded system of measurement as valu-
able in providing a more sensitive risk prediction for adverse
health outcomes.12,25 The higher mortality rates for the FP
and FI in this study may be associated with the lower socio-
economic status (SES) of the NWAHS region compared with
the Australian population.26 The use of routinely collated
data from electronic health records in both the primary care
and acute settings are likely to enhance the feasibility of
automated repeat measurements of frailty,27,28 and evolving
wearable technologies may provide real-time data on the
dynamic nature of the frailty syndrome.29,30 These develop-
ments call for a new generation of dynamic frailty studies.
Strengths of this study were the use of population-based
data for both the FP and FI, and 10 years of follow-up mat-
ched to official death records. Limitations of this study
included a lack of some aging-specific variables such as walk-
ing speed or cognitive impairment in the data set, the use of
a modified FP, and the lower SES of the NWAHS in compar-
ison with the broader Adelaide metropolitan area. Addition-
ally, the inclusion of only community-dwelling participants
in this study, and the exclusion of 360 participants from the
returning cohort who were more likely to be older, have
lower income status, and higher baseline frailty prevalence
than those included, is likely to have resulted in an underesti-
mation of frailty prevalence at baseline and follow-up, and it
may have weakened the mortality prediction for frailty at
follow-up. Furthermore, the 4.5-year interval between base-
line and follow-up allows the effect of time to become more
evident with participants in the returning sample more likely
Table 2. Discriminative Ability of Frailty Phenotype and Frailty Index at Baseline and at Follow-up for Predicting
Mortalitya
Whole sample (n = 909)
AUC (95% CI)
1 y 2 y 4 y 6 y 8 y 10 y
FP at baseline
Model 1: Continuous FP .87 (.81-.94)* .78 (.71-.85)* .73 (.68-.79)* .68 (.63-.73)* .66 (.62-.71)* .67 (.62-.71)*
Model 2: 5-Category FP .87 (.80-.93)* .78 (.71-.85)* .73 (.68-.80)* .69 (.64-.74)* .67 (.63-.72)* .67 (.63-.71)*
Model 3: 3-Category FP .85 (.77-.93)* .77 (.69-.84)* .71 (.66-.78)* .68 (.63-.73)* .67 (.62-.71)* .66 (.62-.71)*
FI at baseline
Model 4: Continuous FI .83 (.74-.92)* .76 (.69-.84)* .73 (.67-.79)* .68 (.63-.73)* .65 (.61-.70)* .66 (.62-.70)*
Model 5: 10% Increment FI .82 (.73-.92)* .79 (.72-.86)* .76 (.71-.81)* .71 (.66-.76)* .68 (.64-.73)* .68 (.64-.72)*
Model 6: 3-Category FI .80 (.70-.90)* .75 (.68-.83)* .73 (.68-.79)* .70 (.65-.74)* .68 (.64-.72)* .68 (.64-.72)*
Returning sample (n = 549) b
FP at follow-up 1.6 yc 3.6 yc 5.6 yc
Model 1: Continuous FP - - - .85 (.80-.91)* .82 (.76-.88)* .80 (.74-.85)*
Model 2: 5-Category FP - - - .88 (.83-.94)* .84 (.78-.90)* .80 (.75-.85)*
Model 3: 3-Category FP - - - .87 (.83-.91)* .83 (.77-.88)* .79 (.73-.84)*
FI at follow-up
Model 4: Continuous FI - - - .87 (.82-.92) * .82 (.77-.87)* .80 (.75-.85)*
Model 5: 10% Increment FI - - - .87 (.82-.92)* .85 (.80-.89)* .81 (.76-.86)*
Model 6: 3-Category FI - - - .85 (.80-.89)* .83 (.78-.87)* .80 (.75-.85)*
Abbreviations: AUC, area under the curve; FI, frailty index; FP, frailty phenotype.
Note: 5-Category FP, no. of characteristics: 0, 1, 2, 3, 4-5; 3-Category FP, no. of characteristics: 0, non-frail; 1-2, pre-frail, ≥3, frail; 10% Increment FI: 0%-
10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, >50%; 3-Category FI (proportion of deficits): 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail.
*P < .001.
aAUC for years survived from baseline. Adjusted for age, sex, education, and income. Follow-up mean = 4.5 years.
bAUC for the returning sample at follow-up is based on survival years from baseline.
cMean years between follow-up measurement and survival years from baseline.
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to have higher levels of frailty at follow-up, which is to be
expected for an aging cohort. Additionally, the Continuous
FP is an ordinal measure that does not fulfill the precondi-
tions of most parametric statistical tests; however, nearly all
articles treat this as a continuous measure, as we have done.
In conclusion, this study identified that recency of frailty
measurement is important for predicting survival. Although
frailty measurement was a significant predictor of mortality
risk up to 10 years, recency of measurement was a stronger
predictor. Routine assessment of frailty in older adults was
highlighted as important in the clinical setting,7,8 which can
feasibly be measured using routinely collected data.6,27,28 The
findings from this study have implications for the clinical set-
ting where a more recent frailty assessment is likely to provide
the best information about the health status of older adults,
taking into account the dynamic nature of the frailty condition
and that regular reevaluation is necessary to keep this frailty
profile up to date.
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Chapter 9 
The combination of frailty and sarcopenia is an important mortality 
predictor: North West Adelaide Health Study findings 
This chapter is a reproduction of a paper submitted to the Journal of Gerontology Series A. The 
statement of authorship and paper (.pdf) follow over the page. 
Additional table(s) and/or figure(s) are provided in the Supplementary material for Chapter 9. 
9.1  Summary 
Background: Frailty and sarcopenia are age-related conditions with shared features and 
associated with adverse health outcomes. Relatively little is known about outcomes of these 
conditions in combination. The aim of this study was to examine the predictive ability of frailty 
and sarcopenia classification on mortality. 
Methods: Frailty was measured in this cohort of 716 community-dwelling adults (mean age 
74.1 (6.1) years, 55.5% female) using the frailty phenotype (FP) and frailty index (FI), and 
sarcopenia using the revised European consensus definition. Participants were classified as: 
neither frail nor sarcopenic; frail-only; sarcopenic-only; or both frail and sarcopenic. All 
participants had a minimum of 10-years mortality follow-up. 
Results: Classification as both frail and sarcopenic resulted in a multivariable model resulted 
in significantly elevated mortality risk for the FP (HR = 4.78, p<.001) and FI (HR = 4.90, 
p<.001), which was over four times that of those neither frail nor sarcopenic.  Frail-only was 
also a significant mortality predictor for both the FP (HR = 1.78, p=.010) and FI (HR = 2.05, 
p<.001), while sarcopenic-only approached significance in the FP model (HR = 1.71, p=.100) 
and the FI model (HR = 2.01, p=.081). Significant associations were maintained in a sensitivity 
analysis that excluded weak grip strength from both the FP and FI. 
Conclusions: Individuals identified as frail would benefit from screening and assessment for 
sarcopenia, and vice versa for those identified as sarcopenic, as the mortality risk for 




9.3 Submission to the Journal of Gerontology Series A 
The combination of frailty and sarcopenia is an important mortality 
predictor: North West Adelaide Health Study findings 
Introduction 
Frailty and sarcopenia are two common conditions experienced by older adults, 
with evidence to suggest that both are associated with adverse outcomes such as 
hospital admission, disability, and mortality (Clegg, Young, Iliffe, Rikkert, & 
Rockwood, 2013; Cruz-Jentoft & Sayer, 2019). Frailty is described as a state of 
reduced physiological reserve and failure of homeostatic mechanisms (Clegg et al., 
2013), while sarcopenia is a skeletal muscle disorder characterized by loss of muscle 
mass and function (Cruz-Jentoft & Sayer, 2019). Increasingly, frailty and sarcopenia 
are being examined together, as these conditions share features in common, in 
particular in relation to lower lean mass and physical function (Cesari, Landi, Vellas, 
Bernabei, & Marzetti, 2014). 
Internationally, frailty prevalence in community-dwelling adults aged ≥65 years has 
been estimated as ranging between 4% to 17% (9.9% weighted mean) using the FP 
approach, and between 4% to 59% (13.6% weighted mean) using an accumulated 
deficits approach (i.e., Frailty Index [FI]) which classifies frailty based on a 
proportion of deficits present (Collard, Boter, Schoevers, & Oude Voshaar, 2012). 
The FI typically classifies a higher proportion of individuals as frail compared to the 
more physical definitions of frailty as it relies on a more comprehensive approach 
(Blodgett, Theou, Kirkland, Andreou, & Rockwood, 2015; Thompson, Theou, 
Adams, Tucker, & Visvanathan, 2018). While both approaches to measurement are 
strongly correlated, there is only modest agreement in terms of frailty classification 
(Thompson, Theou, Yu, et al., 2018). We have previously described that both the FP 
and FI are significantly predictive of mortality up to 10 years in this cohort, where 
frailty prevalence was 18.3% FP and 48.1% FI (Thompson, Theou, Tucker, Adams, & 
Visvanathan, 2019). 
Sarcopenia prevalence has been estimated at 10% in adults aged ≥60 years (Shafiee 
et al., 2017). We have previously reported the prevalence of sarcopenia as being 6.2% 
for men and 9% for women aged ≥ 65 years in the North West Adelaide Health 
Study (NWAHS) cohort (Yu et al., 2014). Prevalence varies on the method of 
measurement utilised, and in this cohort sarcopenia has been defined as the lowest 
20% of the study population for low appendicular muscle mass (ASM) (male: < 7.36 
kg/m2, female: < 5.81 kg/m2), and < 30kg (male) and < 20kg (female) for weak grip. 
The significant association between sarcopenia and increased mortality risk has 
been established internationally (pooled HR = 1.60, p = .216) (Liu et al., 2017), 
however, this relationship is yet to be examined in an Australian cohort.  
The prevalence of frailty and sarcopenia in combination has been explored in a 
small number of studies. Mori et al (2019) identified 3.6% of participants in a 
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population of Japanese community-dwelling adults (n=331, mean age 71.5 [SD 5.1] 
years, 72% female) as being both frail (using FP approach) and sarcopenic, while 
Yoshimura and colleagues (2019) identified 2.1% as being both frail (FP) and 
Sarcopenic in a Japanese community-dwelling cohort (n=963, mean age 72.2 [SD 7.6] 
years, 67% female). This proportion was higher (18%, FP) for a Spanish sample of 
either hospitalized or geriatric outpatient attending adults (n=444, mean age 77.3 
[SD 8.4] years, 45% female) (Bernabeu-Wittel et al., 2019), and for a sample of 
participants attending a Dutch geriatric outpatient clinic (n = 299, mean age 82.4 [SD 
7.1] years, 65% female) at 42% (n=8) FP and 25% (n=1) FI (Reijnierse et al., 2016). This 
is the only study to date that has examined frailty, using both approaches, and 
sarcopenia. 
The adverse health outcomes associated with frailty and sarcopenia individually 
have been described in a number of studies, with frail participants having a 
significantly higher mortality risk than their non-frail counterparts (pooled RR = 
1.50, p < .001 for FP, and RR = 1.15, p < .001 for FI) (Shamliyan, Talley, 
Ramakrishnan, & Kane, 2013), and likewise for survival of sarcopenic individuals 
(pooled RR = 3.60, p < .001) (Beaudart, Zaaria, Pasleau, Reginster, & Bruyere, 2017). 
However, to the best of our knowledge, no study to date has examined the 
relationship between the combination of frailty and sarcopenia and survival in a 
community-based cohort of men and women.  It is important to understand the 
nature of this relationship for prognostication as well as when determining a 
treatment regimen.   
The aims of this study were to report on the combined prevalence of frailty and 
sarcopenia, and to examine the predictive ability of frailty alone, sarcopenia alone 
and sarcopenia in combination with frailty on mortality over 10 years in adults aged 




This study was a secondary analysis of the North West Adelaide Health Study 
(NWAHS), a longitudinal population survey of community-dwelling adults 
randomly selected from households in the North-West region of Adelaide (Grant et 
al., 2009). At each study stage, participants attended a clinic and completed phone 
and written surveys. As the probability of selection was known, data were weighted 
to the area population. SA Health Human Research Ethics Committee (Reference 
number HREC/15/TQEH/61) provided ethics approval. 
Participants in this study were aged ≥65 years who completed stage 2 (2004-2006). 
Stage 2 data were used as the basis of all frailty and sarcopenia markers. We 
excluded participants who were lacking 3 or more valid FP characteristics, with <27 
valid FI responses (20% missing) or who were lacking DEXA data. Excluded 
participants were significantly older (mean age 75.9 (SD 6.9) years) than those 
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included. Participants were matched to official death records in order to determine 
mortality, and all participants had a minimum of 10 years of follow-up from 
baseline. 
Frailty Phenotype (FP) 
Frailty for the FP was measured in this study using a modified version of that 
proposed by Fried and colleagues (Fried et al., 2001). A dichotomous FP 
classification was used, where participants with three or more of the following 
characteristics present were classified as frail: weight loss, weak grip strength, 
exhaustion, slowness, and low physical activity level, while participants with 0-2 
characteristics were classified as non-frail (See Supplementary Table S1 for cut 
points of each FP characteristic). Grip strength (kg) was based on the mean of three 
measurements of the dominant hand using a grip dynamometer (Lafayette 
Instrument Company, IN, USA). For sensitivity analysis, a 4-variable FP was used 
which excluded grip strength. The characteristics of the FP used in this study have 
been described elsewhere (Thompson, Theou, Yu, et al., 2018). 
Frailty Index (FI) 
We developed a 34-item FI following a standard methodology (Searle, Mitnitski, 
Gahbauer, Gill, & Rockwood, 2008), with variables coded as between 0, for no 
deficit, and 1, for maximum expression of deficit. A dichotomous FI classification 
was used where participants with 0 to ≤ 0.21 were classified as non-frail; and those 
with > 0.21 deficits were frail. (See Supplementary Table S1 for FI variables 
included). Grip strength, a sarcopenia biomarker, was a FI variable in this study, 
and used the same cut points as the FP. For sensitivity analysis, a 33-item FI was 
used which excluded grip strength. The characteristics of the FI used in this study 
have been described elsewhere (Thompson, Theou, Yu, et al., 2018). 
Sarcopenia 
Individuals were classified as sarcopenic if both of the following criteria were 
present: weak grip strength and low SMI. (See Supplementary Table S1 for cut 
points of each sarcopenia characteristic).  
Weak grip strength for sarcopenia was stratified by sex as: Male, < 30kg; Female, < 
20kg (Yu et al., 2014). Appendicular skeletal muscle mass (ASM) in this study was 
measured using Dual Energy X-Ray Absorptiometry (DXA), and was defined as the 
sum of lean soft-tissue masses for arms and legs, assuming that all non-fat and 
nonbone tissue are skeletal muscle. A Lunar PRODIGY scanner (GE Medical 
Systems, Madison, WI) in conjunction with Encore 2002 software and a DPX+ (GE 
Medical Systems, Madison, WI) scanner in conjunction with LUNAR software 
version 4.7e were used.  
Low SMI cut points were based on the lowest 20% of the study population stratified 
by sex: Male, < 7.36 kg/m2; Female, < 5.81 kg/m2 (Yu et al., 2014). The characteristics 
of sarcopenia used in this study meet the revised European consensus definition 
(Cruz-Jentoft et al., 2019), and have been described elsewhere (Yu et al., 2014). 
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Data Analysis 
We used SPSS version 23 (IBM Corporation, Armonk, NY) for statistical analysis in 
this study. Case weights for the cohort were used in reporting percentages and for 
analysis to ensure that the sample was representative of the population. An alpha 
value of 0.05 was used for statistical significance. We reported descriptive 
characteristics of the sample for the number and proportion classified as frail by the 
FP (FP-frail), frail by the FI (FI-frail), and sarcopenic. 
Complex samples procedures were used in SPSS to allow for the effect of the sample 
design on the standard error of estimates. Complex samples Cox regression was 
used to model survival, which allowed for the sample design, and we reported the 
hazard ratio.  
Multivariable analysis was performed separately for FP-frailty, FI-frailty, and 
sarcopenia, adjusting for sex, age, education level, and income. Multivariable 
analyses were also performed in models which classified participants as: neither 
frail or sarcopenic; frail-only; sarcopenic-only; and both frail and sarcopenic, for 
both the FP and FI. Pearson’s correlation was performed between both frailty 
measures and sarcopenia, as continuous variables. In order to minimize 
measurement overlap between frailty and sarcopenia, a sensitivity analysis was 
conducted by excluding frailty cases for which weak grip strength was part of the 
qualifying criteria, for both the FP and FI. Additionally, we examined the interaction 
between frailty and sarcopenia for both the FP and FI by fitting a Cox model that 
included the main effects of frailty and sarcopenia as well as an interaction term 
between frailty and sarcopenia. We performed ANOVA with post hoc multiple 
comparisons to compare mean FP and FI values for those classified as frail only or 
both frail and sarcopenic, to examine the severity of frailty for each classification. 
Results 
In this longitudinal cohort of 716 community-dwelling Australian adults aged ≥65 
years (mean age 74.1 (6.1) years, 55.5% female), 18.3% were classified as frail using 
the FP, 49.3% frail using the FI, and 9.8% Sarcopenic. Descriptive characteristics of 
the sample and relationship with frailty and sarcopenia classification are reported in 
Table 1. (see Supplementary Table S2 for descriptive characteristics by classification 
as neither, only or both frail and sarcopenic) The proportion of participants 
classified according to FP or FI frailty status, and FP or FI frailty status with 
sarcopenia is presented in Figure 1. While the FP and FI were strongly correlated (r = 
.764, p < .001), there was a moderate significant correlation between both the FP and 
sarcopenia (r = .479, p < .001), and the FI and sarcopenia (r = .330, p = .003). There 
was no significant difference in mean frailty scores between those classified as FP 
frail-only and both FP-frail and sarcopenic. However, FI frail-only participants had a 
significantly lower proportion of deficits compared to those both FI-frail and 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Mortality Risk - Frailty & Sarcopenia Separate 
Participants who were classified as FP-frail had over double the adjusted mortality 
risk (HR = 2.23, 95%CI -= 1.55-3.22, p < .001) of their non-frail counterparts, which 
was also the case for FI-frail participants (HR = 2.18, 95%CI = 1.55-3.07, p < .001), and 
sarcopenic participants (HR = 2.45, 95%CI = 1.57-3.81, p < .001) (Table 2). (See 
supplementary Table S4 for results stratified by sex). 
Table 2.  Relationship of frailty classification (Frailty Phenotype and Frailty Index) and Sarcopenia with survival 
(over 10 years), with FP frailty, FI frailty, and sarcopenia analysed individually. Complex samples Cox 
regression, adjusted for: age, sex, income, education. 
Unadjusted Adjusted 
n (%) HR (95%CI) p-value HR (95%CI) p-value 
Total 716 - - 
FP Frailty 
Non-Frail 598 (81.7) 1 1 
Frail 118 (18.3) 2.87 (2.09, 3.93) p < .001* 2.23 (1.55,3.22) p < .001* 
FI Frailty 
Non-Frail 387 (50.7) 1 1 
Frail 329 (49.3) 2.31 (1.72, 3.12) p < .001* 2.18 (1.55, 3.07) p < .001* 
Sarcopenia 
Non-Sarcopenic 646 (90.2) 1 1 
Sarcopenic 70 (9.8) 3.59 (2.45, 5.25) p < .001* 2.45 (1.57, 3.81) p < .001* 
Note. HR, Hazard Ratio; 95%CI, 95% Confidence Interval. FP categories: 0-2 characteristics, non-frail; ≥3 characteristics, 
frail. FI categories: 0 to ≤ 0.21 deficits, non-frail; > 0.21 deficits, frail. Sarcopenia categories: 0-1 characteristics, not 
sarcopenic; 2 characteristics, sarcopenic. The follow-up window for mortality was from study entry over the period 2004-
2006 to a censoring date of 30/9/2016, with a minimum of 10 years of mortality data for all participants. 
* p < 0.05
Mortality risk - Frailty & Sarcopenia Combined
For the FP and sarcopenia examined together, 4.5% of participants were classified as both
FP-frail and sarcopenic, while 13.8% were FP-frail-only and 5.3% sarcopenic-only, with the
remaining 76.4% as neither FP-frail nor sarcopenic (Table 3). For the FI and sarcopenia
examined together, 6.5% were classified as both FI-frail and sarcopenic, while 42.8% were
FI-frail-only and 3.3% sarcopenic-only, with the remaining 47.4% as neither FI-frail nor
sarcopenic (Table 3). 4.3% of participants were classified as frail and sarcopenic by both
frailty instruments. (See supplementary Table S5 for results stratified by sex).
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Table 3.  Relationship of frailty and sarcopenia status with survival (over 10 years).  Complex samples Cox 
regression. Adjusted for: age, sex, income, education. 
n (%) 
Unadjusted 
HR (95% CI) p-value 
Adjusted  
HR (95%CI) p-value 
Total 716 - - 
FP Frailty & Sarcopenia Status 
Neither frail nor sarcopenic 558 (76.4) 1 1 
Frail only 88 (13.8) 2.48 (1.71, 3.61) p < .001* 1.78 (1.15, 2.76) p = .010* 
Sarcopenic only 40 (5.3) 2.96 (1.71, 5.14) p < .001* 1.71 (.90, 3.23) p = .100 
Both frail and sarcopenic 30 (4.5) 6.66 (4.05, 10.97) p < .001* 4.78 (2.79, 8.19) p < .001* 
FI Frailty & Sarcopenia Status 
Neither frail nor sarcopenic 362 (47.4) 1 1 
Frail only 284 (42.8) 2.18 (1.57, 3.03) p < .001* 2.05 (1.42, 2.96) p < .001* 
Sarcopenic only 25 (3.3) 3.26 (1.65, 6.43) p < .001* 2.01 (.91, 4.83) p = .081 
Both frail and sarcopenic 45 (6.5) 7.16 (4.40, 11.67) p < .001* 4.90 (2.84, 8.47) p < .001* 
Note. HR, Hazard Ratio; 95%CI, 95% Confidence Interval. FP categories: 0-2 characteristics, non-frail; ≥3 characteristics, 
frail. FI categories: 0 to ≤ 0.21 deficits, non-frail; > 0.21 deficits, frail. Sarcopenia categories: 0-1 characteristics, not 
sarcopenic; 2 characteristics, sarcopenic. The follow-up window for mortality was from study entry over the period 2004-
2006 to a censoring date of 30/9/2016, with a minimum of 10 years of mortality data for all participants. 
* p < 0.05
Classification as both FP-frail and sarcopenic resulted in a more than quadrupled mortality 
risk (HR = 4.78 95%CI = 1.15-2.76, p < .001) compared to the reference category of neither 
FP-frail nor sarcopenic, in a multivariable analysis that adjusted for age, sex, income and 
education.  
This was also the case for those who were FI-frail and sarcopenic (HR = 4.90, 95%CI = 2.84-
8.47, p < .001). Figure 2 presents survival curves based on frailty or sarcopenia classification 
for both FP and FI models. Mortality risk was also significantly elevated for frail-only 
participants for both the FP (HR = 1.78 95%CI = 2.79-8.19, p = .010) and FI (HR = 2.05, 
95%CI = 1.42-2.96, p < .001). Classification as sarcopenic-only approached significance in 
both the FP model (HR = 1.71, 95%CI = .90-3.23, p = .100) and the FI model (HR = 2.01, 
95%CI = .91-4.83, p = .081). Survival patterns with similar significant associations were 
evident in a sensitivity analysis which excluded frailty cases for which weak grip strength 
was part of the qualifying criteria, for both the FP and FI (Supplementary Table S6). In a 
model which included an interaction term between frailty and sarcopenia, the interaction was 
non-significant (p = .749) (data not shown). 
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Figure 2. Survival curves for frailty and sarcopenia classification predicted from complex samples Cox regression 
(n=716), for: a) Frailty Phenotype (FP) and Sarcopenia; b) Frailty Index (FI) and Sarcopenia. Adjusted for age, sex, 
income, education. A minimum of 10 years of mortality data was available for all participants. FP categories: 0-2 
characteristics, non-frail; ≥3 characteristics, frail. FI categories: 0 to ≤ 0.21 deficits, non-frail; > 0.21 deficits, frail. 
Sarcopenia categories: 0-1 characteristics, not sarcopenic; 2 characteristics, sarcopenic. HR, Hazard Ratio; 95%CI, 95% 
Confidence Interval. The follow-up window for mortality was from study entry over the period 2004-2006 to a censoring 
date of 30/9/2016, with a minimum of 10 years of mortality data for all participants. * p < 0.05  
Discussion 
The combined presence of frailty and sarcopenia (for both the FP and FI) in this 
population sample of community-dwelling adults aged ≥65 years resulted in a 
quadrupled mortality risk compared to those classified as neither frail nor 
sarcopenic. This risk was exponentially higher than those classified as frail-only 
(both FP and FI), and sarcopenic-only (for both FP and FI models), which were still 
both significantly higher at around double that of the reference group of neither frail 
nor sarcopenic. 
In this study 4.5% of participants were classified as both frail and sarcopenic using 
the FP approach while the proportion was 6.5% using the FI. The combined 
prevalence in this study is similar to that of two Japanese cohorts of older adults at 
3.6% and 2.1% respectively which both used the FP approach (Mori & Tokuda, 2019; 
Yoshimura et al., 2019), although the comparatively higher mean age of our cohort 
may account for a slightly higher rate. The proportion of participants classified as 
either frail (FP or FI) or sarcopenic in this cohort (Figure 1) illustrates the notion of 
the FP being a ‘physical subset’ of frailty as a whole as proposed by Cruz-Jentoft 
(2019), and while sarcopenia might be closely related to frailty, and be considered a 
biological substrate of frailty, not all sarcopenic individuals were frail. The 
sarcopenia biomarker of grip strength was included in the FI in this study. It is 
important to note that the variables used to construct a FI, particularly those that are 
also sarcopenia biomarkers, are likely to affect the combined prevalence of FI frailty 
and sarcopenia. This might account for difference between prevalence of 6.5% in our 
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study, compared with 0.3% a geriatric outpatient cohort with a FI that did not 
include any sarcopenia variables (Reijnierse et al., 2016). 
Those classified as sarcopenic in this cohort also had a more than doubled mortality 
risk over 10 years of follow up in a multivariable analysis. This finding is similar to 
that of DeBuyser et al (2016) where mortality was significantly higher (HR: 2.50, p = 
.006) for community-dwelling men with sarcopenia over 15 years follow-up. To the 
best of our knowledge, however, this is the first description of the relationship 
between sarcopenia and survival in a population cohort of both men and women.  
Notably, when we classified participants as frail-only (for both the FP and FI), 
sarcopenic-only, and both frail and sarcopenic and compared to the reference 
category of neither frail nor sarcopenia, we identified an almost five-fold increase in 
mortality risk for those classified as both frail and sarcopenic (both FP and FI) in a 
multivariable analysis. Findings were similar in a sensitivity analysis which 
identified that frailty and sarcopenia acted independently, and with no significant 
difference in frailty severity for frail-only compared versus both frail and sarcopenic 
for the FP, however, there was a significant difference in FI proportion of deficits 
between groups. The implications for the clinical setting are that each condition 
needs to be identified separately in order to build an accurate patient prognostic 
profile, and severity of frailty, particularly for the FP, is not necessarily indicative of 
the presence of sarcopenia. Very few studies have examined the combination of 
frailty and sarcopenia and associated mortality risk, with the exception of a sample 
of hospitalized older adults with multimorbidity (Bernabeu-Wittel et al., 2019), and 
a sample of outpatient geriatric clinic participants (Reijnierse et al., 2016). 
Bernabeu-Wittel and colleague’s (2019) study of hospitalized or geriatric outpatient 
attending older adults with multimorbidity identified that participants with 
combined frailty (FP) and sarcopenia had a similar significantly worse 12-month 
survival profile to frail-only participants compared to non-frail individuals. 
However, the multimorbidity profile of this cohort makes it difficult to compare 
findings with our population cohort, as multimorbidity is independently associated 
with poor survival (Nunes, Flores, Mielke, Thume, & Facchini, 2016). The only 
population-level study of frailty and sarcopenia survival analysis by DeBuyser and 
colleagues (2016), using the Study of Osteoporotic Fractures (SOF) frailty index 
method, did not report on the combined classification of both frail and sarcopenic as 
such. To the best of our knowledge, our study is the first to report on the combined 
presence of frailty and sarcopenia and associated mortality in a community-based 
population cohort of Australian older adults. 
Our findings highlight the adverse effect of the combined presence of frailty and 
sarcopenia on the survival of older adults. These results have important clinical 
implications, where frail individuals should be screened and assessed for 
sarcopenia, and vice versa, in order to identify those at greatest risk of mortality, and 
to use prognosis to guide discussion around management of these conditions. As 
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weakness, is a shared criterion of frailty and sarcopenia, its presence is likely 
indicative of the loss of lean muscle mass. A stepwise approach to screening and 
assessment should be considered to enhance the feasibility of identifying either 
condition in the clinical setting, as simple screening instruments exist for both frailty 
or sarcopenia that can be used to identify individuals who would benefit from a 
comprehensive geriatric assessment (Cesari et al., 2016; A. Clegg, Rogers, & Young, 
2015; Yu, Khow, Jadczak, & Visvanathan, 2016). Both frailty and sarcopenia can be 
either delayed or reversed through similar, complementary interventions consisting 
of exercise in combination with other strategies such as protein supplementation 
(Dent et al., 2018; Puts et al., 2017). 
This study has a number of limitations. Firstly, as a general population study, some 
ageing specific variables were not available for analysis such as cognition and gait 
speed. Furthermore, the lower socioeconomic status of the North West region of 
Adelaide in comparison to the larger metropolitan area may have resulted in a 
higher proportion of frail and sarcopenic individuals. 
The proportion of participants classified as frail is likely to vary for the FI based on 
the number and range of FI variables included (Theou et al., 2015); for the FP based 
on modifications to the FP variables (Theou et al., 2015); and for both approaches 
based on the characteristics of the population studied. The implications of 
modifications to the FP for this cohort have been discussed in detail elsewhere 
(Thompson, Theou, Yu, et al., 2018). 
Conclusions 
The small proportion of participants in this study who were both frail and 
sarcopenic experienced a more than doubled mortality risk in comparison with 
those with either condition individually. Weakness, which is a sheared feature of 
both frailty and sarcopenia, is likely indicative of loss of lean muscle mass and 
represents a particularly heightened state of vulnerability for older adults. 
Individuals who are identified as frail in the clinical setting should also be screened 
and assessed for sarcopenia, and vice versa, and offered appropriate intervention.  
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FRAIL Scale: Predictive validity and diagnostic test accuracy 
This chapter is a reproduction of a paper submitted for publication to the Australasian Journal on 
Ageing, and is currently under review.  
Additional table(s) and/or figure(s) are provided in the Supplementary material for Chapter 10. 
10.1  Summary 
Objectives: Frailty is a common geriatric syndrome, and older adults would benefit from 
screening for this condition which can be delayed or prevented. This study examined the 
predictive validity of the FRAIL Scale for mortality over 10 years, and diagnostic test accuracy 
(DTA) against the reference standard of the frailty phenotype (FP).  
Design: Population-based cohort. 
Setting: Community-dwelling Australia. 
Participants: 846 participants aged ≥65 years (mean age 74.3 [SD 6.3] years, 54.8% female). 
Measurement: Frailty was measured using a modified FRAIL Scale (≥3 characteristics) and a 
modified FP (≥3 characteristics). Mortality was matched to official death records with a 
minimum 10 years follow-up.  
Results: The FRAIL Scale demonstrated significant predictive validity for mortality up to 10 
years in an adjusted analysis (Frail HR: 2.60, p < .001). The FRAIL Scale and FP were 
significantly correlated (r=.619, p<.001). The FRAIL Scale demonstrated acceptable DTA 
findings against the FP for Specificity (86.8%) and Youden index (0.50), but not Sensitivity 
(63.6%), or area under receiver operator curve (auROC) (0.75) for ≥3 characteristic cut-point. 
All DTA estimates were acceptable when a cut-point of ≥2 characteristics was used instead 
(Sensitivity: 95.6%, Specificity: 64.1%, Youden Index: 0.60, auROC: 0.80). 
Conclusion: The FRAIL Scale is a valid predictor of mortality. DTA estimates of FP frailty 
were maximised when a FRAIL Scale cut point of ≥2 characteristics was used, making this 
instrument a potentially useful screening tool for frailty in the community setting. 
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10.3 Submission to the Australasian Journal on Ageing 
FRAIL Scale: Predictive validity and diagnostic test accuracy 
Introduction 
Frailty is a geriatric syndrome common among older adults that is amenable to 
intervention (Clegg, Young, Iliffe, Rikkert, & Rockwood, 2013; Puts et al., 2017). 
There have been calls for frailty to be routinely screened among this population 
(Theou & Rockwood, 2012), primarily due to the dynamic nature of the condition 
where deterioration is not always an inevitable outcome (Thompson, Theou, 
Adams, Tucker, & Visvanathan, 2018). 
Frailty is a state of decreased physiological reserve which places individuals 
at greater risk of adverse outcomes following stressor events (Clegg et al., 2013). 
One of the most commonly used definitions of frailty is the phenotype 
approach of Fried and colleagues (2001) which defines frailty as being 
present when 3 or more of the following 5 characteristics are present: weak grip 
strength, slow gait speed, exhaustion, low physical activity, and 
unintentional weight loss. 
There are a number of frailty screening instruments which have been identified 
as being reliable and valid across various settings (Apostolo et al., 2017; Dent, 
Kowal, & Hoogendijk, 2016; Drubbel et al., 2014; Pijpers, Ferreira, 
Stehouwer, & Nieuwenhuijzen Kruseman, 2012; Sutton et al., 2016), and 
two systematic reviews have examined the diagnostic test accuracy (DTA) of 
frailty screening instruments against a frailty reference standard (Clegg, Rogers, 
& Young, 2015; Pialoux, Goyard, & Lesourd, 2012). 
Good screening tests should have high sensitivity and specificity, however, in 
reality there may be a compromise of one estimate against the other (Leeflang, 
Deeks, Gatsonis, Bossuyt, & Group, 2008). When screening for geriatric conditions, 
such as frailty, higher sensitivity is preferred over specificity, as it is preferable to 
incorrectly classify individual as frail and rule out a diagnosis after further 
assessment, than miss individuals (Nunes, Duarte, Santos, & Lebrao, 2015). Other 
useful estimates in evaluating the DTA of screening instruments include the 
Youden index which is a summary of DTA estimates, and the area under the 
receiver operator curve (auROC) which quantifies the overall ability of a test to 
discriminate between two outcomes (Carter, Pan, Rai, & Galandiuk, 2016). 
The FRAIL Scale, developed by Morley and colleagues (2012), is a self-
reported screening instrument for frailty. This is a short and easy to administer 
tool which has been identified as practical for use in identifying frailty in the 
general practice setting, and has been recommended as a preferred 
instrument in the Australian primary care setting (Burgess & Hercus, 2017). 
The FRAIL Scale has demonstrated preliminary evidence in favour of its predictive 
validity for mortality (Kojima, 2018). 
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A few studies have validated the FRAIL Scale in populations of Australian women 
(Gardiner, Mishra, & Dobson, 2015; Lopez, Flicker, & Dobson, 2012; Susanto, 
Hubbard, & Gardiner, 2018) and men (Hyde et al., 2010) separately. Individuals 
with three or more FRAIL characteristics present are classified as frail, while those 
with 1-2 characteristics are pre-frail, and those with no characteristics are non-frail 
(Morley et al., 2012).  
Three studies have examined the diagnostic test accuracy (DTA) of the FRAIL Scale 
against the FP. DTA estimates were similar in a study by Braun and colleagues 
(2018) (Sensitivity: 50.0%, Specificity: 92.0%) and by Mijnarends et al (2015) 
(Sensitivity: 68.4%, Specificity: 96.2%), while sensitivity estimates were considerably 
lower in a recent Australian study by Ambagtsheer and colleagues (2019) 
(Sensitivity: 30.0%, Specificity 94.2%). These findings suggest that the FRAIL Scale 
performed well at ruling out the presence of frailty through high 
specificity, but fails to correctly identify an adequate number of those who were 
frail due to low sensitivity. Differences in DTA estimates across these studies 
may be attributable to differing sample sizes, and different study populations. 
Further examination of the psychometric properties of the FRAIL Scale is 
required in a variety of settings, and the Australian context in particular, 
where it has been proposed as a preferred screening instrument for frailty 
(Burgess & Hercus, 2017). 
The aim of this study was to examine the predictive validity for mortality 
and diagnostic test accuracy of the FRAIL Scale against a reference standards of 
the frailty phenotype in a community-dwelling cohort of Australian older adults. 
Methods 
Sample 
This study was a secondary analysis of the North West Adelaide Health 
Study (NWAHS), a randomly selected longitudinal population survey of 
community-dwelling adults drawn from households in the North-West region 
of Adelaide (Grant et al., 2009). Participants attended a clinic and completed 
both phone and written surveys. As the probability of selection was known, data 
were weighted to the area population. SA Health Human Research Ethics 
Committee (Reference number HREC/15/TQEH/61) provided ethics approval. 
Participants included in this study were aged ≥65 years who completed stage 2 
(2004-2006). 
We excluded participants (n = 99) who were lacking any FRAIL Scale or 
FP variables. Participants were matched to official death records in order to 
determine mortality, and all participants had a minimum of 10 years of 
follow-up from baseline. 
The index tests and reference standards used in this study were not 
‘administered’ as such in NWAHS, rather, variables were drawn from available 
data to construct each measure. Therefore, the results of neither index tests, nor 
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reference standards were available to assessors. We are unable to report on 
the interval between administration of index test and reference standard for the 
same reason. 
Index test: FRAIL Scale 
The FRAIL Scale is comprised of five characteristics: fatigue, resistance, ambulation, 
illnesses, and loss of weight (Morley et al., 2012). We used some modified variables 
in the construction of the scale (see Supplementary Table S1 for details of variables). 
Each FRAIL Scale characteristic was scored 0-1, and scores ranged from 0 (best) to 5 
(worst). Individuals with ≥3 characteristics were categorised as frail, 1-2 
characteristics as pre-frail, and no characteristics as non-frail.  
Reference Standard: Frailty Phenotype 
A modified FP was used in this study, where participants with three or more of 
the following characteristics present were classified as frail: weight loss, weak 
grip strength, exhaustion, slowness, and low physical activity level, while 
participants with 0-1 characteristics were classified as pre-frail, and those with no 
characteristics as non-frail (Fried et al., 2001). Modifications to FP variables 
are reported in Supplementary Table S1. The characteristics of the FP used in 
our study have been described previously (Thompson, Theou, Yu, et al., 2018). 
Diagnostic Test Accuracy Minimum Thresholds
In this study we used the following acceptable minimum thresholds: ≥80% for 
sensitivity (Apostolo et al., 2017; Forti et al., 2012), ≥60% for specificity (Forti et 
al., 2012), ≥0.50 for Youden Index (Carter et al., 2016), and ≥80.0% for auROC 
(Sutorius, Hoogendijk, Prins, & van Hout, 2016). 
Analysis 
We used SPSS version 23 (IBM Corporation, Armonk, NY) for statistical analysis 
in this study. 
Case weights for the cohort were used in reporting percentages and for analysis 
to ensure that the sample was representative of the population. An alpha value of 
0.05 was used for statistical significance. We reported descriptive characteristics 
of the sample for the number and proportion classified as frail by the FRAIL 
Scale, frail by the FP (FP-frail), and sarcopenic. We performed 
significance testing of cross-tabs using a Pearson chi-squared test.  
Correlation was calculated between continuous versions of the FRAIL Scale and 
FP to examine their relationship. Complex samples procedures were used in 
SPSS to allow for the effect of the sample design on the standard error of estimates. 
Survival was modelled using complex samples cox regression which allowed for 
the sample design, and was reported as a hazard ratio. Multivariable analysis 
was performed adjusting for sex, age, education level, and income. We cross-
tabulated the results of index tests against references standards with case weighting 
applied and used Stata Statistical Software Release 15 (StataCorp LLC, College 





We included 846 participants from this community-dwelling population of older 
adults (mean age 74.3 (SD 6.3) years, 54.8% female). Frailty prevalence was 
measured at 22.5% by the FRAIL Scale, and 18.7% for the FP (Table 1). Frail 
individuals were significantly (p<.05) more likely to be female and older age group 
(≥75 years) across all frailty measures compared with their non-frail counterparts. 
There was a strong significant correlation between continuous versions of the FRAIL 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FRAIL Scale validity and DTA 
Individuals classified as frail by the FRAIL Scale had significantly more than double 
the mortality risk (HR: 2.60, 95% CI: 1.78-3.80, p<.001) over 10 years of follow up in 
an analysis adjusted for age, sex, education, and income compared with their non-
frail counterparts (Table 2 and Figure 1). Stratified by sex, the hazard ratio for frail 
men was 2.26 (95%CI: 1.39-3.69, p < .001) while frail women had more than triple the 
mortality risk of those who were non-frail (HR: 3.19, 95%CI: 1.57-6.51, p = .001) 
Cross-tabulation of the FRAIL Scale frailty classification against the reference 
standard of the FP, were used to generate estimates of DTA (see Supplementary 
Table S2 for 2x2 tables).  
The FRAIL Scale produced acceptable estimates of Specificity (86.8%, 95%CI: 84.0%-
89.2%) and Youden Index (0.50) against the FP using a cut point of ≥3 characteristics, 
however Sensitivity (63.6 95%CI: 55.3%-70.8%) and AUC (0.75 95%CI: 0.71, 0.79) 
were below acceptable thresholds (Table 3). When a cut point of ≥2 characteristics 
was used, all estimates were acceptable (Sensitivity: 95.6%, Specificity: 64.1%, 
Youden Index: 0.60, auROC: 0.80). 
Table 2.  FRAIL Scale classification and mortality risk (Hazard Ratio). Weighted multivariable analysis adjusted 
for age, sex, education and income. 
Unadjusted Adjusted 
HR (95%CI) p-value HR (95%CI) p-value 
Whole Sample (n = 846) 
FRAIL Scale – Whole Sample 
Non-frail (n = 303) 1 - 1 - 
Pre-frail (n = 374) 1.40 (1.03, 1.91) .031* 1.32 (0.95, 1.84) .095 
Frail (n = 169) 2.63 (1.88, 3.68) <.001* 2.60 (1.78, 3.80) < .001* 
FRAIL Scale – Male 
Non-frail (n = 172) 1 - 1 - 
Pre-frail (n = 180) 1.29 (0.90, 1.84) .170 1.24 (0.85, 1.81) .254 
Frail (n = 67) 2.44 (1.59, 3.77) <.001* 2.26 (1.39, 3.69) .001* 
FRAIL Scale – Female 
Non-frail (n = 131) 1 - 1 - 
Pre-frail (n = 194) 2.07 (1.14, 3.77) .017* 1.51 (0.74, 3.09) .255 
Frail (n = 102) 4.35 (2.40, 7.87) <.001* 3.19 (1.57, 6.51) .001* 
HR, Hazard Ratio. 95%CI, 95% confidence interval. FRAIL Scale categories (number of characteristics): 0, non-frail; 1-2, 
pre-frail; ≥3, frail. The follow-up window for mortality was from study entry over the period 2004-2006 to a censoring date 
of 30/9/2016. (Minimum of 10 years of mortality data for all participants). 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The FRAIL Scale demonstrated significant predictive validity (frail HR: 2.60) against 
mortality up to 10 years in this cohort of community-dwelling older adults. The 
FRAIL Scale produced acceptable Specificity, and Youden Index estimates only 
against the reference standard of the FP using the FRAIL Scale cut point of ≥3 
characteristics. All DTA estimates were acceptable when ≥2 characteristics was used 
as a cut point for the FRAIL Scale. 
When stratified by sex, our mortality findings for FRAIL Scale for women (HR: 3.19) 
were similar to an age-equivalent Australian cohort of women (3 characteristics HR: 
3.15; 4+ characteristics HR: 4.52) (Lopez et al., 2012). Likewise for men in this study 
(HR: 2.26), where findings were similar to those of an equivalent cohort of 
Australian men (3 characteristics HR: 2.27; 4+ characteristics HR: 3.97) (Hyde et al., 
2010). Importantly, this is the first study to report on FRAIL Scale validity for 
mortality in an Australian cohort of both men and women. The clinical implications 
of our findings are that individuals identified as frail using the FRAIL Scale have an 
elevated mortality profile and would benefit from further investigation of their 
frailty status, and targeting with appropriate intervention. 
The acceptable DTA estimates for specificity of the FRAIL Scale against the FP 
reference standard in this study (86.8%) are similar to those reported in other studies 
which also examined FRAIL Scale DTA against the FP, with estimates ranging from 
92.0% to 96.2% (Ambagtsheer et al., 2019; Braun et al., 2018; Mijnarends et al., 2015). 
Our sensitivity estimate (63.3%), which was below the acceptable threshold, was in 
the higher range compared to values reported elsewhere (30.0% to 68.4%). 
Variability in DTA estimates across studies may be attributable to population source 
and baseline frailty prevalence, sample size, and method of index test and reference 
standard measurement. This last point is particularly applicable to this study 
where several variables were modified in both measures. Additionally, we 
note that DTA acceptability criteria used in this study were based on the 
work, and readers should use their discretion in interpreting findings. For 
clinicians, our findings indicate that the FRAIL Scale, while effective at ruling out 
FP frailty, is likely to miss a number of individuals who are frail as measured by the 
FP. 
The DTA estimates of the FRAIL Scale were improved and all met acceptability 
criteria when a FRAIL Scale cut point of ≥2 characteristics was used. There is 
potential value in trading off higher sensitivity for lower specificity in the clinical 
setting where it is preferable to identify as many frail individuals as possible, 
accepting a higher number of false positives, rather than to miss those who are 
actually frail (Nunes et al., 2015). A strategy for maximising the feasibility of this 
approach to frailty screening in primary care would be to use a stepwise process of 
increasingly more detailed assessment which may result in a comprehensive 
geriatric assessment (Theou & Rockwood, 2012). In the clinical setting, a FRAIL 
Scale score of 2 or more characteristics may be a useful indicator for further frailty 
assessment, as it is less likely to miss individuals who are FP frail than a cut-point of 
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3 characteristics. However, this finding should be confirmed in other studies before 
widespread use. 
There were a number of important limitations with our study. As a secondary 
analysis of an already existing dataset of a general population study, some 
important ageing specific variables were not collected, therefore, modifications were 
made to some FRAIL Scale and FP variables. The use of modified measures is likely 
to affect prevalence, predictive validity and DTA findings, and therefore 
generalisability of results. In particular, we used self-reported difficulty walking 
100m for slowness in the FP, and used measured weight loss over 4.5 years for both 
the FRAIL Scale and FP instead of self-reported weight loss for each. We have 
attempted to partly address this limitation by providing information on variable 
definitions and cut-points in Supplementary TableS1, and distribution of individual 
variables based on frailty classification in Table 1. We, therefore, urge caution in the 
interpretation and generalisability of these DTA findings to other populations and 
settings. 
Another limitation of this study was that as the FRAIL Scale and FP were not 
administered as individual tests, and instead were operationalised during 
secondary analysis, we were unable to report on feasibility of administration. 
Further research is required investigating the DTA of the FRAIL Scale, which 
also examines different cut-points, against the FP, as well as examining predictive 
mortality over short time periods.
Conclusion 
The FRAIL Scale was a significant predictor of morality up to 10 years in this sample 
of community-dwelling older adults, however, the measure did not meet a number 
of key DTA acceptability criteria against the reference standard of the FP. Predictive 
validity is an important indicator of an instrument’s usefulness, despite less than 
acceptable DTA findings. When a FRAIL Scale cut-point of ≥2 characteristics was 
used, all DTA estimates were acceptable. The FRAIL Scale is a potentially useful tool 
in the primary care setting. 
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Frailty state utility and minimally important difference: Findings from 
the North West Adelaide Health Study 
This chapter is a reproduction of a paper submitted for publication to Age and Ageing. The 
statement of authorship and paper (.pdf) follow over the page. 
Additional table(s) and/or figure(s) are provided in the Supplementary material for Chapter 11. 
11.1  Summary 
Background: Frailty is a dynamic condition for which a range of interventions is available. 
Health state utilities are based upon the preference that individuals place on health states and 
outcomes and form a critical component for economic evaluation. This is a topic yet to be 
examined in detail for frailty. Likewise, little has been reported on minimally important 
difference (MID), the extent of change in frailty status that individuals consider to be 
important. 
Objectives: The objectives of the study were to examine the relationship between frailty status, 
for both the frailty phenotype (FP) and frailty index (FI), and utility (preference-based health 
state), and to determine a minimally important difference (MID) for both frailty measures. 
Design and setting: Population-based cohort of community-dwelling Australian older adults. 
Participants: 874 individuals aged ≥ 65 years (54% female), mean age 74.4 (6.2) years. 
Measurements: Frailty was measured using the FP and FI. Utilities were calculated using the 
six-dimensional (SF-6D) Health Survey, with Australian and UK weighting applied. 
Results: For both the FP and FI, frailty was significantly statistically associated (p < .001) with 
lower utility in an adjusted analysis (age, sex, education, and income) using both Australian 
and UK weighting. Between person MID for the FP was identified as 0.59 (SD 0.31) (anchor-
based) and 0.59 (distribution-based), while for the FI, MID was 0.11 (SD 0.05) (anchor-based) 
and 0.07 (distribution-based). 
Conclusions: Frailty is significantly associated with lower preference-based health state utility. 
Frailty MID can be used to inform design of clinical trials and their economic evaluation, as 




11.3 Submission to Age and Ageing 
Frailty state utility and minimally important difference: Findings from the 
North West Adelaide Health Study 
Introduction 
Frailty is increasingly recognised as a dynamic and potentially modifiable condition 
where a range of interventions for treatment, prevention or delay are available 
(Kojima, Taniguchi, Iliffe, Jivraj, & Walters, 2019; Puts et al., 2017). Frailty may be 
considered as a state of decreased functional reserve and resistance to stressors as a 
result of a cumulative decline in multiple physiological systems (Clegg, Young, 
Iliffe, Rikkert, & Rockwood, 2013; Fried et al., 2001). Frailty is common among older 
adults and is associated with a range of adverse outcomes including mortality, 
disability, falls and hospitalisation (Fried et al., 2001; Joosten, Demuynck, Detroyer, 
& Milisen, 2014; Shamliyan, Talley, Ramakrishnan, & Kane, 2013). 
Frailty has a demonstrated inverse association with quality of life (QOL) (Crocker et 
al., 2019; Kojima, Iliffe, Jivraj, & Walters, 2016). The association reflects a dose-
response effect with increasing frailty accounting for substantially lower QOL 
(Kojima et al., 2016). QOL can be represented in terms of utilities, which represent 
preferences that individuals or groups place on a set of health outcomes, such as 
frailty status. Utilities range between 1 (perfect health) and 0 (dead) and are 
important outcomes that may be used in evaluating the comparative effectiveness of 
health interventions (Drummond, Sculpher, Torrance, O'Brien, & Stoddart, 2005). 
However, general utility measures can suffer from floor effects which makes 
identifying changes in health status for those in poorer health status difficult 
(Turner, Campbell, Peters, Wiles, & Hollinghurst, 2013). 
Despite a range of studies describing the association between frailty and QOL at a 
population level (Crocker et al., 2019; Kojima et al., 2016), to the best of our 
knowledge there have been no population level estimates using preference-based 
measures of health-state utility, which can be used in health economic evaluation of 
frailty interventions (Neumann, Goldie, & Weinstein, 2000). Drawing utility data 
from a range of sources, particularly cohort surveys, is an important component of 
economic evaluation, particularly when coupled with health state transition data as 
it improves the reliability and generalisability of estimates (Drummond et al., 2005; 
Neumann et al., 2000). 
A challenge remains for clinicians and researchers in interpreting statistically 
significant changes in frailty status when examining frailty interventions, namely, 
what level of incremental change in utility is sufficient to be considered as clinically 
meaningful? Minimally Important Difference (MID) is the smallest change in a 
treatment outcome which an individual would perceive as being important 
(Wyrwich et al., 2005). MID may be useful in providing a patient perspective that 
informs clinical decision making regarding the effectiveness of frailty interventions 
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(Sloan, Cella, & Hays, 2005). As far as we are aware, no studies have yet 
published frailty MID findings, which is an additional unique feature of our study. 
The aims of this study were to examine the relationship between frailty status, 
for both the frailty phenotype (FP) and frailty index (FI), and utility (preference-
based health state) in a community dwelling cohort, and to determine a MID 
for both frailty measures. 
Methods 
The North West Adelaide Health Study (NWAHS) is a representative longitudinal 
study of the population of the North-West region of Adelaide, South Australia 
(Grant et al., 2006; Grant et al., 2009). This study included participants aged ≥65 
years who were interviewed and attended a clinic for a biomedical examination. 
Individuals unable to answer questions in English at the initial recruitment stage 
were excluded from the study, as were individuals living in residential institutions, 
such as nursing homes. Stage 2 (2004-06) data were used in this study.  
This study was approved by the Queen Elizabeth Hospital Ethics Committee 
(HREC/15/TQEH/6) 
Frailty phenotype 
A modified FP was used in this study where individuals with 3+ characteristics 
(out of five) variables (weight loss, weakness, slowness, exhaustion, and low 
activity) were classified as frail, those with 1-2 characteristics as pre-frail, and 
those with no characteristics present as non-frail (Fried et al., 2001). The modified 
FP used in this study has been described previously (Thompson, Theou, Yu, 
et al., 2018). FP variables are detailed in Supplementary Table S1. The FP is 
scaled on a 0-5 integer scale with 0 indicating no frailty characteristics present 
and a maximum of five frailty characteristics being present. 
Frailty index 
We developed a FI consisting of 34 variables following a standard 
methodology (Searle, Mitnitski, Gahbauer, Gill, & Rockwood, 2008). 
(Supplementary Table S1). Recoding procedures were applied for categorical, 
ordinal and interval variables such that they could be mapped to the interval 0–
1, where 0 = absence of a deficit, and 1= full expression of the deficit. These 
individual deficit scores were combined in an index, where 0 = no deficit present, 
and 1 = all 34 deficits present. Individuals with >0.21 proportion of deficits were 
classified as frail, 0.10 and 0.21 deficits as pre-frail, and <0.10 deficits as non-frail. 
The FI used has been described previously (Thompson, Theou, Yu, et al., 2018).
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Utility (preference-based health state) 
Health state utility was captured by using the short-form (SF-36) health survey 
(Ware et al., 1993). Data from the SF-36 were used to generate utilities for each study 
participant by applying the SF-6D preference based scoring algorithm (Brazier, 
Roberts, & Deverill, 2002). We reported SF-6D values using both the original UK 
weighting (Brazier et al., 2002), and Australian weighting (Model B) as reported by 
Norman and colleagues (Norman et al., 2013). The utility scores of the UK SF-6D 
range from 0.29 to 1.00 compared to -0.363 to 1.00 for the Australian weighting. With 
the Australian weighting, certain states are rated worse than being dead. SF-36 
variables used in generating Sf-6D utility scores were excluded from the FI. 
Minimally important difference 
There is no single measure of MID, rather, multiple approaches may be used to 
identify a plausible range within which MID falls (King, 2011; Revicki, Hays, Cella, 
& Sloan, 2008; Sloan et al., 2005), two of which include anchor-based and 
distribution-based methods. The use of multiple approaches and triangulation of 
methods is recommended to address the variability of instruments and estimates in 
varying populations (Sloan et al., 2005). 
Anchor-based methods to MID link changes in the outcome variable to another 
important variable, called an ‘anchor’ (Revicki et al., 2008; Sloan et al., 2005). Such an 
anchor should be easily interpretable, used to measure health status, and 
moderately correlated (at least 0.30) with the variable of interest (King, 2011). Self-
reported health is one such anchor which provides valuable information on an 
individual’s global health status and is predictive of mortality (Idler & Benyamini, 
1997). We used question 1 from the SF-36: “In general, would you say your health is: 
excellent, very good, good, fair, poor.” as the anchor in this study (which is not part 
of the SF-6D). We took a weighted average of the difference in both FP (scores of 0 to 
5) and FI (scores of 0 to 1) continuous scores between each successive category of
SF36-q1. The average was weighted by the number of observations contributing to
each mean score. The use of cross-sectional data in this study allows for estimation
of between-group and between-person MID, however, longitudinal data is required
to report within-person estimates of minimally important change (King, 2011).
Distribution-based methods reflect the concept of using a distribution of observed 
scores in a sample as the basis for estimating MID (Revicki et al., 2008). The 
distribution method is considered to be a convenient proxy for MID, however, it has 
no external reference point to an anchor (King, 2011). A ½ SD estimate has been 
suggested as an appropriate distribution based measurement of MID, and while not 
this is not necessarily ‘’minimal’’, it is a useful conservative estimate for a clinically 
meaningful difference (i.e., it is obviously important) (Revicki et al., 2008; Sloan et 




All statistical analyses were performed using SPSS version 23 (IBM Corporation. 
Armonk, NY). Cohort case weights (weighted by number in the household, age 
group, sex and Estimated Resident Population data) were used in analysis, and 
reporting mean scores and percentages to ensure the sample was representative of 
the North West Adelaide population (Grant et al., 2006). Descriptive characteristics 
were reported as percentages. Analysis of variance testing of statistical significance 
between frailty classification levels and QOL was measured using an alpha value of 
0.05, and post hoc mean comparison was performed using Tukey’s least significant 
difference. We also performed a means comparison using complex samples general 
linear model to adjust for other covariates. Correlation analysis was performed 
between continuous frailty measures and the self-reported health anchor.  
Results 
In this longitudinal cohort of community-dwelling Australian older adults (n = 874, 
mean age 74.4 (SD 6.2) years, 54% female), 18.5% (146/874) of participants were 
classified as frail by the FP, and 48.8% (400/874) frail by the FI (Table 1). 
Health state utility was significantly lower for frail individuals as well as pre-frail 
individuals in comparison to their non frail counterparts for both the FP and FI, 
using Australian and UK weighting for the SF-6D, for both unadjusted and adjusted 
analyses. (Table 2) Tukey analyses demonstrated significant differences between all 
levels of frailty (non-frail, pre-frail, and frail) for both the FP and FI in unadjusted 
analysis (data not shown). Likewise, for each level of frailty classification in complex 
samples general linear regression model adjusting for covariates: age, sex, 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The anchor of self-reported health was significantly correlated with both the FP (r = 
0.43, p < .001) and FI (r = 0.69, p < .001). Using the anchor-based approach of the 
weighted average of the difference in both FP and FI continuous scores between 
each successive category of SF36 question 1 (self-reported health status), 0.59 (SD 
0.31) was the MID for the FP, while 0.11 (SD 0.05) was the MID for the FI (Table 3). 
Using a distribution-based approach of ½ SD of mean frailty scores, 0.59 was a MID 
for the FP, and 0.07 was the MID for the FI (Table 3). 
Table 3. Minimally important difference (MID) for the frailty phenotype and frailty index. 











Frailty Phenotype 0.59 (0.31) 0.59 
Frailty Index 0.11 (0.05) 0.07 
Mean and SD reported using cohort case weights. 
The FP is scaled on a 0 to 5 integer scale with a score of 0 indicating no frailty characteristics and a maximum of five 
characteristics. 
The FI is scored on a 0 to 1 scale where 0 = no deficit present, and 1 = all 34 deficits present. 
a
 Anchor method: a weighted average of the difference in both FP and FI continuous scores between each successive 
category of SF36 question 1.  “In general, would you say your health is: excellent, very good, good, fair, poor”. 
b
 Distribution method, ½ standard deviation of mean continuous frailty measures. 
Discussion 
The novel findings from this study were the identification of frailty and pre-frailty 
classification as being significantly associated with lower preference-based health 
state utility for both the FP and FI compared to their non-frail counterparts in this 
cohort of South Australian older adults. This association applied to both the UK and 
Australian weightings of the SF-6D in adjusted analysis. Additionally, we have 
reported the first group-level MID for frailty for both the FP and FI. 
Our findings are consistent with a number of studies that have previously examined 
the relationship between increased frailty and lower QOL (Crocker et al., 2019; 
Kojima et al., 2016), however, our study is the first to report the QOL finding as a 
utility value for a population cohort. This is important as utilities are a requirement 
for cost utility analysis, the most prevalent form of economic evaluation and health 
economic modelling. Frailty state utilities have been reported in within-trial 
economic evaluations of frailty interventions (Fairhall et al., 2015; Sandberg, 
Jakobsson, Midlov, & Kristensson, 2015), and a model-based economic evaluation 
by Karnon and colleagues (2017) using a sample from a harmonised population 
cohort of frail individuals matched to the participant characteristics of a frailty 
intervention study. The adjusted SF-6D utility values (UK weighting) for FP pre-frail 
and frail individuals in our study (FP pre-frail: 0.75 and FP frail: 0.62) were similar to 
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those reported by Karnon et al (2017) (FP Pre-frail: 0.65, FP frail: 0.57). These 
findings of population level frailty state utility data, in combination with the longer 
time horizons of state transition data, previously reported for the NWAHS cohort 
(Thompson, Theou, Adams, Tucker, & Visvanathan, 2018), provide important data 
for model-based economic evaluation of frailty interventions (Drummond et al., 
2005; Neumann et al., 2000). However, caution should be used in the generalisability 
of findings to other populations and settings, and ideally, multiple data sources 
should be used to inform model-based economic evaluations. 
MID estimates for both the FP and FI were identified using cross-sectional anchor-
based and distribution-based methods in this cohort. For the FP, 0.59 was an 
important difference based on both anchor-based and distribution-based methods. 
As 1 point is the smallest increment of the FP, it can be assumed that a change of this 
magnitude is minimally important. For the FI, MID ranged from 0.07 (distribution 
method) to 0.11 (anchor method). The anchor of self-reported health status was 
moderately correlated with the FP and strongly with the FI in this study, meeting an 
anchor requirement of being moderately correlated with the outcome of interest 
(King, 2011). We suggest researchers use the anchor-based estimate as this is based 
on an external reference, over the distribution-based estimate which may be 
considered a useful proxy (King, 2011). It is important to note that these MID values 
are specific to self-reported health and the ½ SD method. Results may be different if 
different outcomes are used. We caution against overinterpretation of these MID 
findings as our estimates represent a ‘plausible range’ of difference for continuous 
frailty scores (King, 2011). Additionally, our cross-sectional analysis does not allow 
us to report within-person estimates of minimally important change in frailty, which 
require change over time (King, 2011).  
We believe that this is the first time that MID has been reported for frailty for either 
the FP or FI. Typically, findings from studies that have examined frailty 
interventions, have reported change in frailty status or change in the number of 
frailty characteristics or proportion of deficits present (Liu, Ng, Seah, Munro, & Wee, 
2019; Puts et al., 2017). Our MID results allow these findings to be re-interpreted 
from the perspective of meaningful difference as rated by older adults themselves, 
although with caution due to the between-person nature of our estimates. When the 
results of a multifactorial frailty intervention RCT by Cameron and colleagues (2013) 
are examined from the MID perspective of our study, the non-significant FP change 
in the intervention group over 0-3 month of 0.56 (SD 1.10) approaches minimal 
importance, while the significant change of 0.80 (SD 1.19) over 0-12 months meets 
the criterion of a MID from a population perspective. Our MID findings will be of 
interest to clinicians evaluating frailty intervention outcomes as MID is important 
for assessing effectiveness from a consumer perspective. Additionally, researchers 
might use our MID results when looking to perform power calculations for 
participant numbers for future frailty intervention studies.  
126
There were a number of limitations with our study. Aging specific variables such as 
cognition and gait speed were not available for this cohort, therefore, we used a 
modified FP which may have affected frailty prevalence estimate. The lower 
socioeconomic status (SES) of the North West region of Adelaide, compared with 
the broader metropolitan area, suggests our findings may not be representative of 
the Australian or other population. The exclusion of individuals living in residential 
care from this study means that our frailty utility and MID findings do not apply to 
this group. An additional limitation is that we looked at the MID cross sectionally, 
whereas minimally important change requires longitudinal data for change over 
time. This is an important topic for future research. 
In conclusion, we identified that frailty was significantly associated with lower 
utility for both the FP and FI. Additionally, we identified MIDs for both measures. 
These findings are relevant to the design of frailty RCTs, health economic 
evaluations of frailty interventions, and to clinicians evaluating patient 
responsiveness to frailty interventions. 
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Chapter 12 
Discussion, future directions, and conclusions 
12.1  Discussion 
The goal at the commencement of this thesis was to use population level data to illustrate the 
impact and course of frailty in community-dwelling older adults. My interest in this topic has its 
origins in my 20-plus years of clinical and allied health management experience in community-
based aged care and rehabilitation as an occupational therapist. Working in this field has offered 
me opportunities to see individuals both decline physically and cognitively into advanced frailty 
and end-of-life care, but also to observe them recover from illness and frailty, and to make 
improvements in physical functioning, participation in daily life, and quality of life. Much of the 
heterogeneity of health, functioning, and survival across the ageing populations, and my clients, 
may be attributable to frailty (Rockwood & Howlett, 2018). An important focus of my clinical 
practice has been on recommending strategies for clients that can prevent, delay, or reverse frailty. 
Over recent years my clinical work has increasingly dealt with Aboriginal aged care, where social 
determinants of health play a noticeable part in the wellbeing of this population. 
As the Australian and global population ages over coming decades, a clear understanding of 
frailty will be required in order to maximise the health outcomes of frail older people 
(World Health Organization, 2015). A challenge facing researchers in the field of frailty, as 
well as clinicians looking to apply research findings, is that a consensus on the method of frailty 
measurement is yet to be achieved (Clegg, Young, Iliffe, Rikkert, & Rockwood, 2013). The 
research projects reported in this thesis examined two of the key approaches to frailty measurement 
with a view to the results being informative and useful to health policy makers and practitioners 
alike. Both population level planning and face-to-face clinical care are important in managing 
frailty and promoting healthy ageing (Hoogendijk et al., 2019). 
The following paragraphs provide a summary of the research projects included in this thesis. 
The study in Chapter 4 described frailty prevalence in Australian older adults. Frailty was 
measured in DYNOPTA and North West Adelaide Health Study (NWAHS) using the frailty 
phenotype (FP). We identified 20.5% of participants as frail, while a further 47.9% were pre-
frail. Frailty was significantly higher for women (approximately double that of men), increased 
significantly with advancing age for both sexes, and was significantly higher for women 
who were widowed, divorced or never married.  
The study in Chapter 5 reported the prevalence of frailty and associated factors in the 
NWAHS using the FP and frailty index (FI). Frailty prevalence was higher when assessed using 
the FI; the FP classified 18% of participants as frail, and the FI 48%. The measures were strongly 
correlated but had only a modest agreement for frailty classification, with 37% of participants 
classified as non-frail by the FP being classified as frail by the FI. Socioeconomic factors 
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and other health determinants contribute to higher frailty levels. Being older, a current smoker, 
and having multimorbidity and polypharmacy were associated with higher frailty levels by 
both tools. Female, low income, obesity, and living alone were associated with the FI. This 
difference in sensitivity of frailty measures has clinical implications, where the choice of tool 
may impact the accurate identification of frailty.  The higher frailty prevalence of 20.5% reported 
in Chapter 4 compared to 18% in this chapter is likely attributable to the higher proportion of 
females and older age (DYNOPTA and NWAHS: 86% female and median age 80 years) compared 
with 55% female and mean age 74 years in NWAHS only.
The study in Chapter 6 measured frailty state transitions and factors associated with improvement 
or worsening frailty status in the NWAHS. Frailty was measured using the frailty phenotype (FP) 
and the frailty index (FI) with repeated measures at 4.5 years follow-up. Improvement 
in frailty state was common for both tools, while the majority of participants remained stable, 
and many transitioned to a worse level of frailty. A number of characteristics were 
associated with worsening and improvement of frailty status. Multimorbidity, obesity, age 
and sex were associated with frailty transitions for both tools. Among the factors that were 
identified as associated with frailty transitions, age and sex are non-modifiable, but 
multimorbidity, obesity, polypharmacy and living status may be targeted. These factors pose 
different risks for frailty transition at different stages of the frailty process, as does frailty 
classification itself and, hence, suggests a tailored approach in targeting vulnerable individuals.   
Chapter 7 was a systematic review with the aim of determining the diagnostic test accuracy 
of self-reported and/or self-administered frailty screening instruments against two 
frailty reference standards, the FP and FI, for community-dwelling older adults. There 
were 24 studies that met selection criteria. Four self-reported screening instruments 
(PRISMA-7, Groningen Frailty Indicator, Self-Reported Health, and Self-Reported 
Physical Activity) across three studies met minimum sensitivity and specificity 
thresholds (80% and 60% respectively). However, in most cases, study design 
considerations limited the reliability and generalisability of the results. The current evidence 
for the DTA of many screening instruments does not support their widespread use to identify 
frailty in community dwelling adults. Predictive validity, which was outside the scope of this 
review, may be an alternative outcome to inform health policy and decision making 
regarding instrument selection for different populations. Further well-designed DTA studies 
of self-reported screening instruments to identify frailty are required. 
The study in Chapter 8 examined the relationship between frailty status (at baseline and 
follow-up) and mortality in the NWAHS using both the FP and FI. For both 
measures, baseline frailty was a significant predictor of mortality up to 10 years, with 
initially good predictive ability decreasing over time. Repeated measurement at follow-up 
resulted in good prediction compared to lower discrimination of equivalent baseline 
frailty status. Frailty measurement at follow-up was a stronger predictor of mortality 
compared to baseline. Frailty change for the Continuous FI was a significant predictor of 
decreased or increased mortality risk based on corresponding improvement or worsening of 
score. This study found that recency of frailty measurement is important for predicting 
survival.  
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The study in Chapter 9 examined the predictive ability of frailty and sarcopenia classification on 
mortality in the NWAHS. Frailty was measured using the FP and FI. Sarcopenia was 
measured using the revised European consensus definition. Classification as both frail and 
sarcopenic resulted in significantly elevated mortality risk for both the FP and FI measures. The 
risk or mortality was, in fact, over four times the risk for those neither frail nor sarcopenic. Frail-
only was also a significant mortality predictor at double the rate of non-frail individuals, while 
sarcopenic-only approached significance for both frailty instruments.  
The study in Chapter 10 examined the predictive validity of the FRAIL Scale and diagnostic test 
accuracy (DTA) against the reference standards of the FP. The FRAIL Scale demonstrated 
significant predictive validity for mortality up to 10 years in an adjusted analysis, more than double 
that of non-frail participants, and was significantly correlated with the FP. The FRAIL Scale 
demonstrated acceptable DTA findings against the FP for Specificity (86.8%) and Youden index 
(0.50), but not Sensitivity (63.6%), or area under receiver operator curve (auROC) (0.75) for ≥3 
characteristic cut-point. All DTA estimates were acceptable when a cut-point of ≥2 characteristics 
was used instead (Sensitivity: 95.6%, Specificity: 64.1%, Youden Index: 0.60, auROC: 0.80).  
The study in Chapter 11 examined the relationship between frailty status, for both the FP and 
FI, and utility (preference-based health state), and to determine a minimally important difference 
(MID) for both frailty measures. Utilities were calculated using the six-dimensional health survey 
(SF-6D) Health Survey, with Australian and UK weighting applied. For both the FP and 
FI, frailty was significantly associated with lower utility. Between-person MID for the FP was 
identified as 0.59 (anchor-based) and 0.59 (distribution-based), while for the FI, MID was 0.11 
(anchor-based) and 0.07 (distribution-based). 
12.2  Significance and contribution 
This PhD research has generated new knowledge and contributed significantly to the 
scientific literature in the area of frailty. 
A major contribution to the public health of Australian older adults to emerge from this PhD 
research is the reporting of Australian frailty prevalence data across multiple longitudinal studies, 
and a comparison of both forms of frailty measurement in the Australian context (Chapters 4 
and 5). These findings, when published in the Australasian Journal on Ageing, were 
accompanied by an editorial by Vasi Naganathan (2018), highlighting the importance of 
these findings in the Australian setting. 
Prevalence estimates (Chapter 4) were used as the basis for a publication by Taylor and 
colleagues (2019) which examined geospatial modelling of the prevalence and changing 
distribution of frailty in Australia, and was published in the Journal of Experimental 
Gerontology. This publication addressed the call from a Commonwealth funded report by 
Burgess and Hercus (2017) for geospatial data about the current and future distribution of 
Australia’s frail and pre-frail population 
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in order to inform policy, resource allocation and planning initiatives that aim to treat and reverse 
frailty. The resulting interactive online frailty mapping resource, using data from Chapter 4, covers 
all of Australia is accessible at: http://www.spatialonline.com.au/frailtyestimates. (See Figure 12.1.) 
Chapter 4 has four citations to date (Kojima, Walters, Iliffe, Taniguchi, & Tamiya, 2019; 
Naganathan, 2018; Taylor et al., 2019; Zucchelli et al., 2019). Data from Chapter 4 have been 
included in a systematic review by Kojima and colleagues (2019) examining marital status and 
frailty.  
Figure 12.1.  Screen capture of frail estimates 2011 and 2027 for Adelaide from 
interactive online frailty mapping resource by Taylor et al (2019). 
Chapter 5 has had six citations (excluding self-citation) (Amiri & Behnezhad, 2019; Arakawa 
Martins et al., 2019; Ge, Liu, Tang, Lu, & Szanton, 2019; Ge, Liu, Liu, et al., 2019; Hale, Shah, & 
Clegg, 2019; Naganathan, 2018). Data from this chapter were included in a systematic review by 
Amiri and associates (2019) examining the relationship between smoking and frailty. 
Chapter 6 has been cited six times by other authors (Brothers & Rockwood, 2019; Buto et al., 
2019; Haji Ali Afzali et al., 2019; Kojima, Taniguchi, Iliffe, Urano, & Walters, 2019; Ofori-Asenso 
et al., 2019; Visvanathan et al., 2018). Data from this chapter were included in the systematic 
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reviews of Ofori-Aseno and colleagues (2019) on frailty incidence in community-dwelling older 
adults, and the review of Kojima et al. (2019) which examined factors associated with 
improvement in frailty status. 
A number of chapters in this thesis have direct relevance for the identification and management of 
frailty in the primary care setting. In Chapter 6, we highlighted the fact that frailty is dynamic and 
that improvement and remaining stable are possible. This was further emphasised in the mortality 
findings in Chapter 8, which indicate that a regular review of frailty status is important to account 
for the changeability of frailty. The importance of investigating the presence of sarcopenia in 
combination with frailty is another factor which will contribute to clinical practice in terms of 
informing prognosis and management of individuals with both conditions (Chapter 9).  
The reporting of diagnostic test accuracy (DTA) estimates (Chapter 7) for various screening 
instruments for frailty will be of value to clinicians and policy makers in identifying suitable 
instruments for consideration in primary care and for population level screening. Likewise, the 
DTA and predictive validity findings for the FRAIL Scale (Chapter 10) provide useful information 
on the performance of these instruments in an Australian context.  
The findings on frailty state utility and minimally important difference (MID) have important 
clinical, health economic, and research implications. Chapter 11 reports the first known population-
level data on frailty state utility, which is an important component of health economic evaluation. 
(Drummond, Sculpher, Torrance, O'Brien, & Stoddart, 2005; Neumann, Goldie, & Weinstein, 
2000). Likewise, in Chapter 11 the reporting of MID findings for both frailty instruments provides 
a valuable patient perspective that informs clinical decision making regarding the effectiveness of 
frailty interventions, as well as being novel information to inform the design of clinical trials.  
The message about frailty, its modifiability, and strategies for assessment and intervention, has 
been communicated to general practitioners (GPs) across Australia in an article published in 
Australian Doctor in the Therapy Update section. The Therapy Update is an important section of 
this magazine in terms of providing GPs with the latest information on the identification and 
management of different health conditions, and in this case frailty. Aspects of Chapter 2 were the 
basis of this publication.  
Another contribution arising from this PhD has been to incorporate the findings about the dynamic 
and modifiable nature of frailty into a video: ‘Frailty: Every step you take matters!’ (Archibald et 
al., 2019). (See Figure 12.2.) This video was designed with a knowledge translation and consumer 
health literacy aim of providing the latest research on frailty and its management to consumers. The 
video is accessible to the public online and has had nearly 2,400 views to date. This video can be 
accessed at: https://www.youtube.com/watch?v=41cMkvsaOOM. 
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Figure 12.2.  Screen captures from the video: ‘Frailty: Every step you take matters!’ 
(Archibald et al., 2019).
12.3  Future directions 
As a result of the research presented in this thesis, a number of research priorities have been 
identified: 
 Further examination of frailty prevalence and associated factors in Australian
longitudinal population studies is required. Regularly re-examining population level
prevalence is necessary to address differences in cohort groups with correspondingly
different social composition and health status (Bell & Jones, 2015). Updated prevalence
data has practical implications for policy development, health and social service
planning, and predictive mapping. Population ageing studies are particularly important,
where additional effort is focused on recruiting the oldest old and individuals with
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physical limitations to provide a representative sample (Bonk, 2010; Stanziano, 
Whitehurst, Graham, & Roos, 2010). 
 In addition to prevalence, routinely reviewing the trajectory of frailty in Australian
cohorts is also important to provide a picture of the natural course of this condition.
which provides policy planners and clinicians with a better understand of prognosis,
and is necessary for health economic modelling of frailty interventions.
 Further research is required to refine the process of frailty screening, assessment and
intervention, in particular:
– Continued investigation of the properties of both the frailty phenotype (FP) and
frailty index (FI), their shared characteristics, and the implications of using either in
clinical practice or in planning for population ageing.
– Does screening for frailty in the community and General Practice actually result in
better outcomes?
– What interventions are effective in treating and preventing frailty in primary care? If
these interventions are effective, how can they be implemented in the real world and
scaled up?
– Further investigation is required into the DTA properties of frailty screening
instruments, in particular the FRAIL Scale, and examination of DTA estimates
using various cut-points of this instrument. Effective screening for frailty potentially
leads to comprehensive assessment and the offering of timely intervention.
 As health-state utility and MID for frailty classification have been reported for the first
time in this thesis, further research is required to compare these estimates with those of
other population cohorts.
My career direction following the completion of the PhD candidature is that of a clinician 
researcher. In addition to continuing my current work as an occupational therapist, I have been 
successful in being appointed to a Research Fellow position with the NHMRC Centre for Research 
Excellence in Frailty and Health Ageing in 2020.  
From a clinical perspective, the detailed understanding of frailty that I have developed over 
my PhD candidature has had a direct influence on the quality of clinical care that I deliver to my 
clients (who are primarily Aboriginal older adults in metropolitan Adelaide, as well as a rural 
outreach service in Port Lincoln). Identifying, discussing, and planning interventions for 
modifiable factors contributing to frailty are elements of a key strategy in delivering my clinical 
service. This role as a clinician researcher resulted in my invitation to participate in the planning 
and delivery of a System Wide Health and Wellbeing Strategy Workshop for South Australia 
Health. The Health and Wellbeing Strategy 2019-2024 is a State-wide, system-level strategy 
developed to meet future health challenges, specifically focused on South Australia’s health 
priorities for the next five years (SA Health, 2019). In particular, my participation involved the 
interview of a health consumer to explore barriers and facilitators to personalised high quality 
care in the health system. This video can be accessed at: https://www.youtube.com/watch?
v=7MNxpQ3dq2c 
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I have also delivered workshops and training on the identification and management of frailty and 
promotion of healthy ageing to service coordinators, managers, and direct care staff of Aboriginal 
Community Services. 
One of the immediate research priorities when I commence as a research fellow in 2020 will be 
to analyse data from the Frailty In Residential Sector Over Time (FIRST) Study. FIRST is a 
three year prospective cohort study involving 12 residential aged care facilities of Resthaven Inc. 
across South Australia and including approximately 756 residents (Jadczak, 2019). Specifically, 
analysis will be of minimally important difference in the frailty status of residents. These 
findings will be important in order to understand the perceived effectiveness of interventions 
that aim to improve function and quality of life from the perspective of individuals living in 
residential care.  
Other future studies that combine both my research and clinical interests will be to examine 
frailty specifically in Aboriginal populations, and the effectiveness of strategies to address it. 
There has been only limited examination of frailty in this vulnerable population, and the need 
for further research has been described as urgent (Hyde et al., 2016). My well-established clinical 
connection with Aboriginal health and aged care services will help to facilitate this work. 
12.4  Conclusion 
The research for this thesis has demonstrated that frailty is common in community-dwelling older 
adults, however, a downward trajectory of decreased function and worsening health is not 
always inevitable. As frailty is a dynamic condition, a regular review of frailty status and offering 
targeted interventions as appropriate, are likely to result in improved quality of life. A range 
of simple screening tools for frailty is available for use in primary care as a first step in a 
process that may lead to comprehensive management.   
The findings in this thesis have important clinical implications for both the identification 
and management of frail individuals, and for promoting healthy ageing by offering 
preventative strategies. A key message from this thesis for health practitioners and older adults 
is that, despite frailty being common, it can be either prevented, reversed, or delayed. 
This thesis has generated new evidence and strengthened the evidence base relating to the 
frailty burden in Australia. As a result, there is increased awareness of frailty's dynamic nature, 
which has the potential to drive interest among policy makers and clinicians alike in intervening 
to improve the health outcomes of older adults. 
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Frailty Phenotype 
Variable Coding Frequency 
n (sample %, weighted 
sample %) 
Histogram 
Characteristic present against age 
10% Weight loss 
between phase 1 
and 2 
0: <10% weight loss 
1: >10% weight loss 
0 = 876 (92.7, 92.7) 
1 = 69 (7.3, 7.3) 
Missing = 0 
Exhaustion 
‘everything was an 
effort’ and ‘could 
not get going’ 
Original Fried criteria 
used. 
0 = 772 (81.7, 80.7) 
1 = 131 (13.9, 14.3) 













65 70 75 80 85 65 70 75 80 85


















Weak Grip strength 
– mean of dominant
hand 
Original Fried criteria 
used (stratified by sex 
& BMI quartiles) 
0 = 575 (60.8, 57.9) 
1 = 360 (38.1, 40.9) 
Missing = 10 (1.1, 1.3) 
Walking 100m 
SF-36 – 11 
Substitute for slow 
walk speed 
0: not limited at all, 
limited a little 
1: limited a lot 
0 =  853 (90.3, 90.1) 
1 = 73 (7.7, 7.7) 
Missing = 19 (2.0, 2.1) 
Low physical activity 
level 




Walk = 3.5 METs
Mod = 5.0 METs
Vig = 7.5 METs
0: >100 METs per 
week (equates to 150 
mins mod exercise) 
1: <100 METs per 
week 
0 = 529 (56.0, 54.4) 
1 = 404 (42.8, 44.0) 
Missing = 12 (1.3, 1.6) 
Frailty Index 
Variable Coding Frequency 
n (sample %, weighted 
sample %) 
Histogram 
Deficit present against age 
10% Weight loss 
between phase 1 and 
2 
0: <10% weight loss 
1: >10% weight loss 
0 = 876 (92.7, 92.7) 
1 = 69 (7.3, 7.3) 
Missing = 0 
Weak Grip strength – 
mean of dominant 
hand 
Uses Fried criteria 
(stratified by sex & 
BMI quartiles) 
0 = 575 (60.8, 57.9) 
1 = 360 (38.1, 40.9) 






0 =  764 (80.8, 82.0) 
1 =  153 (16.2, 14.8) 
Missing = 28 (3.0, 3.1) 
Systolic blood 
pressure mean 
0: <160 mmHg 
1: ≥160 
0 = 828 (87.6, 86.9) 
1 = 114 (12.1, 12.7) 
Missing = 3 (0.3, 0.4) 
Diastolic blood 
pressure mean 
0: <90 mmHg 
1: ≥90 
0 = 831 (87.9, 87.7) 
1 = 111 (11.7, 11.9) 
Missing = 3 (0.3, 0.4) 
Stroke and/or TIA 0: no 
1: yes 
0 = 831 (87.9, 86.7) 
1 = 79 (8.4, 8.9) 
Missing = 35 (3.7, 4.4) 
Any Mental health 
problem (anxiety, 
depression, stress, 
other mental health) 
0: no 
1: yes 
0 = 798 (84.4, 83.9) 
1 = 112 (11.9, 11.8) 
Missing = 35 (3.7, 4.4) 
Heart Attack 0: no 
1: yes 
0 = 816 (86.3, 86.3) 
1 = 94 (9.9, 9.4) 
Missing = 35 (3.7,  4.4) 
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Angina 0: no 
1: yes 
0 = 822 (87.0, 86.5) 
1 = 88 (9.3, 9.2) 
Missing = 35 (3.7, 4.4) 
Osteoporosis 0: no 
1: yes 
0 = 795 (84.1, 82.7) 
1 = 115 (12.2, 13.0) 
Missing = 35 (3.7, 4.4) 
OA 0: no 
1: yes 
0 = 744 (78.7, 77.5) 
1 =  166 (17.6, 18.2) 
Missing = 35 (3.7, 4.4) 




0 = 847 (89.6, 88.5) 
1 = 63 (6.7, 7.2) 
Missing = 35 (3.7, 4.4) 
Diabetes 0: no 
1: yes 
0 = 785 (83.1, 82.3) 
1 = 157 (16.6, 17.4) 
Missing = 3 (0.3, 0.3) 
Falls 0: none 
0.5: 1 fall 
1: 2+ falls 
0 = 598 (63.3, 61.1) 
0.5 = 173 (18.3, 18.4) 
1 = 134 (14.2, 15.8) 





1: 1+ hospital 
admission 
0 = 809 (85.6, 84.8) 
1 = 97 (10.3, 10.3) 
Missing = 35 (4.1, 4.8) 
Low physical activity 
level 
Montgomerie et al 
[29] method: 
<100 METs / week
(inactive)
Walk = 3.5 METs
Mod = 5.0 METs
Vig = 7.5 METs
0: >100 METs per week 
(equates to 150 mins 
mod exercise) 
1: <100 METs per week 
0 = 529 (56.0, 54.4) 
1 = 404 (42.8, 44.0) 
Missing = 12 (1.3, 1.6) 
Keep mind on what 
you were doing 
CES-D 5 
0: rarely & some/little, 
1: occasional & most 
0 = 797 (84.3, 83.3) 
1 = 102 (10.8, 11.3) 
Missing = 46 (4.9, 5.4) 
Everything was an 
effort 
CES-D 7 
0: rarely & some or a 
little 
1: occasional or 
moderate & most or all 
(scoring matches 
phenotype) 
0 = 801 (84.8, 84.2) 
1 = 99 (10.5, 10.6) 
Missing = 45 (4.8, 5.2) 
Felt lonely 
CES-D 14 
0: rarely & some/little, 
1: occasional & most. 
0 = 849 (89.8, 89.6) 
1 = 54 (5.7, 5.5) 
Missing = 42 (4.4, 5.0) 
Could not get going 
CES-D 20 
0: rarely & some or a 
little 
1: occasional or 
moderate & most or all 
(phenotype coding) 
0 = 821 (86.9, 85.7) 
1 = 80 (8.5, 9.0) 
Missing = 44 (4.7, 5.3) 
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Your health is 
SF-36 – 1 
0: excellent, very good, 
good 
1: fair, poor 
0 = 692 (73.2, 72.0) 
1 = 249 (26.3, 27.6) 
Missing = 4 (0.4, 0.4) 
Lifting or carrying 
groceries 
SF-36 - 5 
0: not limited at all 
0.5: limited a little 
1: limited a lot 
0 = 451 (47.7, 44.4) 
0.5 = 365 (38.6, 40.4) 
1 = 125 (13.2, 14.7) 
Missing = 4 (0.4, 0.5) 
Climbing several 
flights of stairs 
SF-36 - 6 
0: not limited at all 
0.5: limited a little 
1: limited a lot 
0 = 203 (21.5, 19.3) 
0.5 = 416 (44.0, 42.8) 
1 = 311 (32.9, 36.4) 
Missing = 15 (1.6, 1.5) 
Climbing one flight of 
stairs 
SF-36 7  
0: not limited at all 
0.5: limited a little 
1: limited a lot 
0 = 435 (46.0, 43.0) 
0.5 = 341 (36.1, 37.5) 
1 = 155 (16.4, 17.9) 
Missing = 14 (1.5, 1.5) 
Bending, kneeling or 
stooping 
SF-36 - 8 
0: not limited at all 
0.5: limited a little 
1: limited a lot 
0 = 236 (25.0, 23.0) 
0.5 = 474 (50.2, 51.0) 
1 = 231 (24.4, 25.6) 
Missing = 4 (0.4, 0.4) 
Walking more than 
1km 
SF-36 - 9 
0: not limited at all 
0.5: limited a little 
1: limited a lot 
0 = 389 (41.2, 38.6) 
0.5 = 299 (31.6, 31.1) 
1 = 244 (25.8, 29.0) 
Missing = 13 (1.4, 1.3) 
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Walking 100m 
SF-36 – 11 
0: not limited at all, 
limited a little 
1: limited a lot 
(Phenotype – walk 
speed) 
0 =  853 (90.3, 90.1) 
1 = 73 (7.7, 7.7) 
Missing = 19 (2.0, 2.1) 
Extent physical & 
emotional probs 
interfered – social 
activities 
SF-36 – 20 
0: not at all 
0.33: slightly 
0.67: moderately 
1:quite a bit & 
extremely 
0 = 633 (67.0, 65.6) 
0.33 = 157 (16.6, 17.3) 
0.67 = 84 (8.9, 9.7) 
1 = 67 (7.1, 7.1) 
Missing = 4 (0.4, 0.3) 
full of life 
SF-36 – 23 
0: all the time & most 
time 
0.5: good bit &  some 
1: a little & none of the 
time 
0 = 434 (45.9, 44.2) 
0.5 = 370 (39.2, 40.8) 
1 = 134 (14.2, 14.2) 
Missing = 7 (0.7, 0.7) 
calm & peaceful 
SF-36 – 26 
0: all the time & most 
time 
0.5: good bit & some 
1: a little & none of the 
time 
1 = 610 (64.6, 63.0) 
0.5 = 259 (27.4, 28.1) 
1 = 73 (7.7, 8.5) 
Missing = 3 (0.3, 0.4) 
worn out 
SF-36 – 29 
0: a little & none of the 
time 
0.5: some & good bit 
1: all the time & most 
time 
0 = 521 (55.1, 52.7) 
0.5 = 348 (36.8, 39.1) 
1 = 73 (7.7, 7.9) 
Missing = 3 (0.3, 0.4) 
tired 
SF-36 – 31 
0: a little & none of the 
time  
0.5: some & good bit 
1: all the time & most 
time 
0 = 394 (41.7, 39.7) 
0.5 = 452 (47.8, 49.0) 
1 = 96 (10.2, 10.9) 
Missing = 3 (0.3, 0.4) 
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I’m as healthy as 
anybody I know 
SF-36 - 34 
0: def true 
0.25: mostly true 
0.5: don’t know 
0.75: mostly false 
1: def false 
0 = 226 (23.9, 23.1) 
0.25 = 389 (41.2, 41.7) 
0.5 = 188 (19.9, 20.1) 
0.75 = 83 (8.8, 8.9) 
1 = 51 (5.5, 5.5) 
Missing = 7 (0.7, 0.8) 
 
My health is 
excellent 
SF-36 - 36 
0: def true, mostly 
true,  
0.5: don’t know 
1: mostly false, def 
false 
 
0 = 546 (57.8, 55.7) 
0.5 = 134 (14.2, 15.0) 
1 = 230 (24.3, 25.1) 
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Chapter 6. Table S1. Frailty category and death status at 4.5 years mean follow up according to 
baseline frailty category. Percentage by baseline frailty status. 
Baseline Frailty Status Follow-up Frailty Status, n(%) 
Non-frail Pre-frail  Frail Dead Total 
Phenotype 
Whole Sample 
   Non-frail 120 (47.7) 78 (33.9) 13 (6.9) 22 (11.5) 233 
   Pre-frail 82 (23.1) 167 (44.7) 47 (15.4) 61 (16.8) 357 
   Frail 2 (1.8) 19 (19.8) 40 (36.9) 45 (41.4) 106 
   Total 204 (27.5) 264 (37.2) 100 (16.2) 128 (19.1) 696 
Male 
   Non-frail 64 (48.2) 43 (36.0) 4 (3.5) 16 (12.3) 127 
   Pre-frail 40 (23.6) 74 (39.1) 19 (11.2) 46 (26.1) 179 
   Frail 0 (0.0) 9 (20.5) 16 (34.1) 22 (45.5) 47 
   Total 104 (29.2) 126 (35.4) 39 (11.6) 84 (23.8) 353 
Female 
   Non-frail 56 (46.6) 35 (33.0) 9 (10.7) 6 (9.7) 106 
   Pre-frail 42 (22.5) 93 (49.7) 28 (18.8) 15 (8.9) 178 
   Frail 2 (3.0) 10 (19.4) 24 (38.8) 23 (38.8) 59 
   Total 100 (25.8) 138 (39.3) 61 (20.2) 44 (14.7) 343 
Frailty Index 
Whole Sample 
   Non-frail 94 (54.4) 50 (26.6) 20 (11.4) 11 (7.6) 175 
   Pre-frail 33 (13.6) 87 (38.0) 74 (37.1) 25 (11.3) 219 
   Frail 3 (1.0) 22 (7.4) 185 (61.5) 92 (30.1) 302 
    Total 130 (17.3) 159 (21.4) 279 (42.3) 128 (19.0) 696 
Male 
  Non-frail 60 (63.2) 19 (18.4) 11 (10.3) 8 (8.0) 98 
  Pre-frail 17 (12.3) 42 (34.9) 36 (34.9) 20 (17.9) 115 
  Frail 2 (0.8) 10 (8.0) 72 (51.2) 56 (40.0) 140 
  Total 79 (21.7) 71 (19.8) 119 (34.6) 84 (23.9) 353 
Female 
  Non-frail 34 (42.3) 31 (36.6) 9 (14.1) 3 (7.0) 77 
  Pre-frail 16 (15.0) 45 (41.1) 38 (39.3) 5 (4.7) 104 
  Frail 1 (0.5) 12 (7.0) 113 (68.8) 36 (23.8) 162 
 Total 51 (12.9) 88 (22.9) 160 (49.3) 44 (14.9) 343 
Note: Frailty Phenotype cut points (number of deficits): 0 = Not Frail, 1-2 = pre-frail, 3+ = Frail; Frailty Index cut points 
(proportion of deficits): 0 to ≤.10 = not frail, >.10 to ≤.21 = vulnerable, and >.21 = frail. 
Chapter 6. Table S2. Frailty category and death status at 4.5 years mean follow up according to 
baseline frailty category. Percentage of whole sample.  
Baseline Frailty Status Follow-up Frailty Status 
n (%) 
Non-frail Pre-frail Frail Dead Total 
Frailty Phenotype 
   Non-frail 120 (15.3) 78 (10.9) 13 (2.2) 22 (3.7) 233 (32.1) 
   Pre-frail 82 (11.9) 167 (23.1) 47 (7.9) 61 (8.7) 357 (51.6) 
   Frail 2 (0.3) 19 (3.2) 40 (6.0) 45 (6.8) 106 (16.3) 
   Total 204 (27.5) 264 (37.2) 100 (16.2) 128 (19.1) 696 (100) 
Frailty Index 
   Non-frail 94 (12.6) 50 (6.1) 20 (2.6) 11 (1.8) 175 (23.1) 
   Pre-frail 33 (4.2) 87 (11.9) 74 (11.6) 25 (3.5) 219 (31.2) 
   Frail 3 (0.4) 22 (3.4) 185 (28.1) 92 (13.8) 302 (45.7) 
    Total 130 (17.3) 159 (21.4) 279 (42.3) 128 (19.0) 696 (100) 
Note: Frailty Phenotype cut points (number of deficits): 0 = Not Frail, 1-2 = pre-frail, 3+ = Frail; Frailty Index cut points 
(proportion of deficits): 0 to ≤.10 = not frail, >.10 to ≤.21 = vulnerable, and >.21 = frail. 
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Chapter 6. Table S3. Frailty state transitions: Better, same, and worse (worse includes dead) at 4.5 






Better 103 (15.5) 58 (7.9) 
Same 327 (44.4) 366 (52.6) 
Worse or Dead 266 (40.1) 272 (39.5) 
Worse = a more severe frailty state, including death, compared with baseline state;  Improved = 
a less severe frailty state compared with baseline state 
Chapter 6. Table S4. Univariate logistic regression for variables associated with frailty phenotype 
transitions in frailty states over 4.5 years, adjusted for time between clinic appointments. Reference 
category is ‘same’.   
Odds Ratio (95% Confidence Interval) P-Value 
Baseline Frailty Status Non-Frail Pre-Frail Pre-Frail Frail Frail 
Follow up Status Worse Improved Worse Improved Worse 
Sex 
   Male 1 1 1 1 1 
   Female 1.09 (.63, 1.89) .83 (.47, 1.44) .77 (.46, 1.29) .88 (.29, 2.63) .47 (.17, 1.34) 
Age Group 
65-74 years 1 1 1 1 1 
>75 years .55 (.30, 1.02) .32 (.19, .55)* 2.11 (1.09, 4.10)* .13 (.04, .46)* 1.51 (.51, 4.48) 
Education Level 
    1 Up to secondary  2.41 (.56, 10.27) .95 (.09, 9.91) .35 (.06, 2.18) 1.49 (.45, 4.92) -
    2 Trade / Cert / Dip  1.77 (.41, 7.66) 1.02 (.09, 11.00) .44 (.07, 2.86) - - 
    3 Bachelor degree+  1 1 1 1 1 
Income Groups 
    1 Up to $20k  2.44 (.62, 9.57) .64 (.13, 3.12) 6.26 (.23, 170.12) 1.10 (.35, 3.46) -
    2 $20-$40k  1.58 (.41, 6.03) .89 (.18, 4.40) 5.76 (.21, 158.60) - - 
    3 $40-$60k  1.65 (.35, 7.84) 1.76 (.29, 10.81) 7.09 (.22, 226.34) - - 
    4 More than $60k 1 1 1 1 1 
Smoking Status† 
    3 Never smoked  1 1 1 1 1 
    2 Former smoker  1.34 (.76, 2.35) .63 (.35, 1.13) .78 (.46, 1.33) .55 (.18, 1.70) .94 (.33, 2.66) 
    1 Current smoker 1.02 (.24, 4.22) 1.53 (.433, 5.40) 1.13 (.33, 3.88) .94 (.14, 6.24) .22 (.01, 3.69) 
Alcohol Consumption†‡ 
    Not at risk 1 1 1 1 1 
    Excess  1.10 (.43, 2.82) 1.02 (.44, 2.36) .70 (.31, 1.60) 2.70 (.43, 17.08) 1.22 (.17, 9.04) 
Waist Circumference †§ 
    Normal 1 1 1 1 1 
    Obese  1.45 (.83, 2.53) .45 (.26, .79)* .53 (.31, .89)* 1.87 (.56, 6.22) .98 (.34, 2.82) 
Multimorbidity 
0-1 conditions 1 1 1 1 1 
2+ conditions 3.94 (1.75, 8.89)* .67 (.36, 1.25) 1.23 (.72, 2.10) .52 (.18, 1.51) .47 (.17, 1.32) 
Polypharmacy 
0-4 medication 1 1 1 1 1 
5+ medications 1.21 (.68, 2.14) .44 (.24, .78)* .91 (.55, 1.53) .39 (.13, 1.18) .37 (.13, 1.11) 
Living Arrangements† 
    Lives with others  1 1 1 1 1 
    Lives alone  1.13 (.60, 2.14) .59 (.31, 1.14) 1.34 (.76, 2.38) .50 (.14, 1.86) 2.89 (.96, 8.72) 
OR = Odds Ratio; 95%CI = 95% Confidence Interval; – = unable to estimate; Improved = a less severe frailty state compared 
with baseline state; Worse = a more severe frailty state, including death, compared with baseline state; Obesity = Waist 
Circumference: male >102cm, female >88cm; Excess alcohol consumption = >14 drinks per week and/or >4 drinks per 
session. 
* P < .05
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Chapter 6. Table S5. Univariate logistic regression for variables associated with frailty index transitions in 
frailty states over 4.5 years, adjusted for time between clinic appointments. Reference category is ‘same’ 
Odds Ratio (95% Confidence Interval) P-Value 
Baseline Frailty Status Non-Frail Pre-Frail Pre-Frail Frail Frail 
Follow up Status Worse Improved Worse Improved Worse 
Whole Sample 
Sex 
   Male 1 1 1 1 1 
   Female 1.52 (.78, 2.97) 1.86 (.72, 4.83) 1.13 (.57, 2.22) .72 (.29, 1.79) .46 (.25, .84)* 
Age Group 
65-74 years 1 1 1 1 1 
>75 years .61 (.29, 1.29) .27 (.13, .59)* 4.14 (.84, 20.40) .14 (.07, .28)* 7.19 (1.52, 34.05)* 
Education Level 
    Up to secondary  .88 (.18, 4.36) - .80 (.12, 5.45) - .21 (.02, 1.90)
    Trade / Cert / Dip  .43 (.08, 2.17) - .70 (.10, 4.91) - .29 (.03, 2.74)
    Bachelor degree+  1 1 1 1 1 
Income Groups 
    Up to $20k  2.42 (.38, 15.39) .88 (.16, 4.95) 3.03 (.68, 13.51) - .25 (.01, 5.95)
    $20-$40k  1.57 (.25, 9.71) 1.19 (.22, 6.39) 2.51 (.56, 11.29) - .14 (.01, 3.51)
    $40-$60k  1.37 (.18, 10.31) .46 (.02, 10.00) 2.45 (.34, 17.85) - .18 (.01, 5.77)
    More than $60k 1 1 1 1 1 
Smoking Status† 
    Never smoked  1 1 1 1 1 
    Former smoker  1.70 (.40, 7.15) .36 (.02, 7.27) 2.07 (.37, 11.63) - .81 (.19, 3.52) 
    Current smoker 1.18 (.60, 2.34) .33 (.11, .95)* 1.11 (.56, 2.20) .52 (.20, 1.39) 1.37 (.73, 2.55) 
Alcohol Consumption†‡ 
    Not at risk 1 1 1 1 1 
    Excess  1.03 (.37, 2.89) .50 (.09, 2.84) .90 (.33, 2.50) .13 (.00, 4.39) .51 (.17, 1.52) 
Waist Circumference †§ 
    Normal 1 1 1 1 1 
    Obese  2.03 (1.03, 3.99)* .30 (.11, .83)* .58 (.29, 1.16) .42 (.17, 1.05) .76 (.41, 1.38) 
Multimorbidity (FI24) 
0-1 conditions 1 1 1 1 1 
2+ conditions 6.29 (1.45, 27.22)* .88 (.27, 2.85) 1.46 (.67, 3.29) .08 (.02, .46)* .59 (.32, 1.10) 
Polypharmacy 
0-4 medication 1 1 1 1 1 
5+ medications 1.83 (.88, 3.80) .87 (.32, 2.36) 1.44 (.72, 2.87) .26 (.09, .74)* 1.09 (.60, 1.99) 
Living Arrangements† 
    Lives with others  1 1 1 1 1 
    Lives alone  .59 (.27, 1.29) .60 (.18, 2.07) 1.40 (.64, 3.07) .62 (.21, 1.87) 2.41 (1.25, 4.65)* 
OR = Odds Ratio; 95%CI = 95% Confidence Interval; – = unable to estimate; Improved = a less severe frailty state compared 
with baseline state; Worse = a more severe frailty state, including death, compared with baseline state; Obesity = Waist 
Circumference: male >102cm, female >88cm; Excess alcohol consumption = >14 drinks per week and/or >4 drinks per 
session; FI24 = a 24 item FI that excludes all chronic conditions. 
* P < .05
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Chapter 6. Figure S1. Flow Diagram of Participants 
Attended stage 2 clinic 
(n = 945) 
Excluded: 
• Missing ≥ 20% Frailty Index
(FI) variables (n = 36)
Eligible for baseline 
analysis 
(n = 909) 
Excluded: 
• Lost to follow up (n = 120)
• Missing ≥ 20% Frailty Index
variables or ≥ 3 Frailty
Phenotype variables from
stage 3 (n = 93)
Eligible for frailty state 
transition analysis 
(n = 696) 
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Supplementary Material Chapter 7 
Chapter 7. Table S1: Search Syntax.  
Diagnostic test accuracy of self-reported frailty screening instruments in identifying 
community-dwelling older people at risk of frailty and pre-frailty: A systematic review.  
• Embase
(kihon AND check* OR (reported AND edmonton AND frail AND ('scale'/exp OR scale)) OR
((frail* OR prefrail*) AND (screen* OR index* OR tool* OR instrument*) AND ((self NEXT/5
(evaluat* OR assess* OR diagnos* OR test* OR report* OR administ*)) OR survey* OR
postal* OR questionnaire* OR reported*)))
• PubMed
((((((frail*[tw]) OR prefrail*[tw])) AND ((((((((((Diagnostic Self Evaluation[mh]) OR Self-
report*[tw]) OR Postal*[tw]) OR Self-diagnos*[tw]) OR Survey*[tw]) OR Questionnaire*[tw])
OR reported*[tw]) OR Self-assess*[tw]) OR Self-test*[tw]) OR Self-administ*[tw])) AND
((((screen*[tw]) OR instrument*[tw]) OR tool*[tw]) OR index*[tw]))) OR ((Kihon Check*[tw])
OR Reported Edmonton Frail Scale*[tw])
• Scopus
( ( TITLE-ABS-KEY ( frail*  OR  prefrail* ) )  AND  ( TITLE-ABS-KEY ( ( screen*  OR  instrument*
OR  tool*  OR  index* ) ) )  AND  ( ( TITLE-ABS-KEY ( self  PRE/5  ( evaluat*  OR  assess*  OR 
diagnos*  OR  test*  OR  report*  OR  administ* ) ) )  OR  ( TITLE-ABS-KEY ( questionnaire* 
OR  survey*  OR  postal  OR  reported ) ) ) )  OR  ( TITLE-ABS-KEY ( ( kihon  AND check* ) ) ) 








o 7. Reported Edmonton Frail Scale.mp.






o 14. (Self adj5 report$).mp.
o 15. (Self adj5 assess$).mp.
o 16. (Self adj5 test$).mp.
o 17. (Self adj5 administ$).mp.
o 18. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
o 19. index$.mp.
o 20. 4 or 5 or 6 or 19
o 21. Kihon Check$.mp.
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o 22. 7 or 21
o 23. 3 and 18 and 20
o 24. 22 or 23
• CINAHL
((TX ((Kihon AND Check*))) OR (TX ((Reported AND Edmonton AND Frail AND Scale)))) OR
(((TX (frail*)) OR (TX (prefrail*))) AND ((TX (screen*)) OR (TX (tool*)) OR (TX (index*)) OR (TX
(instrument*))) AND ((TX (self W5 (evaluat* OR assess* OR diagnos* OR test* OR adminst*
OR report*))) OR (TX (questionnaire*)) OR (TX (survey*)) OR (TX (postal)) OR (TX
(reported))))
• Web of Science
#9 #8 OR #4 OR #3 DocType=All document types; Language=All languages; 
#8 #7 AND #2 AND #1 DocType=All document types; Language=All languages; 
#7 #6 OR #5 DocType=All document types; Language=All languages; 
#6 TS=(self NEAR/5 (evaluat* OR assess* OR diagnos* OR test* OR report* OR administ*)) DocType=All document types; Language=All languages; 
#5 TS=( questionnaire* OR survey* OR postal OR reported ) DocType=All document types; Language=All languages; 
#4 TS=( reported edmonton frail scale* ) DocType=All document types; Language=All languages; 
#3 TS=( kihon check* ) DocType=All document types; Language=All languages; 
#2 TS=( screen* OR instrument* OR tool* OR index* ) DocType=All document types; Language=All languages; 
#1 TS=( frail* OR prefrail* ) DocType=All document types; Language=All languages; 
• PsycINFO
1 (frail* or prefrail*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 
2 (screen* or instrument* or tool*OR index*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 
3 (questionnaire* or survey* or postal or reported).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 
4 (self adj5 (evaluat* or assess* or diagnos* or test* or report* or administ*)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 
5 (kihon and check*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 
6 Reported Edmonton Frail Scale.mp. 
7 3 or 4 
8 1 and 2 and 7 
9 5 or 6 or 8 
• Pedro
Searched for frail* and prefrail* in abstract or title
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• ProQuest Dissertations & Theses Global
(ab(frail* OR prefrail*) OR ti((frail* OR prefrail*))) AND screen* AND all((self PRE/5 (evaluat*
OR assess* OR diagnos* OR test* OR report* OR administ*) OR questionnaire* OR survey*
OR postal))
• Open Grey
*frail* AND (screening* OR instrument* OR tool* OR index*) lang:"en"



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 7. Figure S1: Forest Plots for Selected Studies 
a) Sensitivity Forest Plot (Reference Standard = Frailty Phenotype)
Note: Forest plots were generated only for index tests with more than one study comparing sensitivity
and specificity against the reference standard.
FI, Frailty Index. FP, Frailty Phenotype. FRAIL, FRAIL Scale. GFI, Groningen Frailty Indicator. PRISMA-7, Program of Research on 
Integration of Services for the Maintenance of Autonomy 7 Instrument. TP, True Positive, FP False Positive, FN False Negative, 
TN True Negative  
b) Sensitivity Forest Plot (Reference Standard = Frailty Index)#
#FI threshold: ≥ 0.08 Drubbel et al 2013.  > 0.21: McCaul et al 2015.  > 0.25: Ntanasi et al 2018.   ≥ 0.25: Braun et al 2017, 
Theou et al 2013. > 0.35: Dong et al 2017. 
FI, Frailty Index. FP, Frailty Phenotype. FRAIL, FRAIL Scale. GFI, Groningen Frailty Indicator. PRISMA-7, Program of Research on 
Integration of Services for the Maintenance of Autonomy 7 Instrument. TP, True Positive, FP False Positive, FN False Negative, 
TN True Negative  
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Supplementary Material Chapter 8 
 
Chapter 8. Table S1. Frailty Phenotype and Frailty Index Variables  
 
Frailty Phenotype  Frailty Index (34-item)  
Weight Loss: > 10% weight loss 
over four years (clinic 
measurement) 
Weakness: original method 
Exhaustion: original method 
Slowness: Self-report ‘a lot’ to 
health limits walking 100m 
(SF36 q11) 
Low Activity Level: Australian 
Bureau of Statistics National 






Rheumatoid and any other arthritis 
Stroke or TIA 
Diabetes 
Any mental health problem 
Systolic blood pressure 
Diastolic blood pressure 
10% weight loss over 4 years 
FEV1/FVC post ratio 
Weak grip strength  
Falls 
Hospital emergency admission 
Low activity level (<100 METs per week) 
Healthy as anybody I know 
Health is excellent  
Self-reported health 
Health limits lifting or carrying groceries 
Health limits climbing several flights of stairs 
Health limits climbing one flight of stairs 
Health limits bending, kneeling or stooping 
Health limits walking more than 1km 
Health limits walking 100m 
Felt lonely 
Felt that could not get going 
Difficulty keeping mind on what you were 
doing 
Felt everything was an effort  
Physical & emotional problems interfered 
with social activities 
Felt full of life 
Felt calm and peaceful 
Felt worn out 
Felt tired 
METs, metabolic equivalent of task; SF36, 36-Item Short Form Health Survey; TIA, transient ischaemic attack; FEV1/FVC, forced expiratory 




Chapter 8. Table S2 Baseline descriptive characteristics and frailty classification of participants who died 
before 31/07/2018 or who were lost to follow-up. 




n (%) n (%) 
Total 147 213 
Sex 
Male 101 (62.4) 99 (39.5) 
Female 46 (37.6) 114 (60.5) 
Age Groups 
65-74 years 44 (27.7) 113 (47.0) 
≥75 years 103 (72.3) 100 (53.0) 
Education Level a 
Up to secondary  87 (61.2) 141 (71.5) 
Trade / Cert / Dip  48 (35.1) 60 (26.0) 
≥Bachelor degree 6 (3.8) 6 (2.4) 
Income Groups a 
Up to $20k 84 (61.1) 118 (58.1) 
$20-$40k 318 (60.8) 57 (32.8) 
$40-$60k 8 (6.5) 11 (6.9) 
>$60k 2 (1.6) 3 (2.2) 
5-Category FP
0 characteristics 27 (20.1) 55 (23.8) 
1 characteristic 33 (19.7) 68 (30.9) 
2 characteristics 35 (24.1) 46 (20.8) 
3 characteristics 34 (25.2) 29 (17.6) 
≥4 characteristics 18 (10.9) 15 (6.9) 
3-Category FP
Non-frail 27 (20.1) 55 (23.8) 
Pre-frail 68 (43.8) 114 (51.7) 
Frail 52 (36.1) 44 (24.5) 
10% Increment FI 
0-10% 15 (10.3) 36 (16.3) 
10-20% 26 (15.8) 63 (26.6) 
20-30% 30 (22.1) 46 (21.4) 
30-40% 39 (24.1) 31 (16.6) 
40-50% 22 (17.2) 22 (12.3) 
>50% 15 (10.5) 15 (6.7) 
3-Category FI
Non-frail 15 (10.3) 36 (16.3) 
Pre-frail 29 (19.0) 65 (27.5) 
Frail 103 (70.8) 112 (56.2) 
n unweighted. % reported using cohort case weights. 5-Category FP (number of 
characteristics): 0, 1, 2, 3, 4-5. 3-Category FP (number of characteristics): 0, non-
frail; 1-2, pre-frail, ≥ 3, frail. 10% Increment FI: 0-10%, 10-20%, 20-30%, 30-40%, 
40-50%, > 50%. 3-Category FI (proportion of deficits): 0 to ≤.10, non-frail; >.10 to
≤.21, pre-frail; >.21, frail.
a missing nor included.
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Chapter 8. Table S3 Mortality rates by baseline descriptive characteristics, frailty status for the frailty 
phenotype (FP) and frailty index (FI). 
n (%) dead within 
n (%) 1 year 2 years 4 years 6 years 8 years 10 years 
Whole sample 909 19 (2.0) 37 (4.1) 86 (9.5) 153 (17.5) 214 (24.8) 292 (33.8) 
Sex 
Male 453 (45.2) 8 (1.6) 22 (4.8) 54 (11.2) 104 (23.1)* 140 (31.5)* 180 (40.1)* 
Female 456 (54.8) 11 (2.4) 15 (3.5) 32 (8.1) 49 (13.0) 74 (19.2) 112 (28.6) 
Age Groups 
65-74 years 554 (56.3) 4 (0.7)* 13 (2.2)* 30 (5.4)* 46 (8.5)* 63 (12.2)* 96 (17.8)* 
≥75 years 355 (43.7) 15 (3.7) 24 (6.5) 56 (14.7) 107 (29.1) 151 (40.9) 196 (54.3) 
Education Level a 
Up to secondary 569 (63.5) 15 (2.6) 28 (4.7) 57 (9.6) 93 (17.0) 128 (23.6) 181 (33.2) 
Trade / Cert / Dip 288 (30.6) 3 (1.0) 7 (3.0) 22 (8.6) 49 (18.0) 72 (26.9) 93 (34.1) 
≥Bachelor degree 25 (2.5) 1 (3.6) 1 (3.6) 3 (10.8) 5 (19.4) 7 (29.5) 9 (35.4) 
Income Groups a 
Up to $20k 462 (46.5) 13 (2.8) 24 (5.1) 54 (10.9) 86 (18.3) 115 (25.9) 157 (35.5)* 
$20-$40k  281 (33.5) 3 (1.3) 5 (2.0) 17 (7.6) 34 (14.3) 51 (20.3) 76 (28.9) 
$40-$60k  59 (6.8) 1 (1.3) 3 (6.5) 5 (9.8) 8 (13.0) 13 (21.3) 19 (31.8) 
>$60k  26 (2.6) 0 (0) 0 (0) 0 (0) 2 (8.3) 2 (8.3) 3 (11.6) 
5-Category FP
0 characteristics 289 (30.1) 0 (0)* 1 (0.4)* 12 (5.3)* 27 (10.8)* 45 (177)* 68 (26.3)* 
1 characteristic 289 (30.8) 3 (1.0) 10 (3.2) 18 (5.4) 36 (11.3) 49 (15.9) 69 (22.1) 
2 characteristics 181 (20.8) 5 (2.3) 10 (5.0) 24 (12.4) 36 (20.3) 51 (29.1) 68 (38.5) 
3 characteristics 108 (13.8) 6 (5.5) 9 (8.5) 18 (15.3) 35 (32.8) 44 (41.9) 59 (58.0) 
   ≥4 characteristics 42 (4.5) 5 (10.8) 7 (16.5) 14 (33.4) 19 (44.9) 25 (59.9) 28 (67.0) 
3-Category FP
Non-Frail 289 (30.1) 0 (0)* 1 (0.4)* 12 (5.3)* 27 (10.8)* 45 (17.7)* 68 (26.3)* 
Pre-frail 470 (51.6) 8 (1.5) 20 (3.9) 42 (8.3) 72 (15.0) 100 (21.2) 137 (28.7) 
Frail 150 (18.3) 11 (6.8) 16 (10.5) 32 (19.8) 54 (35.8) 69 (46.4) 87 (60.2) 
10% Increment FI 
0-10% 211 (21.5) 0 (0)* 0 (0)* 6 (2.9)* 16 (8.1)* 28 (13.1)* 44 (21.4)* 
10-20% 266 (28.1) 5 (1.8) 10 (3.7) 17 (6.1) 27 (9.4) 43 (16.2) 65 (24.6) 
20-30% 182 (21.0) 2 (1.0) 5 (2.3) 13 (7.1) 31 (18.7) 46 (27.5) 63 (35.3) 
30-40% 129 (14.7) 3 (2.7) 8 (6.6) 22 (15.7) 39 (26.6) 49 (37.2) 59 (45.7) 
40-50% 80 (10.0) 5 (5.5) 6 (7.5) 17 (20.6) 24 (33.5) 27 (37.2) 35 (50.7) 
>50% 41 (4.7) 4 (7.8) 8 (17.9) 11 (27.0) 16 (42.2) 21 (51.7) 26 (65.2) 
3-Category FI
Non-Frail 211 (21.5) 0 (0)* 0 (0) 6 (2.9)* 16 (8.1)* 28 (13.1)* 44 (21.4)* 
Pre-frail 285 (30.4) 5 (1.7) 10 (3.4) 18 (6.1) 30 (10.4) 47 (16.9) 69 (24.6) 
Frail 413 (48.1) 14 (3.2) 27 (6.3) 62 (14.5) 107 (26.3) 139 (35.0) 179 (45.1) 
n unweighted. % reported using cohort case weights. 5-Category FP (number of characteristics): 0, 1, 2, 3, 4-5. 3-
Category FP (number of characteristics): 0, non-frail; 1-2, pre-frail, ≥ 3, frail. 10% Increment FI: 0-10%, 10-20%, 20-30%, 
30-40%, 40-50%, > 50%. 3-Category FI (proportion of deficits): 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail.
a missing nor included.
* p < 0.05 (main effects reported) 
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Chapter 8. Table S4 Frailty status at baseline and follow-up status for the 3-Category Frailty Phenotype and 
Frailty Index 
Follow-up Frailty Status, n (%) 
Baseline 
Frailty Status 
Non-Frail Pre-frail Frail  Dead a Missing b Total 
Frailty Phenotype 
Non-Frail  118 (37.5) 77 (27.2) 12 (5.1) 27 (10.7) 55 (19.5) 289 (100) 
Pre-frail 78 (16.6) 163 (33.2) 47 (11.6) 68 (13.8) 114 (24.8) 470 (100) 
Frail 2 (1.2) 18 (12.7) 34 (20.6) 52 (32.1) 44 (33.3) 150 (100) 
Total 198 (20.1) 258 (27.6) 93 (11.3) 147 (16.2) 213 (24.8) 909 (100) 
Frailty Index 
Non-Frail  93 (44.0) 47 (20.2) 20 (9.3) 15 (7.8) 36 (18.7) 211 (100) 
Pre-frail 33 (10.5) 87 (29.5) 71 (27.6) 29 (10.2) 65 (22.2) 285 (100) 
Frail 3 (0.7) 19 (4.6) 176 (42.1) 103 (23.9) 112 (28.7) 413 (100) 
Total 129 (13.0) 153 (15.5) 267 (30.7) 147 (16.3) 213 (24.6) 909 (100) 
n unweighted. % reported using cohort case weights. Frailty Phenotype (number of characteristics): 0, non-frail; 1-2, 
pre-frail, ≥ 3, frail. Frailty Index (proportion of deficits): 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail. 
a Died before 31/07/2018 
b Participants who were either lost to follow-up or who had insufficient valid FP or FI variables at follow-up. 
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Chapter 8. Table S5 Mortality rates by baseline descriptive characteristics, frailty status 
(frailty phenotype (FP) and frailty index (FI)) for the returning sample (n = 549). 
 
   n (%) dead  
years from baseline 
 n (%)  6 years  8 years 10 years 
Returning sample 549  3 (0.7) 26 (5.0) 70 (13.1) 
Sex      
Male 253 (43.0)  2 (1.0) 13 (5.5) 39 (15.8) 
Female 296 (57.0)  1 (0.4) 12 (4.3) 30 (10.8) 
Age Groups      
65-74 years  397 (67.8)  1 (0.4) 8 (2.7)* 28 (7.6)* 
≥75 years  152 (32.2)  2 (1.2) 17 (9.1) 41 (24.3) 
Education Level a      
Up to secondary  341 (61.9)  2 (0.9) 13 (4.4) 42 (13.0) 
Trade / Cert / Dip  180 (32.7)  1 (0.4) 11 (5.8) 25 (14.2) 
≥Bachelor degree  13 (2.3)  0 (0) 0 (0) 1 (4.6) 
Income Groups a      
Up to $20k  260 (43.6)  2 (1.2) 15 (6.8) 39 (17.0) 
$20-$40k  193 (38.2)  1 (0.3) 8 (4.3) 24 (12.80 
$40-$60k  40 (7.5)  0 (0) 1 (2.2) 4 (7.1) 
>$60k  21 (3.0)  0 (0) 0 (0) 1 (4.5) 
5-Category FP      
   0 characteristics 207 (34.9)  0 (0) 8 (3.7)* 24 (11.9)* 
   1 characteristic 188 (34.4)  1 (0.4) 5 (1.8) 18 (8.2) 
   2 characteristics 100 (19.7)  1 (1.3) 7 (8.4) 16 (17.5) 
   3 characteristics 45 (9.2)  1 (3.1) 4 (11.2) 10 (25.7) 
   ≥4 characteristics 9 (1.7)  0 (0) 1 (10.6) 1 (10.6) 
3-Category FP      
   Non-frail 207 (34.9)  0 (0) 8 (3.7) 24 (11.9)* 
   Pre-frail  288 (54.1)  2 (0.7)  12 (4.2) 34 (11.5) 
   Frail  54 (10.9)  1 (2.6) 5 (11.1) 11 (23.3) 
10% Increment FI     
   0-10%  160 (26.3)  1 (0.5) 7 (3.1) 17 (9.4) 
   10-20%  177 (32.7)  0 (0) 8 (5.5) 21 (12.9) 
   20-30%  106 (20.1)  1 (1.5) 4 (4.3) 16 (14.4) 
   30-40%  59 (11.5)  0 (0) 3 (5.3) 10 (18.0) 
   40-50% 36 (7.0)  1 (3.5) 2 (7.0) 3 (11.8) 
   >50% 11 (2.4)  0 (0) 1 (7.6) 2 (21.8) 
3-Category FI      
   Non-frail 160 (26.3)  1 (0.5) 7 (3.1) 17 (9.4) 
   Pre-frail 191 (35.5)  0 (0) 8 (5.1) 21 (11.8) 
   Frail 198 (38.1)  2 (0.7) 10 (5.6) 31 (16.6) 
n unweighted. % reported using cohort case weights. 5-Category FP (number 
of characteristics): 0, 1, 2, 3, 4-5. 3-Category FP (number of characteristics): 
0, non-frail; 1-2, pre-frail, ≥ 3, frail. 10% Increment FI: 0-10%, 10-20%, 20-
30%, 30-40%, 40-50%, > 50%. 3-Category FI (proportion of deficits): 0 to ≤.10, 
non-frail; >.10 to ≤.21, pre-frail; >.21, frail. 
a missing nor included. 




Chapter 8. Table S6. Frailty classification (frailty phenotype and frailty index) at baseline and follow up and 
mortality risk (Hazard Ratio) for the returning sample (n = 549). Baseline and Follow-up frailty classification are 
considered separately. Weighted multivariable analysis adjusted for age, sex, education and income.  
Returning Sample (n = 549) Baseline Follow up  
Frailty Phenotype (FP) Adj HR (95%CI) p-value Adj HR (95%CI) p-value 
Model 1: Continuous FP per 1 score 1.26 (1.02-1.57) .035* 1.57 (1.27-1.92) < .001* 
Model 2: 5-Category FP 
0 characteristics (n = 207) - - - - 
1 characteristic (n = 188) 1.05 (.60-1.84) .874 .88 (.44-1.77) .720 
2 characteristics (n = 100) 1.31 (.68-2.52) .421 1.83 (.94-3.55) .073 
3 characteristics (n = 45) 2.27 (1.06-4.84) .035* 2.80 (1.41-5.58) .003* 
4-5 characteristics (n = 9) 1.71 (.43-6.77) .445 5.43 (2.25-13.09) < .001* 
Model 3: 3-Category FP 
Non-frail (n = 207) - - - - 
Pre-frail (n = 288) 1.14 (.68-1.89) .626 1.27 (.71-2.29) .417 
Frail (n = 54) 2.16 (1.06-4.40) .033* 3.49 (1.83-6.64) < .001* 
Frailty Index (FI) 
Model 4: Continuous FI per .01 score 1.02 (1.00-1.03) .061 1.04 (1.02-1.06) < .001* 
Model 5: 10% Increment FI 
0-10% (n = 160) - - - - 
10-20% (n = 177) 1.20 (.62-2.31) .591 2.07 (.81-5.32) .129 
20-30% (n = 106) 1.84 (.93-3.65) .080 3.44 (1.37-8.65) .009* 
30-40% (n = 59) 2.21 (1.05-4.63) .036* 3.60 (1.35-9.62) .011* 
40-50% (n = 36) 1.58 (.62-4.00) .338 5.09 (1.98-13.08) .001* 
> 50% (n = 11) 2.43 (.56-10.51) .235 9.73 (3.32-28.50) < .001* 
Model 6: 3-Category FI 
Non-frail (n = 160) - - - - 
Pre-frail (n = 191) 1.23 (.64-2.36) .530 2.01 (.79-5.10) .143 
Frail (n = 198) 1.98 (1.10-3.56) .023* 4.80 (2.07-11.16) < .001* 
Adj HR, Adjusted Hazard Ratio. 5-Category FP (number of characteristics): 0, 1, 2, 3, 4-5. 3-Category FP (number of 
characteristics): 0, non-frail; 1-2, pre-frail, ≥ 3, frail. 10% Increment FI: 0-10%, 10-20%, 20-30%, 30-40%, 40-50%, > 
50%. 3-Category FI (proportion of deficits): 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail.  
The follow up window for mortality was from study entry to a censoring date of 30/9/2016. (Minimum of 10 years 
of mortality data for all participants). 
* p < 0.05
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Chapter 8. Table S7. Frailty classification (frailty phenotype and frailty index) at baseline 
and mortality risk (Hazard Ratio) for the whole sample (n = 909). Weighted multivariable 
analysis adjusted for age, sex, education and income.  
Whole Sample (n = 909) Baseline 
Frailty Phenotype (FP) Adj HR (95%CI) p-value 
Model 1: Continuous FP per 1 score 1.34 (1.19-1.52) < .001* 
Model 2: 5-Category FP 
0 characteristics (n = 289) - - 
1 characteristic (n = 289) .80 (.56-1.15) .222 
2 characteristics (n = 181) 1.34 (.90-1.99) .152 
3 characteristics (n = 108) 1.97 (1.29-3.01) .002* 
4-5 characteristics (n = 42) 3.14 (1.81-5.45) < .001* 
Model 3: 3-Category FP 
Non-frail (n = 289) - - 
Pre-frail (n = 470) .97 (.70-1.34) .847 
Frail (n = 150) 2.15 (1.46-3.15) < .001* 
Frailty Index (FI) 
Model 4: Continuous FI per .01 score 1.03 (1.02-1.03) < .001* 
Model 5: 10% Increment FI 
0-10% (n = 211) - - 
10-20% (n =266) 1.36 (.89-2.07) .159 
20-30% (n =182) 1.99 (1.27-3.12) .003* 
30-40% (n = 129 2.86 (1.80-4.55) < .001* 
40-50% (n = 80) 2.66 (1.54-4.59) < .001* 
> 50% (n = 41) 3.98 (2.09-7.59) < .001* 
Model 6: 3-Category FI 
Non-frail (n = 211) - - 
Pre-frail (n = 285) 1.36 (.89-2.06) .153 
Frail (n = 413) 2.63 (1.77-3.90) < .001* 
Adj HR, Adjusted Hazard Ratio. 5-Category FP (number of characteristics): 
0, 1, 2, 3, 4-5. 3-Category FP (number of characteristics): 0, non-frail; 1-2, 
pre-frail, ≥ 3, frail. 10% Increment FI: 0-10%, 10-20%, 20-30%, 30-40%, 40-
50%, > 50%. 3-Category FI (proportion of deficits): 0 to ≤.10, non-frail; >.10 
to ≤.21, pre-frail; >.21, frail.  
The follow up window for mortality was from study entry to a censoring 
date of 30/9/2016. (Minimum of 10 years of mortality data for all 
participants). 
* p < 0.05
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Supplementary Material Chapter 9 
Chapter 9. Table S1. Frailty Phenotype, Frailty Index, and Sarcopenia Variables 
Variable Description 
Frailty Phenotype Variables 
Weight loss >10% weight loss over 4 years (clinic measurement: Phase 1 and Phase 2)
Weakness Grip strength (kg) measured using dynamometer in the lowest 20% at baseline stratified by sex and body mass index
(BMI) quartiles:
Male: BMI ≤ 24, Grip ≤ 29 BMI 24.1-26, Grip ≤ 30 BMI 26.1-28, Grip ≤ 30 BMI > 28, Grip ≤ 32
Female: BMI ≤ 23, Grip ≤ 17 BMI 23.1-26, Grip ≤ 17.3 BMI 26.1-29, Grip ≤ 18 BMI > 29, Grip ≤ 21 
Exhaustion Two questions used from the CES–D Depression Scale. How often in the last week did you feel:  
a) I felt that everything I did was an effort, b) I could not get going.
Scoring: rarely or none (0), some or a little (1), moderate (2), most (3). Characteristic present when answering “2” or
“3” to either question.
Slowness Self-report to the question: Health limits you a lot walking 100m. (SF36 q11)
Low Activity Australian Bureau of Statistics National Health Survey. <100 Metabolic Equivalents (METs) per week.





Rheumatoid and any other 
arthritis 
Stroke or TIA 
Diabetes 
Any mental health problem 
10% weight loss over 4 years 
(FP) 
Systolic blood pressure 
Diastolic blood pressure 
FEV1/FVC post ratio 
Weak grip strength (FP cut 
points used) 
Falls 
Hospital emergency admission 
Low activity level (<100 METs 
per week) (FP) 
Healthy as anybody I know 
Health is excellent 
Self-reported health 
Health limits lifting or carrying 
groceries 
Health limits climbing several 
flights of stairs 
Health limits climbing one flight of 
stairs 
Health limits bending, kneeling or 
stooping 
Health limits walking more than 
1km 
Health limits walking 100m (FP) 
Felt lonely 
Could not get going (FP) 
Difficulty keeping mind on what 
you were doing 
Felt everything was an effort (FP) 
Physical & emotional problems 
interfered with social 
activities 
Felt full of life 
Felt calm and peaceful 
Felt worn out 
Felt tired 
Sarcopenia Variables 
Low Skeletal Muscle 
Index (SMI) 
Low SMI (Male: < 7.36 kg/m2, Female: < 5.81 kg/m2) was based on DEXA measured appendicular skeletal muscle 
mass (ASM). 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 9. Table S3. ANOVA mean number of FP frailty characteristics or FI proportion of deficits, 
based on classification as frail only, or both frail and sarcopenic. 
n (%) Mean (SD) p-value 
Total - 
FP Frailty & Sarcopenia Status 
Frail only 88 (13.8) 3.2 (0.8) p = .729 
Both frail and sarcopenic 30 (4.5) 3.4 (0.6) 
FI Frailty & Sarcopenia Status 
Frail only 284 (42.8) 0.34 (0.1) p = .016* 
Both frail and sarcopenic 45 (6.5) 0.38 (0.1)  
FP categories: 0-2 characteristics, non-frail; ≥3 characteristics, frail. FI categories: 0 to ≤ 0.21 
deficits, non-frail; > 0.21 deficits, frail. Sarcopenia categories: 0-1 characteristics, not sarcopenic; 
2 characteristics, sarcopenic. 
* p < 0.05 
Chapter 9. Table S4. Relationship of frailty classification (Frailty Phenotype and Frailty Index) and 
Sarcopenia with survival (over 10 years), with FP frailty, FI frailty, and sarcopenia analysed 
individually, stratified by sex. Complex samples Cox regression, adjusted for: age, income, education. 
Adjusted Male Female 
n (%) HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value 
Total 716 - - 
FP Frailty 
Non-Frail 598 (81.7) 1 1 1 
Frail 118 (18.3) 2.23 (1.55,3.22) p < .001* 2.02* 2.52* 
FI Frailty 
Non-Frail 387 (50.7) 1 1 1 
Frail 329 (49.3) 2.18 (1.55, 3.07) p < .001* 2.22* 2.18* 
Sarcopenia 
Non-Sarcopenic 646 (90.2) 1 1 1 
Sarcopenic 70 (9.8) 2.45 (1.57, 3.81) p < .001* 2.23* 2.52* 
HR, Hazard Ratio; 95%CI, 95% Confidence Interval. FP categories: 0-2 characteristics, non-frail; ≥3 characteristics, 
frail. FI categories: 0 to ≤ 0.21 deficits, non-frail; > 0.21 deficits, frail. Sarcopenia categories: 0-1 characteristics, not 
sarcopenic; 2 characteristics, sarcopenic. The follow-up window for mortality was from study entry over the period 
2004-2006 to a censoring date of 30/9/2016, with a minimum of 10 years of mortality data for all participants. 
* p < 0.05 
Chapter 9. Table S5. Relationship of frailty and sarcopenia status with survival (over 10 years) 
stratified by sex.  Complex samples Cox regression. Adjusted for: age, income, education. 
n (%) 
Adjusted  
HR (95%CI) p-value 
Male 
HR (95%CI) p-value 
Female 
HR (95%CI) p-value 
Total 716 - - - 
FP Frailty & Sarcopenia Status 
Neither frail nor sarcopenic 558 (76.4) 1 
Frail only 88 (13.8) 1.78 (2.79, 8.19) p = .010* 1.48 2.17* 
Sarcopenic only 40 (5.3) 1.71 (.90, 3.23) p = .100 1.49 1.88 
Both frail and sarcopenic 30 (4.5) 4.78 (1.15, 2.76) p < .001* 3.51* 6.43* 
FI Frailty & Sarcopenia Status 
Neither frail nor sarcopenic 362 (47.4) 1 
Frail only 284 (42.8) 2.05 (1.42, 2.96) p < .001* 2.08* 2.13* 
Sarcopenic only 25 (3.3) 2.01 (.91, 4.83) p = .081 1.90 2.11 
Both frail and sarcopenic 45 (6.5) 4.90 (2.84, 8.47) p < .001* 4.11* 6.22* 
HR, Hazard Ratio; 95%CI, 95% Confidence Interval. FP categories: 0-2 characteristics, non-frail; ≥3 characteristics, frail. FI 
categories: 0 to ≤ 0.21 deficits, non-frail; > 0.21 deficits, frail. Sarcopenia categories: 0-1 characteristics, not sarcopenic; 2 
characteristics, sarcopenic. The follow-up window for mortality was from study entry over the period 2004-2006 to a 
censoring date of 30/9/2016, with a minimum of 10 years of mortality data for all participants. 
* p < 0.05 
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Chapter 9. Table S6. Relationship of frailty (grip strength excluded from frailty measures) and 
sarcopenia status with survival (over 10 years).  Complex samples Cox regression.  
Unadjusted 
HR (95% CI) p-value 
Adjusted – Model 1 
HR (95%CI) p-value 
Adjusted – Model 2 
HR (95%CI) p-value 
Total - - - 
FP Frailtya & Sarcopenia Status 
Neither frail nor sarcopenic 1 1 1 
Frail only 2.70 (1.60, 4.58) p < .001* 1.86 (1.05, 3.27) p = .032* 1.78 (1.02, 3.12) p = .043* 
Sarcopenic only 3.45 (2.25, 5.29) p < .001* 2.36 (1.45, 3.85) p = .001* 2.41 (1.47, 3.96) p = .001* 
Both frail and sarcopenic 6.89 (3.20, 14.87) p < 
.001* 
3.60 (1.36, 9.57) p = .010* 3.57 (1.43, 8.94) p = .007* 
FI Frailtya & Sarcopenia Status 
Neither frail nor sarcopenic 1 1 - 
Frail only 2.22 (1.60, 3.09) p < .001* 2.06 (1.43, 2.96) p < .001* - 
Sarcopenic only 3.60 (1.87, 6.94) P < .001* 2.10 (0.91, 4.83) p = .081 - 
Both frail and sarcopenic 7.04 (4.29, 11.53) p < 
.001* 
4.91 (2.84, 8.48) p < .001* - 
HR, Hazard Ratio; 95%CI, 95% Confidence Interval. FP categories: 0-2 characteristics, non-frail; ≥3 characteristics, frail. FI 
categories: 0 to ≤ 0.21 deficits, non-frail; > 0.21 deficits, frail. Sarcopenia categories: 0-1 characteristics, not sarcopenic; 2 
characteristics, sarcopenic. The follow-up window for mortality was from study entry over the period 2004-2006 to a 
censoring date of 30/9/2016, with a minimum of 10 years of mortality data for all participants. 
Model 1 - Adjusted for: age, sex, income, education. 
Model 2 - Adjusted for: age, sex, income, education and multimorbidity. 
a Weak grip strength is excluded from frailty measure. 
* p < 0.05 
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Supplementary Material Chapter 10 
Chapter 10. Table S1. FRAIL Scale and Frailty Phenotype variables. 
Variable Description 
FRAIL Scale 
Fatigue During the past 4 weeks did you feel tired? (SF36, q31) A good bit, some, a little, or none of the time = 0;  
all, or most of the time = 1. 
Resistance Health limits you in climbing one flight of stairs? (SF36, q7) Not limited = 0; a little or a lot = 1. 
Ambulation Health limits you walking half a kilometre? (SF36, q10) Not limited = 0; a little, or a lot, = 1. 
Illnesses of the following 11 chronic conditions: Angina, Heart attack, Osteoporosis, Osteoarthritis, Hypertension, 
Rheumatoid/osteo/other arthritis, Stroke or TIA, Diabetes, Any mental health problem, emphysema, asthma. 0-4 
conditions = 0 and 5-11 conditions = 1 
Loss of weight >10% weight loss over 4 years (clinic measurement: Phase 1 and Phase 2) 
Frailty Phenotype 
Weight loss >10% weight loss over 4 years (clinic measurement: Phase 1 and Phase 2) 
Weakness Grip strength (kg) measured using dynamometer in the lowest 20% at baseline stratified by sex and body mass index 
(BMI) quartiles. 
Male BMI ≤ 24, Grip ≤ 29 BMI 24.1-26, Grip ≤ 30 BMI 26.1-28, Grip ≤ 30 BMI > 28, Grip ≤ 32 
Female BMI ≤ 23, Grip ≤ 17 BMI 23.1-26, Grip ≤ 17.3 BMI 26.1-29, Grip ≤ 18 BMI > 29, Grip ≤ 21 
Exhaustion Two questions used from the CES–D Depression Scale. How often in the last week did you feel:  
a) I felt that everything I did was an effort, b) I could not get going.
Scoring: rarely or none (0), some or a little (1), moderate (2), most (3). Characteristic present when answering “2” or
“3” to either question.
Slowness Self-report to the question: Health limits you a lot walking 100m. (SF36 q11)
Low Activity Australian Bureau of Statistics National Health Survey. <100 Metabolic Equivalents (METs) per week.30 
Chapter 10. Table S2. Cross tabulation of FRAIL Scale (number of characteristics present) against 
Frailty Phenotype. 
Index Test Reference Standard 
Frailty Phenotype 
FRAIL Scale ≥3 Condition +ve Condition -ve Total 
Test +ve 100 91 191 
Test -ve 58 597 655 
Total 158 688 846 
FRAIL Scale ≥2 Condition +ve Condition -ve Total 
Test +ve 151 247 398 
Test -ve 7 441 448 
Total 158 688 846 
FRAIL Scale ≥1 Condition +ve Condition -ve Total 
Test +ve 156 405 561 
Test -ve 2 283 285 
Total 158 688 846 
n reported using cohort case weights. Frailty Phenotype (number of characteristics): 
0, non-frail; 1-2, pre-frail; ≥3, frail. 
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Chapter 11. Table S1. Frailty Phenotype and Frailty Index Variables 
Frailty Phenotype Frailty Index (34-item) 
Weight Loss: > 10% weight loss 
over four years (clinic 
measurement) 
Weakness: original method 
Exhaustion: original method 
Slowness: Self-report ‘a lot’ to 
health limits walking 100m 
(SF36 q11) 
Low Activity Level: Australian 
Bureau of Statistics National 






Rheumatoid and any other arthritis 
Stroke or TIA 
Diabetes 
Any mental health problem 
Systolic blood pressure 
Diastolic blood pressure 
10% weight loss over 4 years 
FEV1/FVC post ratio 
Weak grip strength  
Falls 
Hospital emergency admission 
Low activity level (<100 METs per week) 
Healthy as anybody I know 
Health is excellent  
Self-reported health 
Health limits lifting or carrying groceries 
Health limits climbing several flights of 
stairs 
Health limits climbing one flight of stairs 
Health limits bending, kneeling or 
stooping 
Health limits walking more than 1km 
Health limits walking 100m 
Felt lonely 
Felt that could not get going 
Difficulty keeping mind on what you 
were doing 
Felt everything was an effort  
Physical & emotional problems interfered 
with social activities 
Felt full of life 
Felt calm and peaceful 
Felt worn out 
Felt tired 
METs, metabolic equivalent of task; SF36, 36-Item Short Form Health Survey; TIA, transient ischaemic attack; FEV1/FVC, 
forced expiratory volume/forced vital capacity 
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SYSTEMATIC REVIEW PROTOCOLDiagnostic test accuracy of self-reported frailty screening
instruments in identifying community-dwelling older
people at risk of frailty and pre-frailty: a systematic
review protocol
Rachel C. Ambagtsheer1,2  Mark Q. Thompson1  Mandy M. Archibald1  Mavourneen G. Casey2 
Timothy J. Schultz1,3
1National Health and Medical Research Council (NHMRC) Centre of Research Excellence: Frailty and Healthy Ageing, University of Adelaide,
Adelaide, Australia, 2Torrens University Australia, Adelaide, Australia, and 3The Centre for Evidence-based Practice South Australia (CEPSA):
a Joanna Briggs Institute Centre of ExcellenceReview question/objective: The question of this systematic review is: What is the diagnostic test accuracy of self-
reported frailty screening instruments among community-dwelling older people against any of the following
reference standard tests: the frailty phenotype, frailty index and comprehensive geriatric assessment?
Keywords Community-dwelling older people; frailty; pre-frailty; self-reported frailty screening instruments
JBI Database System Rev Implement Rep 2017; 15(10):2464–2468.Background
A ging is universal and inevitable, however, thereis considerable variability in the health and
functional abilities of individuals of the same age
due to factors such as frailty, disability and chronic
disease.1 Frailty results from a cumulative decline
over multiple body systems and is commonly
described as a state of decreased functional reserve
and reduced resistance to stressor events.2 This
increased vulnerability results in higher rates of
morbidity, health service utilization and mortality.3
Frailty is commonly observed amongst older people,
and while there is currently no broad consensus on
its prevalence, a meta-analysis conducted by Collard
et al. suggested a weighted prevalence of 10.7%
among those aged 65 years and over, increasing
commensurately with age.4,5
There are currently two main approaches to
defining frailty. The first is the frailty phenotype,
which describes frailty as a biologic syndrome that is
present when three or more of the following five
physical signs are present: unintentional weight loss,Correspondence:RachelC.Ambagtsheer, rambagtsheer@laureate.net.au
There is no conflict of interest in this project.
DOI: 10.11124/JBISRIR-2017-003363
JBI Database of Systematic Reviews and Implementation Reports
©2017 Joanna Briggs Institute. Unauthorizeself-reported exhaustion, weakness, slow walk speed
and low physical activity.6 The alternate approach is
the cumulative deficits model which incorporates
both physical and psychosocial variables and defines
frailty as the proportion of deficits present in the
individual, represented as a frailty index.7 Despite
the differences between the methods for defining and
measuring frailty, the two approaches are moder-
ately correlated.8
Regardless of how it is defined, frailty is a
dynamic state in which individuals may move
between non-frail and at-risk states, and a number
of interventions have been identified which may
potentially reverse or prevent frailty.3,9 Screening
for frailty in the primary care setting has been
highlighted as an important component in the man-
agement of older adults to ensure that they receive
timely and appropriate interventions.9 Despite calls
for widespread frailty screening of persons within
the study age group, and the existence of a range of
frailty measures, there is not yet a standard approach
to screening for frailty.10 One of the key challenges
in frailty screening is to identify tools with high
sensitivity to ensure frail individuals are correctly
identified, and with high specificity to correctly
diagnose non-frail individuals, so as to avoid unnec-
essary assessment and potential stress to patients.11 2017 THE JOANNA BRIGGS INSTITUTE 2464
d reproduction of this article is prohibited.
179
SYSTEMATIC REVIEW PROTOCOL R.C. Ambagtsheer et al.A number of studies have investigated the suit-
ability of frailty screening measures and have
highlighted that the different conceptual approaches
and methods affect prevalence and accuracy, making
comparison between instruments difficult.12,13 Fur-
thermore, high false positive rates, limited discrimi-
native capability, and the limited quality of
psychometric properties of different instruments
mean that frailty screening is an emerging area of
clinical practice.14-16
The use of self-report measures is another impor-
tant element in frailty screening as physical mea-
surement of frailty in the clinical setting is
potentially time-consuming, and it is difficult to
incorporate a comprehensive geriatric assessment
into routine primary care.12,13 Identification of a
suitable, simple, self-report screening tool that reli-
ably identifies frailty and allows referral for a more
detailed assessment may avoid costs and unneces-
sary assessment.10,13 The potential value of self-
report measures of frailty in the primary care setting
is strengthened by the finding that self-report and
test-based measurement identify similar frailty
characteristics.17
A number of systematic reviews have investigated
the suitability of a variety of frailty screening mea-
sures for use in the primary care setting, however,
these have focused on the performance of a combi-
nation of self-report and test-based measures.13-15,18
A preliminary search of JBI Database of Systematic
Reviews and Implementation Reports, The
Cochrane Library, PROSPERO, PEDro, PubMed,
PsycINFO, CINAHL, Scopus, Web of Science and
Embase identified no listed systematic reviews either
published or currently in progress investigating




Participants will be community-dwelling older peo-
ple, defined as either being of a mean age in a study
population of 65 years and over, or at least half of
the study participants being aged 65 years and over.
Studies in which participants have been recruited
from hospitals but self-report measures have been
used in a community setting will be included. Studies
including participants who have been resident in a
residential care facility (long-term care or nursing
home) will be excluded.JBI Database of Systematic Reviews and Implementation Reports
©2017 Joanna Briggs Institute. UnauthorizeIndex test
The index tests for this review will be all currently
available, diagnostic tests intended to identify frailty
using self-report measures. Some examples of these
self-report frailty instruments include the Reported
Edmonton Frail Scale19 and the Kihon Checklist.20
Reference standards
The reference standards for this review will be
the Frailty Phenotype,6 the Frailty Index7 and/or
Comprehensive Geriatric Assessment.21
Diagnosis of interest
The diagnosis of interest is presence of frailty or pre-
frailty.
Types of studies
This review will consider all observational, cross-
sectional studies assessing the diagnostic test accu-
racy of self-reported frailty screening instruments
against one or more of the specified reference stand-
ards. It will include studies in which the self-report
frailty instrument has been completed by a family
member or nominated person on behalf of the older
person as well as studies where the older person has
completed the instrument himself/herself.
Search strategy
The search strategy aims to find both published and
unpublished studies. The search strategy will use
MeSH (Medical Subject Headings) terms and rele-
vant keywords and will be adapted as appropriate to
each database.
A three-step search strategy will be utilized in this
review. An initial limited search of MEDLINE and
CINAHL will be undertaken, followed by analysis of
the key text words contained in the title and abstract,
and of the index terms used to describe the article.
A second search using all identified keywords and
index terms will then be undertaken across all
included databases. Thirdly, the reference list of
all identified reports and articles will be searched
for additional studies. Only studies published in
English will be considered for inclusion in this
review. In terms of timeframe, only studies published
from 1 January 2000 to the present will be consid-
ered for inclusion in this review. This date has been
selected as both the physical phenotype and accu-
mulated deficits models of frailty were first pub-
lished in 2001. 2017 THE JOANNA BRIGGS INSTITUTE 2465
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SYSTEMATIC REVIEW PROTOCOL R.C. Ambagtsheer et al.The databases to be searched will include MED-
LINE/PubMed,PEDro,Embase,PsycINFO,CINAHL,
Scopus and Web of Science.
Searches for unpublished studies will be per-
formed using ProQuest (Dissertations), Open Grey
and The Grey Literature Report database. Research
centres with a focus on gerontology will also be
identified via a keyword search and expert consul-
tation, and their websites examined for additional
studies of interest.
Initial keywords to be used will be:
1.JBI D
©
Search for frailty: frail OR prefrail2. Search for self-report: self-report, diagnostic
self-evaluation, postal, self-diagnos, survey,
questionnaire, reported, self-assess, self-test,
OR self-admin3. Search for screening tools: screen, instrument,
tool, OR index4. Search for specific screening tools: eg Kihon
Checklist OR Reported Edmonton Frail Scale
tems 1, 2 and 3 will be joined with searchI
operator AND item 4 to be joined to 1–3 with OR.
Assessment of methodological quality
Quantitative papers selected for retrieval will be
assessed by two independent reviewers (RA and
MT) for methodological validity prior to inclusion
in the review using the JBI Critical Appraisal Check-
list for Diagnostic Test Accuracy Studies22 in asso-
ciation with the QUADAS 2 (Quality Assessment of
Diagnostic Accuracy Studies) tool.23 Any disagree-
ments that arise between the reviewers will be




Initial literature search results will be compiled
by one reviewer (RA) and uploaded to Mendeley
Reference Manager (Mendeley Ltd., Elsevier,
Netherlands) to aid in the process of removing
duplicates. A final unique list of studies, along with
abstracts, will be exported to Microsoft Excel, where
the first stage of the selection and screening of studies
will take place.
Selection process
In order to select studies for inclusion, two reviewers
(RA and MT) will review the literature search results
independently in a two-step process. In the first step,atabase of Systematic Reviews and Implementation Reports
2017 Joanna Briggs Institute. Unauthorizethe titles and abstracts will be reviewed for eligibility
against the inclusion criteria. In the second, the full
text of the articles will be obtained and reviewed for
consideration of inclusion. A record will be kept of
the reason for exclusion against each study. Any
disagreements that arise between the reviewers will
be resolved through discussion or with a third
reviewer (MC) where appropriate. Study authors
will be contacted should additional information
be required.
Data items
Quantitative data will be extracted from papers
included in the review by two independent reviewers
(RA and MT) using the standardized data extraction
tool from the Joanna Briggs Institute (JBI),22 which
incorporates most elements of the STARD (Stand-
ards for Reporting of Diagnostic Accuracy) check-
list, and entered into a standardized template within
Microsoft Excel. Calibration exercises will be con-
ducted prior to commencement of the extraction to
ensure a consistent approach across reviewers. The
data extracted from each eligible study will include
specific details about the populations, index and
reference tests, study methods, index test results
and outcomes of significance to the review question.
Study authors will be contacted for additional infor-
mation where necessary to resolve any outstanding
issues or ambiguities.
Data synthesis
Graphic representation of the results of the system-
atic review will take the form of forest plots showing
sensitivity and specificity for the primary studies
included in the review. We will report the number
of true positives, false positives, true negatives and
false negatives in tabular format.
A sub-group analysis will be used to compare the
diagnostic capabilities of the tests, diagnostic capa-
bilities based on significant covariates identified
in the included studies. For example, a study may
report results separately for different patient age
groups, gender or testing conditions.
With regard to meta-analysis, the study will
adopt this basic approach as outlined in the
relevant JBI literature:22 if the same threshold is
used through the primary studies, then we will
estimate the summary sensitivity/specificity. If it is
determined that different thresholds have been used,
then we will produce a summary receiver operating 2017 THE JOANNA BRIGGS INSTITUTE 2466
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SYSTEMATIC REVIEW PROTOCOL R.C. Ambagtsheer et al.characteristic (SROC) curve and estimate the
summary sensitivity/specificity for the different
thresholds used in the articles.
The model used to perform the meta-analysis will
be the Bivariate Model,24 a hierarchical model rec-
ommended by the Cochrane Handbook.25 The
review team will follow the approach reported in
Romano et al.26 and use the Stata ‘‘metandi’’ com-
mand to compute the summarized data.
Heterogeneity between studies will be initially
assessed with reference to the graphical representa-
tion of results outlined above and explored using
subgroup analyses based on the different quantita-
tive study designs included in this review. Where the
extent of heterogeneity cannot be explained, the
findings will be presented in a narrative form includ-
ing tables and figures to aid in data presentation
where appropriate.
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